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PART ONE: THE FORMAL TOTAL SYNTHESIS OF DEHYDROGLIOTOXIN AND THE FIRST 
SYNTHESIS OF AN EPIDISELENODIKETOPIPERAZINE 
AND 
PART TWO: TOWARDS THE TOTAL SYNTHESIS OF THE TETRAPETALONES 
 
 Tuberculosis (TB), caused by Mycobacterium tuberculosis (MTB), affects approximately 
one third of the global population and is associated with nearly two million deaths annually. 
Although there are known cures for TB, current treatment plans suffer due to length, usually 
taking 6–9 months to complete. Additionally, developing countries lack the infrastructure and 
resources necessary to both efficiently diagnose and treat patients. Of particular concern are an 
increasing number of strains of TB that are becoming resistant to the current drug regimens, 
which has been a result of patients beginning, but not completing their treatment. In light of 
these facts it is clear there is a continuing need to develop simplified and shorter treatments for 
TB, and with the increasing prevalence of resistant strains, chemically unique targets should be 
investigated.  
 As part of a collaborative effort with the Hung group at the Broad Institute, we identified 
two related epidithiodiketopiperazine (ETP) natural products, gliotoxin and dehydrogliotoxin, as 
potential candidates for exploration as anti–TB agents. We initially targeted a synthesis of 
dehydrogliotoxin, as it had also never been tested against MTB, whereas gliotoxin was known to 
be active. Additionally, as dehydrogliotoxin was the simpler of the two compounds, we believed 
it could be synthesized more rapidly and also be more amenable to derivatization to form 
structural analogs. The synthetic studies towards dehydrogliotoxin culminated in a formal total 
synthesis that featured a key two step amidation–intramolecular ring–closure.  
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With access to dehydrogliotoxin we were able to test it against MTB and found its activity 
to be comparable to gliotoxin. We next turned our attention to the synthesis of structural analogs 
in hopes of identifying a compound that could potentially be used as an anti–TB therapeutic. In 
that regard, we targeted a compound wherein the disulfide region of the natural product was 
replaced with a diselenide. As an epidiselenodiketopiperazine (ESeP) had never been 
synthesized before, we initially explored the installation of this functional group in a model 
system. These synthetic efforts resulted in the synthesis of an ESeP, both from a simple 
diketopiperazine and directly from an ETP. Additionally, in these model systems, the ESeP 
exhibited comparable activity towards MTB as the ETP.  
 Tetrapetalone A was isolated in 2003 by Hirota and coworkers from a culture filtrate of 
Streptomyces sp. USF–4727. The related compounds tetrapetalones B, C, and D were isolated 
from the same Streptomyces strain in 2004. We became interested in this family of natural 
products due to their interesting structural features and the synthetic challenge they present. 
Salient features of the tetrapetalones include a tetracyclic core containing a tetramic acid, a 
seven–membered ring possessing a trisubstituted double bond, a p–quinol, and a five–
membered ring with a pendant β–rhodinose.  
 Several strategies towards the synthesis of the tetrapetalones have been explored. In 
our initial approach we hoped to form the seven–membered ring of the natural product through 
nucleophilic attack of the aromatic ring onto a pendant palladium π–allyl species. While 
exploring this process, we found that the desired seven–membered product was not formed, 
instead we isolated a product containing a five–membered ring, the result of attack at the wrong 
position of the palladium π–allyl species. Attempts to bias the substrate towards formation of the 
desired seven–membered ring through a transannular palladium π–allyl approach proved 
unfruitful.  
 Our current route features a Friedel–Crafts acylation to form the seven–membered ring 
containing the trisubstituted double bond. The precursor for this approach was built up rapidly 
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from simple starting materials, and the desired Friedel–Crafts reaction proceeds smoothly. 
Furthermore, we have implemented a C–H oxidation protocol to install a synthetic handle, which 
can ultimately be converted to an alkyne that we envision can be transformed into the five–
membered ring bearing the sugar moiety in order to finish the natural product.  
 Concurrent to the approaches described above, we have also targeted the related 
natural product, ansaetherone, which was isolated from the same Streptomyces strain as the 
tetrapetalones and is proposed to be a biosynthetic precursor to the family. The ultimate goal in 
this approach was to develop a synthesis of ansaetherone and explore methods to convert it to 
one of the members of the tetrapetalones in a biomimetic fashion. Our proposed synthesis 
included a key tandem enyne–cross metathesis to form the eleven–membered ring present in 
the natural product. Although this synthesis is still in its infancy, we have accessed a compound 
that is a few synthetic steps away from the precursor to explore the key step. We are currently 
exploring an improved synthesis of this intermediate and ways to elaborate it to the natural 
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Tuberculosis (TB), caused by Mycobacterium tuberculosis (MTB), affects approximately 
one third of the global population and is associated with nearly two million deaths annually.1 
Although there are known cures for TB, most of the problems associated with TB exist in 
developing countries that lack the infrastructure and resources to efficiently diagnose and then 
treat the illness. This establishes a clear and continuing need for economically accessible 
treatments, and the growing presence of TB strains resistant to current drug regimens serves to 
accentuate this need. As part of a collaborative effort with the Hung group at the Broad Institute, 
we have identified two related natural products, gliotoxin and dehydrogliotoxin, as potential 
candidates for further exploration as anti-TB agents.  
1.1. Tuberculosis 
 
Tuberculosis is a serious infection that is mostly localized in the lungs, and is spread by 
inhaling droplets in the air containing the bacteria.2 Once inhaled the bacteria enters the host 
cell through phagocytosis by the alveolar macrophages. Although phagocytosis is the normal 
function of the macrophage, MTB has acquired the ability to survive and replicate within the 
macrophage. It does this by inhibiting the phagolysomes, which are responsible for digesting 
unwanted objects consumed by the macrophage. In most healthy individuals the bacteria is 
contained by isolating the infected macrophage in what is called a tubercle, preventing the 
bacteria from spreading. The tubercle can become calcified and the bacteria can lay dormant 
within for many years. If the immune system is weakened (commonly from another disease 
 3 
such as HIV) the tubercle can liquefy, releasing the bacteria, which can multiply at very high 
rates and eventually spread throughout the body and ultimately lead to death.  
Approximately one third of the global population is infected with MTB, which leads to 
nearly two million deaths annually. Of particular concern is the fact that most cases of TB reside 
in developing countries that lack the resources and infrastructure to efficiently treat the disease. 
Although TB can typically be cured, the drug regimen required usually lasts 6–9 months and 
consists of a combination of multiple drugs. It is often the case, especially in underdeveloped 
countries, that a patient begins treatment, starts to feel better, and stops treatment before the 
disease is fully cured. It is due to this that multi-drug resistant strains of TB are becoming more 
and more prevalent, with nearly 500,000 cases (4.6% of the global burden) as of 2008.1    
The typical treatment of TB consists of a combination of drugs.3 In most cases the 
patient is given the so-called 1st line drugs, isoniazid (1), rifampicin (2), and ethambutol (3) as 
well as any number of the so-called 2nd line drugs such as the fluoroquinolones (4), 
capreomycin (5), amikacin (6a), kanamycin (6b), and others (Figure 1.1). Multi-drug resistant 
strains are those that are resistant to isoniazid and rifampicin. Extensively resistant strains are 
not only resistant to 1 and 2, but also to the fluoroquinolones and at least one of the other three 
2nd line drugs.  
Given the above information it is clear that there is a continuing need to develop new 
therapies for TB. Both more simplified and shorter treatment regimens are needed to encourage 
patents to finish treatments, which will not only lead to the disease being cured, but also to less 
instances of multi-drug and extensively resistant strains. Due to the presence of these resistant 
strains, new targets that are chemically distinct from the existing treatments should be targeted.  
 4 
 
Figure 1.1. Typical drugs used to treat tuberculosis. 
 
1.2. Gliotoxin and Dehydrogliotoxin 
 
In 1936 Weindling and Emerson reported the isolation of a toxic crystalline solid from the 
wood fungus Gliocladium fimbriatum,4 which has since been isolated from a variety of 
microorganisms including Aspergillius fumigatus5 and Penicillium terlikowsii.6 In this initial report 
the molecular formula was erroneously reported as C14H16N2O4S2. In 1943 Johnson and 
coworkers further investigated the physical properties of this compound, now named gliotoxin, 
and with the help of elemental analysis, revised the molecular formula to C13H14N2O4S2.7 The 
first structure of gliotoxin was proposed 20 years later by Johnson and Buchanan, who after 


















































R = Amikacin (6a)




























Figure 1.2. Initially proposed structure of gliotoxin. 
Five years later Johnson and Woodward reported further degradation studies that 
contradicted the previously reported structure of gliotoxin.9 Specifically, they noted that upon 
exposure to alkaline alumina, gliotoxin was converted to diketopiperazine (DKP) 8, which they 
named dehydrodethiogliotoxin. This among other observations led them to propose the revised 
structure 9 as the structure of gliotoxin (Scheme 1.1). This was later confirmed in 1966 by x–ray 
crystallography (Figure 1.3).10  
Scheme 1.1. Degradation of gliotoxin (9) to dehydrodethiogliotoxin (8). 

































In 1966 the related compound, dehydrogliotoxin (10), was isolated from Penicillium 
terlikowsii (Figure 1.4).10 It differs in structure from 9 only by the presence of the aromatic ring in 
10 in place of the dihydrobenzene moiety. 
 
Figure 1.4. Dehydrogliotoxin (10). 
 
Gliotoxin has been known to inhibit MTB since 1950, where it was found to exhibit 
minimum inhibitory concentrations (MICs) ranging from 6 to 45 nM.11 Unfortunately gliotoxin has 
also been found to be toxic, with an LD50 of 25 to 65 mg/kg.7, 11b When this project was started, 
dehydrogliotoxin had never been tested against MTB; however, it had been shown to inhibit 
macrophage phagocytosis in concentrations similar to that of gliotoxin,12 suggesting that it could 
also be relevant to MTB. Given these facts we became interested in gliotoxin, dehydrogliotoxin, 
and analogs of the two as potential anti-TB therapeutics. In the context of analogs, we would 
hope to identify a compound that both retains activity against MTB, but also exhibits less toxicity 
compared to 9 and 10.  
1.3. Biosynthesis 
 
Biosynthetically, gliotoxin derives from the condensation of phenylalanine (11) and 
serine (12), which produces diketopiperazine 13. It is widely believed that after sulfur 
incorporation the aromatic ring is oxidized to arene oxide 14, which undergoes subsequent 
intramolecular attack by the DKP amide nitrogen. Methylation of the remaining free amide 
















































































Chapter Two  
Previous Synthetic Work 
 
Due to their interesting structural features and considerable biological activity, 
epidithiodiketopiperazine (ETP) natural products have received considerable attention from the 
synthetic community. The most well studied class of these ETP natural products is the gliotoxin 
family, with both dehydrogliotoxin and gliotoxin being synthesized by the Kishi group in 1973 
and 1976 respectively.14 More recently other ETPs have been synthesized including gliocladine 
C (17), acetylaranotin (18), chaetocin A (19), and 11,11’-dideoxyverticillin A (20) (Figure 2.1).15 
 
Figure 2.1. Epidithiodiketopiperazine natural products that have recently been synthesized. 
 
 
2.1. Methods to Install the Disulfide Bridge 
 
Along with being the structural feature that defines the ETP natural products, the 
bridging disulfide is also one of the most significant synthetic challenges one faces when 
attempting to prepare any member of the family. To date, there have been three basic 
approaches utilized to install this challenging functional group (Scheme 2.1). The first relies on 
initial radical bromination followed by attack with a sulfur nucleophile such as potassium 
thioacetate, which presumably proceeds through an acyl iminium species. Removal of the 















































radical oxidation to give 26, which can undergo a Lewis or Brønsted acid catalyzed acyl iminium 
formation and trapping with a sulfur nucleophile. The protecting group can be removed to reveal 
bridging disulfide 28 after oxidation (eq. 2).15c, 17 The last method involves deprotonating DKP 25 
with a strong base followed by reacting it with a sulfur electrophile to furnish 27. Bridging 
disulfide 28 is obtained after deprotection and oxidation (eq. 3).18 
 
Scheme 2.1. Methods to install the disulfide bridge into ETPs. 
 
In the context of the total synthesis of gliotoxin, Kishi and coworkers decided that early 
incorporation of the disulfide and further functionalization of the DKP was more promising than 
late stage sulfur incorporation. However, studies on simple substrates revealed the disulfide 
bridge as being sensitive to oxidative, reductive, and basic conditions. To circumvent the 
instability of the disulfide and still utilize a strategy that incorporated sulfur in the early stages, 
they chose to pursue a strategy wherein the requisite sulfur atoms were protected as the 
corresponding dithioacetal. As a proof of concept, simple dithiol 29 was reacted with p–
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 10 
strongly basic, reductive, and some oxidative conditions. Cleavage was realized by first 
oxidizing to the monosulfoxide then adding acid to give disulfide 32 (Scheme 2.2). 
 
Scheme 2.2. Kishi’s use of a dithioacetal as a protecting group. 
 
Given their focus on the early installation of sulfur, the Kishi group needed to develop 
chemistry that would allow for the introduction of numerous other structural components. 
Specifically they needed to alkylate at the bridgehead carbon. Although formation of an anion at 
a bridgehead carbon is normally very difficult, the Kishi group hypothesized that deprotonation 
of the carbon α to the dithioacetal may be possible due to the extra stabilization from the d–
orbital of the neighboring sulfur atom. To test the viability of this alkylation, simple dithioacetal 
30 was exposed to n-BuLi followed by a variety of electrophiles and the corresponding alkylated 
products (33) were obtained in good yields. Furthermore, they found that by resubjecting the 
compound where R = methyl to the reaction conditions, they could get a product (34), where 







































Scheme 2.3. Alkylation of dithioacetal 30. 
 
Interestingly, while performing these alkylations, the Kishi group observed that one 
regioisomeric product would preferentially be obtained depending on which diastereomer of the 
dithioacetal was subjected to the reaction. They hypothesized that the observed regioselectivity 
arose from the fact that one of the sulfurs of the dithioacetal could interact with the nearby 
amide carbonyl to form resonance structure 30’ (Scheme 2.4). The proton α to that carbonyl is 
now much less acidic due to less stabilization from both the sulfur and the carbonyl, leading to 
preferential deprotonation α to the other carbonyl, which does not interact with the dithioacetal. 
  
Scheme 2.4. Resonance structures of dithioacetal 30, illustrating its reactivity. 
 
2.2. Kishi’s Synthesis of Gliotoxin 
 
Based on this body of exploratory research, a synthetic plan for gliotoxin became clear 
and is illustrated below in retrosynthetic fashion (Scheme 2.5). As illustrated, gliotoxin (9) would 
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dialkylation of 36 employing the method they developed for bridgehead anion formation. Alkyl 
chloride 36 would arise from attack of arene oxide 37 with DKP 38. The latter would derive from 
39 after sulfur incorporation and dithioacetal formation.   
 
Scheme 2.5. Kishi’s retrosynthetic analysis of gliotoxin (9). 
 
In the forward sense, Kishi commenced by protecting the amide of known DKP 39. 
Radical bromination and displacement of the bromides with potassium thioacetate gave 
dithioacetate 40. Removal of the acetate protecting groups followed by dithioacetal formation 
produced intermediate 41, which was subjected to concentrated HCl in ethanol to furnish 
racemic DKP 38 as a 1:1 mixture of diastereomers. A subsequent kinetic resolution with benzoyl 
chloride enhanced the diastereomeric ratio to 10:1. Deprotection of the racemic mixture followed 
by reaction with a chiral isocyanate furnished urea 43 as a mixture of two diastereomers, which 
proved to be readily separable via flash chromatography. The urea of the desired enantiomer 















































Scheme 2.6. Kishi’s synthesis of enantiopure dithioacetal 38. 
 
Enantioenriched dithioacetal 38 was reacted with arene oxide 37 in the presence of 
Triton B to give alcohol 44. The free alcohol was acetylated and the t–butyl ester hydrolyzed to 
give carboxylic acid 45, which was converted to mixed anhydride 46. After reduction with 
sodium borohydride, the resultant alcohol was converted to the mesylate and displaced with 
chloride and the acetate removed to give alkyl chloride 36. Dithioacetal 36 was then alkylated in 
the presence of 3.2 equivalents of phenyl lithium and BOMCl to give the desired dialkylated 
product 35. It is important to note that having the alcohol unprotected was crucial in the 
alkylation step to prevent dehydration–aromatization of the hydrated benzene moiety. Removal 
of the benzyl protecting group followed by cleavage of the dithioacetal through initial oxidation to 













1) MOMCl, KOt-Bu, 0 ºC
2) NBS, (BzO)2, CCl4, 77 ºC
3) KSAc, CH2Cl2
1) HCl, MeOH, 50 ºC
2) p-anisaldehyde
        BF3•OEt2, CH2Cl2
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Scheme 2.7. Kishi’s completion of gliotoxin (9). 
 
2.3. Kishi’s Synthesis of Dehydrogliotoxin 
 
Dehydrogliotoxin (10) is structurally related to gliotoxin (9) and contains many of the 
same synthetic challenges including the disulfide moiety, however it lacks the cyclohexadienol 
system. In light of this, the late stages of the synthesis were envisioned to be similar as for 9, 
however construction of the core would require a different approach (Scheme 2.8). 
Dehydrogliotoxin would once again be produced from dialkylation and deprotection of a 
dithioacetal (48), which in this case would be derived from ester 49, the product of an Ullman–
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S1) BCl3, CH2Cl2, 0 ºC
2) m-CPBA, CH2Cl2
then cat. HClO4

























Scheme 2.8. Kishi’s retrosynthetic analysis of dehydrogliotoxin (10). 
 
To initiate the synthesis of dehydrogliotoxin (10), aryl iodide 50 was coupled with DKP 
39 and the resultant carboxylic acid esterified with diazomethane to give aryl DKP 49. In a 
sequence analogous to that of gliotoxin, sulfur was incorporated and protected as the 
dithioacetal and the ester was converted to the alkyl chloride to give 48 over eight steps. A 
single diastereomer of 48 was obtained through fractional crystallization. Exposure of 
dithioacetal 48 to phenyl lithium and BOMCl furnished bisalkylated product 47, which was 




























































    Nitrobenzene, 170 °C
2) CH2N2, MeOH

















  (65% yield two steps)
1) HCl, MeOH, 50 ºC
2)   p-anisaldehyde
        BF3•OEt2, CH2Cl2
1:1 d.r.
1) NaOH, dioxane
2) ClCO2Et, Et3N, CH2Cl2





1) BCl3, CH2Cl2, 0 ºC
2) m-CPBA, CH2Cl2
then cat. HClO4
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4) MsCl, Et3N, CH2Cl2
    then LiCl, DMF
(69% yield four steps)
(72% yield two steps)
 17 
Chapter Three 
Towards the Synthesis of Dehydrogliotoxin 
 
Although we were interested in both gliotoxin (9) and dehydrogliotoxin (10), we choose 
to begin our synthetic efforts by focusing on the synthesis of dehydrogliotoxin (10). In addition to 
being the simpler of the two targets, the fact that 10 had never been tested against MTB helped 
guide our decision. As well as offering quicker access to a potentially interesting anti–MTB 
agent, we believed that 10 might more readily lend itself to derivatization to form structural 
analogs. Given that the primary objective of our efforts was analog generation, rather than 
develop a completely new synthetic approach, we initially decided to reproduce the elegant 
chemistry developed by Kishi and coworkers.  
3.1 Intermolecular Copper Mediated Aryl-Amidation 
 
The first task at hand was preparing the precursors for Kishi’s copper–mediated Ullman–
type coupling. The necessary coupling partners 3919 and 5020 were synthesized as outlined in 
Scheme 3.1. Dipeptide 55 was synthesized by an EDCI mediated peptide coupling of acid 53 
and amine 54. The Boc protecting group was removed with TFA and DKP 39 formed by 
refluxing in methanol. The requisite aryl iodide (50) was synthesized in one step from benzoic 
acid 56 by ortho–lithiation followed by quenching with iodine.  
 18 
 
Scheme 3.1. Synthesis of aryl-amide coupling precursors 39 and 50. 
 
With the two coupling partners in hand, we were ready to explore the aryl–amidation 
under Kishi’s conditions. Unfortunately, under these conditions we were unable to obtain the 
desired coupled product 49 (Scheme 3.2).  
 
Scheme 3.2. Attempted aryl–amidation utilizing Kishi’s conditions. 
 
Buchwald and coworkers have studied these aryl–amidation reactions in greater depth in 
the time since Kishi reported his synthesis.21 They have found by combining a diamine ligand 
such as dimethylethylenediamine (57) or cyclohexyldiamine (58) with the copper catalyst, this 
reaction can proceed at lower temperatures than classical Ullman–type conditions (Scheme 
3.3). Another benefit is the use of the copper in catalytic quantities as opposed to the 
stoichiometric amounts utilized by Kishi. The aryl-amidation reaction has also been shown to 
proceed with a palladium catalyst in the presence of a diphosphine ligand such as Xantphos 


















    (73% yield two steps)
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Scheme 3.3. Copper–catalyzed aryl–amidation conditions. 
Scheme 3.4. Palladium–catalyzed aryl–amidation conditions. 
These results prompted us to try alternate coupling conditions in our system (Table 3.1). 
Standard conditions using catalytic copper iodide in the presence of potassium phosphate and 
diamine ligand 57 were attempted first without success (entry 2). Buchwald has suggested that 
the use of a weaker base is advantageous in particularly tough couplings, which led us to try 
potassium carbonate as the base (entries 3 and 4). The coupling was also attempted with 

































Table 3.1. Attempts at using alternate aryl-amidation coupling conditions. 
Reversal of the order of the coupling reaction and ester formation was also attempted
(Table 3.2). Use of either copper iodide or copper chloride in toluene with potassium carbonate 
gave no desired product (entries 1 and 2). A switch to dioxane as a solvent also was attempted 
without success (entries 3 and 4). Lastly, standard palladium–catalyzed conditions proved 














































Table 3.2. Attempted aryl-amidations ultilizing aryl iodide 61. 
 
At this point we were attracted to the idea of using benzylic alcohol 6222 for the synthesis 
of dehydrogliotoxin, due to the fact it is already in the oxidation state required for the 
subsequent steps. The coupling between aryl iodide 62 and DKP 39 was the most extensively 
studied (Table 3.3). We first looked at standard conditions utilizing the three most common 
bases for this reaction: potassium carbonate, potassium phosphate, and cesium carbonate 
(entries 1 – 3). After these proved unsuccessful, diamine ligand 58 was screened (entries 4 and 
5). Replacing the copper source with copper chloride also gave no desired product (entries 6 















































Table 3.3. Attempted aryl-amidation utilizing aryl iodide 62. 
 
To test whether this type of coupling could be carried out with DKP 39, several control 
experiments were conducted. Gratifyingly couplings with DKP 39 and simple aryl iodides such 
as iodobenzene and o–iodoanisole were successful under both copper– and palladium–
catalyzed conditions. Furthermore, couplings with benzylic alcohols, methyl esters, and methyl 
ethers attached to the aryl halide with various substitution patterns are known in the literature;
however there are very few examples of couplings where there are two substituents ortho to the 
halide.21a-c, 23 Such couplings are difficult presumably because formation of the aryl-amide bond 
is very slow, or cannot happen at all, due to sterics. Looking at the mechanism, the first step is 
deprotonation and formation of copper amidate 65. Next is the formation of the aryl-amide bond, 
most likely through an oxidative addition/ reductive elimination sequence. However, if the 
formation of the aryl-amide bond is especially slow, and the rate of deprotonation of the amide is 
particularly fast, then the unreactive cuprate complex 68 is formed, which effectively shuts down





























































Figure 3.1. Mechanism of the copper mediated aryl-amidation. 
 
3.2 Intramolecular Copper Mediated Aryl-Amidation 
 
Having explored several unsuccessful options for intermolecular aryl-amidation, we 
considered a new intramolecular approach (Scheme 3.5). Initially our strategy had been to first 
form bond a by an intermolecular aryl–amidation then bond b by an intramolecular alkylation. It 
is conceivable the same intermediate (69) could be generated by first forming bond b by some 
sort of alkylation then forming bond a through an intramolecular aryl–amidation. We hoped that 
by making this an intramolecular process, we could overcome the difficult coupling step as the 
two coupling partners are in close proximity to each other, and generally intramolecular 



































Scheme 3.5. Revised retrosynthetic analysis of dithioacetal 69. 
 
In accordance with this new strategy, coupling precursor 70 needed to be constructed. 
Both p–methoxybenzyl and benzyl protected DKPs were obtained according to known 
procedures.25 In order to access an appropriate aryl–amidation precursor the alkylations of 71 
and 74 were examined (Scheme 3.6). Benzyl protected DKP 71 could be benzylated with benzyl 
bromide to give 72, a product that lacks the necessary iodide, but still shows that the important 
C-C bond could be formed. Unfortunately, the benzyl protecting groups could not be removed 
from this compound. Hoping that the p–methoxybenzyl protecting group would be removed 
more readily, DKP 74 was also tested in this route. This time utilizing the benzyl bromide22 
needed for the synthesis of dehydrogliotoxin, alkylated product 76 was formed. Unfortunately, 
the protecting groups once again could not be removed and coupling precursor 77 could not be 
formed.   
 
































































Although we could screen other differentially protected DKPs for this alkylation/ 
deprotection sequence, we believed a different approach was warranted. Specifically the 
diketopiperazine ring would be constructed from an amino acid that already contained the 
essential aryl iodide. To that end, coupling precursor 70 would come from DKP formation 
between Boc-sarcosine (78) and unnatural amino acid 79, which itself would ultimately arise 
from alkylation of glycine (80) (Scheme 3.7). 
 
Scheme 3.7. Revised retrosynthetic analysis of coupling precursor 70. 
 
In order to access unnatural amino acid 79, known glycine derivative 81 was prepared.26 
This doubly protected amino acid is known to undergo alkylation with a variety of electophiles 
including benzyl halides. Typically these alkylations are performed under phase–transfer 
conditions; however in our case that proved futile. Conversely, turning to anhydrous conditions 























Scheme 3.8. Alkylation of glycine derivative 81. 
 
With the alkylation complete, the benzophenone imine was hydrolyzed to give amine 79. 
Peptide coupling with Boc-sarcosine (78) gave dipeptide 83, which could be deprotected and 
the ring closed to give coupling precursor 70. Gratifyingly, exposing 70 to standard copper–
catalyzed coupling conditions delivered tricycle 84 in good yield (Scheme 3.9). By performing 
this coupling in an intramolecular fashion we were able to overcome the reactivity issue and 







































Scheme 3.9. Synthesis of tricycle 84. 
3.3 Attempts to Incorporate Sulfur  
 
Having successfully synthesized tricycle 84, we next sought a method for installing the 
requisite disulfide. In analogy to Kishi’s synthesis, we initially attempted to brominate 84; 
however none of the desired product was obtained. Bromination under acidic conditions also 
proved futile (Scheme 3.10).  
 

















































































As outlined in section 2.1, bromination is initially employed in only one of the three 
methods that have led to successful incorporation of sulfur into the DKP framework. Given the 
above results, we next looked at forming an enolate and trapping with a sulfur electrophile. To 
test the viability of this strategy, we first ran a deuterium quenching study of DKP 84 (Table 3.4). 
Using LHMDS as a base at –10 °C lead to a complex mixture of products (entry 1). Switching to 
LDA at –78 °C gave deuterium incorporation solely at the less hindered position, Db (entry 2). 
Warming the solution to 0 °C with LDA as a base not only gave full deuterium incorporation at 
Db, but also gave approximately 50% incorporation at the more hindered position, Da (entry 3). 
The same observation was seen using NaH at 0 °C (entry 4). 
Table 3.4. Deuterium incorperation of tricycle 84. 
 
 
Having demonstrated the feasibility of enolate formation, we next examined the reactivity 
toward various sulfur electrophiles (Table 3.5). Our very first attempt employed the classical 
conditions of sodium amide and elemental sulfur; however no product was observed (entry 1). 
We next surveyed a variety of bases using disulfides as the sulfur electrophile (entries 2 – 5, 7). 
Concerned that the reactivity of the electrophile might be the issue, we turned to a more active 





















LDA -78 0 ~100
LDA 0 ~50 ~100








Although in most of these reactions we observed starting material or decomposition, we did 
observe indole 87 as a byproduct in some cases (Figure 3.2). 
Table 3.5. Attempts at reacting tricycle 84 with a sulfur electrophile. 
 
 
Figure 3.2. Undesired indole byproduct 87. 
 
After unsuccessfully attempting to trap an enolate directly with a sulfur electrophile, we 
explored the use of a silyl enol ether as a nucleophile. However, in our attempts to form bis–silyl 
enol ether 88, we observed no desired product, instead only undesired indole 89 and starting 















































Scheme 3.11. Attempted formation of bis–silyl enol ether 88. 
 
From here it seemed that trapping an enolate or silyl enol ether with an electrophilic 
sulfur reagent was not a viable option, however, there remained a potentially viable approach 
that had not been investigated. This involved oxidizing the DKP with a non–radical oxidant to 
form a hemi–aminal, which would serve as a precursor to an acyl–iminium intermediate which 
would, in turn, react with a sulfur nucleophile. Unfortunately, exposing DKP 84 with either 
Pb(OAc)4 or PhI(OAc)2, while giving a small amount of monoacetate 90, gave undesired indole 
87 as the major product (Scheme 3.12).  
  
Scheme 3.12. Oxidation of DKP 84. 
 
At this point three distinct pathways to incorporate sulfur had been explored 
unsuccessfully. It is not too surprising in hindsight that there were complications involving the 
formation of undesired indole side products given the propensity with which the dihydroindole 
can oxidize to form an aromatic system. Although this route ultimately failed due to the 







































intermolecular aryl–amidation step. Nevertheless, at this point a new route needed to be 

























Chapter Four  
Synthesis of Dehydrogliotoxin 
4.1 Revised Route Towards the Synthesis of Dehydrogliotoxin 
 
Having encountered problems in routes toward the synthesis of dehydrogliotoxin (10) 
that involved both inter– and intramolecular Ullman–type couplings, we sought a synthetic 
strategy that avoided this reaction altogether. Because our ultimate goal was to access 10 in the 
most expedient fashion, we again decided to focus on variations of Kishi’s approach and began 
to consider an alternate strategy utilizing intermediate 49, the product of the problematic aryl–
amidation. Specifically we envisioned a strategy where the recalcitrant C–N bond was 
preassembled and would serve as a template for construction of the DKP (Scheme 4.1). In the 
event, key intermediate 49 would arise from intramolecular ring closure of alkyl chloride 91, the 
bis–amide derived from coupling of aniline 92 and acid 93. Along with generating the necessary 
intermediate 49, an additional potential benefit of this approach is the absence of the metal–
mediated cross coupling that would prohibit the preparation of analogs bearing aryl halides.  
 
Scheme 4.1. Modified retrosynthetic analysis of intermediate 49. 
 
Although simple esterification of the commercially available benzoic acid corresponding 
to aniline 92 would provide the first of the two coupling partners required for our approach, the 


























were pleased to find that large quantities of aniline 92 could be accessed in high yield in four 
steps from inexpensive o–anisidine (94).28 This involved conversion of 94 to the pivaloyl amide 
followed by ortho–lithiation with n–butyl lithium forming an aryl anion that would be quenched 
with carbon dioxide to give benzoic acid 96. Removal of the pivaloyl directing group followed by 
esterification with diazomethane gave aniline 92. Carboxylic acid 93 was synthesized following 
the procedure of Ciufolini wherein sarcosine (97) was acylated with chloroacetyl chloride 
(Scheme 4.2).29 
 
Scheme 4.2. Synthesis of precursors (a) aniline 92 and (b) acid 93. 
 
With straightforward methods to both desired coupling partners in hand, we explored 
their conversion to key intermediate 49. Gratifyingly, the two partners could be joined by first 
converting acid 93 to the acid chloride and adding aniline 92 to give bis–amide 91. The ring–
closure was accomplished upon heating in methanol in the presence of potassium carbonate 
and potassium iodide to give key intermediate 49, thus effecting a formal total synthesis of 







































achieve a formal synthesis, we carried the material through the remaining eleven steps 
according to Kishi’s procedure and obtained dehydrogliotoxin (10) (Scheme 4.3).14b, 14d 
 
Scheme 4.3. Formal total synthesis of dehydrogliotoxin (10). 
4.2 Biological Activity 
 
With a synthesis of dehydrogliotoxin complete, we next were interested in its biological 
activity. Four compounds were sent to our collaborator Dr. Deborah Hung at the Broad Institute. 
Graphs showing the antitubercular activity and human cell toxicity are shown in Figure 4.1, and 
the IC50 values of the antitubercular activity are given in Table 4.1. It was found that synthetic 
dehydrogliotoxin (10) showed significant activity against MTB with an IC50 of 0.13 µM,30 
comparing favorably to gliotoxin (9) our collaborators purchased which exhibited an IC50 of 0.09 
µM. Not surprisingly, 10 also proved significantly toxic as seen in Figure 4.1.b.31 Compound 84, 
which contains the carbon skeleton of dehydrogliotoxin, however lacks the bridging disulfide, 
was not active against MTB and also was the least toxic. Benzyl chloride 48 showed both 
activity against MTB and human toxicity, however this is most likely due to indiscriminate toxicity 
of the benzylic chloride. Lastly dithioacetal 98, which contains the entire dehydrogliotoxin core, 













































supporting the theory that the disulfide is the most important site of the molecule for its observed 
activity. 
 
Figure 4.1. Graphs showing a) antitubercular activity and b) human cell toxicity. 





















































Chapter Five  
Analog Design and the First Synthesis of an Epidiselenodiketopiperazine 
 
With a synthesis of dehydrogliotoxin (10) complete, we next turned our attention to the 
generation of analogs. When examining dehydrogliotoxin we identified three major regions to 
target in analog synthesis: the hydrophobic (blue), the hydrophilic (red), and the disulfide 
(yellow) (Figure 5.1). We initially choose to study the disulfide region.  
 
Figure 5.1. Regions of dehydrogliotoxin that could be modified in analog generation. 
5.1 Replacing the Disulfide with a Diselenide 
 
Although the mode of action of the ETPs is not known, it is believed that the disulfide 
plays an important role in both their activity and their toxicity.13b, 32 In fact it has been shown that 
removal of the disulfide or conversion to a dithioether eliminates antiviral activity in ETPs.16 
Because our eventual goal is accessing potential drug targets, we are interested in finding 
analogs that both retain anti–TB activity, and importantly, exhibit lessened human cell toxicity. 
Toxicity is thought to arise in one of two ways: by forming covalent disulfide bonds with cysteine 
residues in proteins in an unselective fashion or through a redox cycle that forms harmful 
reactive oxygen species (ROS). A schematic showing this redox process is outline in Figure 5.2 















Figure 5.2. Redox cycling of gliotoxin (9) forming harmful reactive oxygen species. 
 
To this end we became interested in replacing the disulfide with a diselenide and thus 
form an epidiselenodiketopiperazine (ESeP). We believed the diselenide would be a good 
bioisostere of the disulfide due to the proximity of the two atoms on the periodic table. Selenium 
is the larger of the two (atomic radius of 1.17 Å vs. 1.04 Å), however that difference is minor 
(only 0.13 Å). As a result of the size difference, the Se–Se bond length (2.30 Å) is larger than 
the S–S bond (2.00 Å). Although there are differences in size of the two, the dimension of the 
unit cell of crystalline hexagonal cystine33 and selenocystine34 are almost identical, suggesting 
that at least in that system the two are isomorphous.35 The disulfide and diselenide also have 
some differences. The difference that we are most interested in exploiting is the redox 
properties of the two. Although the redox properties of ETPs and ESePs have not been 
investigated, the redox potentials of model peptides containing disulfides (E0 = –180 mV), 
diselenides (E0 = –381 mV), and mixed selenosulfides (E0 = –326 mV) have been determined 
using dithiothreitol (DTT, E0 = –323 mV, pH = 7.0) as a reference.36 As can be seen from this 
data, the disulfide is a much better oxidant than the diselenide, which would have implications in 
the redox cycling event described in Figure 5.2. Because it is a better oxidant, more of the open 
dithiol form would be generated, which in turn would lead to a greater production of reactive 
oxygen species. It has been suggested that ROS can play important roles in both cell 
proliferation and cell death, and the difference between the two pathways is dependent on the 




















reported to be –240 mV, while necrotic cells (–150 mV) and apoptotic cells (–170 mV) exhibited 
much more oxidizing environments. Thus, it appears that switching to a diselenide, which would 
favor the closed diselenide form due to its more negative reduction potential, would help reduce 
the presence of ROS in normal cells, which would hopefully lead to lessen toxicity.  
In the literature there are very few examples of bridging diselenides,38 and no examples 
containing the [2.2.2] scaffold we required. Without bias we set off to develop a method to form 
the desired ESeP. To explore this chemistry we first targeted simple ESeP 100 as a model 
system. Our initial strategy was to mimic the method we had previously utilized to incorporate 
sulfur. In that regard, diselenide 100 would come from protecting group removal and oxidation of 
bis–protected selenide 101. Selenium incorporation would arise from a nucleophilic selenium 
reagent reacting with dibromide 22, which would be derived from simple DKP 21. 
 
Scheme 5.1. Retrosynthetic analysis of model diselenide 100. 
 
To investigate this sequence we looked at DKPs protected with either a methyl (102) or 
benzyl (72) group (Scheme 5.2). The bromination was carried out as before and when reacted 
with potassium selenobenzoate, gave diselenides 103 and 104 respectively. Unfortunately, the 
benzoate protecting groups could not be removed in either case under a variety of different 
conditions including: basic, acidic, transesterification (KCN), oxidative (I2), or reductive (DIBAL–
H). Other differentially protected selenium nucleophiles were not fruitful, mostly due to 
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Scheme 5.2. Attempted synthesis of diselenides 105 and 106. 
 
It seemed that reacting a dibromide with a selenium nucleophile was a viable way to 
incorporate selenium, however, because we had problems finding a protecting group that could 
be removed from selenium after incorporation, we sought a method that would incorporate the 
diselenide directly with no protecting groups. Specifically we were interested in reacting a 
diselenide dianion equivalent with an acyl iminium (107) derived from dibromide 22 (Scheme 
5.3). 
 
Scheme 5.3. Proposed reaction of dibromide 22 with a diselenide dianion equivalent. 
 
There are a variety of methods known to generate a diselenide dianion equivalent. 
Initially we tried the classical conditions of combining elemental selenium with either lithium or 
sodium metal to form M2Se2, however no desired product was observed (entries 1 and 2, Table 
5.1). We next looked at other reductants that have been used in this reaction. Unfortunately, 
attempted reductions utilizing superhydride (entry 2), hydrazine (entry 3), or samarium iodide 














    DMF, -45 ºC
(R = Me: 49% yield, two steps)
(R = Bn: 21% yield, two steps)
basic, acidic, KCN





































Table 5.1. Attempts at reacting dibromide 109 with a diselenide dianion equivalent. 
 
 
At this point we were wondering if having the diketopiperazine ring already in place was 
a problem. We thought the diselenide could be installed between two linear amino acids, and 
the DKP could then be formed with the diselenide already in place. To investigate this we 
synthesized bromide 112 from sarcosine derivative 111 through Boc protection and bromination 
under radical conditions (Scheme 5.4.a). Our first attempt utilized elemental selenium and 
superhydride to form the diselenide dianion equivalent. Under these conditions we observed 
none of the desired product, instead obtaining amino acid 111, presumably from reduction with 
superhydride of an in situ generated iminium (Scheme 5.4.b). However, we were able to find 
success by utilizing conditions developed by Krief and Derock to generate a diselenide dianion 
equivalent with elemental selenium, sodium borohydride, DMF, and ethanol, giving diselenide 
113 in moderate yield.39 In a single attempt to form the DKP ring with the diselenide already in 




























Scheme 5.4. a) Synthesis of bromide 112. b) Attempted reaction of bromide 112 with the 
diselenide dianion equivalent derived from Se and superhydride. c) Successful reaction of 
bromide 112 with the diselenide dianion equivalent derived from Se and sodium borohydride. 
Having finally found success forming a diselenide, albeit in a linear system, we decided 
to reinvestigate the system with the DKP already in place. Gratifyingly, by first converting DKP 
72 to the dibromide, diselenide 106 could be formed utilizing the conditions developed by Krief 
and Derock (Scheme 5.5). This constituted the first synthesis of an epidiselenodiketopiperazine 
(ESeP). 
Scheme 5.5. Successful synthesis of diselenide 106 from DKP 72. 
While we were pleased to have successfully synthesized diselenide 106, we ultimately 
wanted to incorporate the diselenide into more complex structures such as dehydrogliotoxin. 
Therefore it would be advantageous to develop a route to convert an ETP to an ESeP directly. 



















































1) NBS, (BzO)2, CCl4, 77°C
2) Se, NaBH4, EtOH, DMF
(33% yield, two steps)
72 106
 42 
would be converted to bis–thiomethyl ether 116 upon reduction with sodium borohydride and 
capture of the resultant thiolates with iodomethane. The sulfur of bis–thiomethyl ether 116 would 
be activated with an electrophile, forming acyl iminium ion 118, which would be reacted with the 
diselenide dianion equivalent to form diselenide 114 (Scheme 5.6).  
 
Scheme 5.6. Proposed synthesis of diselenide 114 from disulfide 115. 
 
Bis–thiomethyl ether 116 was synthesized via a known procedure40 and reacted with a 
variety of electrophiles in hopes of activating the sulfide and promoting acyl iminium ion 
formation (Table 5.2). Hoping to form dimethyl sulfide as a leaving group, a variety of 
methylating conditions were attempted with no success (entries 1–3). Switching to halogenating 
reagents NBS or NCS also lead to no desired product (entries 4 and 5). Eventually we 
discovered that simply utilizing bromine as the electrophile resulted in the conversion of bis–





































Table 5.2. Activation of bisthiomethyl ether 116. 
 
 
With a method to convert bis–thiomethyl ether 115 to dibromide 109 in place, we had 
realized all of the steps in a sequence for converting disulfide 115 to diselenide 106 (Scheme 
5.7). Overall, this sequence involved conversion of ETP 115 to bis–thiomethyl ether 116 with 
sodium borohydride and iodomethane. Reaction of 116 with bromine gave dibromide 109, which 
could be reacted under the same conditions as before to provide ESeP 106 in three steps from 
ETP 115. 
 





































































With the first synthesis of an epidiselenodiketopiperazine accomplished and a method to 
access this ESeP directly from an ETP, we were excited to look at its biological activity against 
MTB. Along with the ETP and ESeP, we were interested in the bis–thiomethyl ether and bis–
selenomethyl ether counterparts due to previous reports that replacing the disulfide with the bis–
thiomethyl ether resulted in loss of activity. Bis–selenomethyl ether 120 was therefore 
synthesized by adding sodium borohydride followed by iodomethane to ESeP 106 (Scheme 
5.8.a). We were also interested in removing the redox active disulfide, while keeping the bicyclic 
scaffold intact. In that regard, we synthesized compound 121, which contained a one–carbon 
linker between the two sulfur atoms, from disulfide 115 (Scheme 5.8.b).   
 
Scheme 5.8. Synthesis of a) bis–selenomethyl ether 120 and b) dithioacetal 121. 
 
With the compounds of interest in hand we sent them to our collaborators for testing 
(Figure 5.3). Disulfide 115, which mimics the epidithiodiketopiperazine natural products, 
exhibited an IC50 of 2.3 µM. This was impressive in itself as 115 is a simplified model of the ETP 
natural products. To our delight diselenide 106 exhibited an IC50 of 2.7 µM, which is comparable 
to the disulfide and suggests that the diselenide could be a potential target for further 
investigation as a drug lead. As expected alkylated disulfides 116 and 121 showed no activity 
against MTB;16 however bis–selenoether 120, although not as potent, was active with an IC50 of 






































however this is most likely a prodrug effect where the acetate is being cleaved in situ and the 
disulfide is forming in the assay. 
 
Figure 5.3. Activity of compounds tested against MTB. 
 
Having successfully found a method to convert an ETP to an ESeP and after 
demonstrating that an ESeP has comparable activity to an ETP in a model system, we next 
looked at translating to a more complex system with the eventual goal of trying this sequence on 
dehydrogliotoxin (Scheme 5.9). Specifically we wanted to see if having substitution on the 
carbon bearing the disulfide would be tolerated in the sequence. To test this disulfide 126 was 
formed in seven steps. Commercially available DKP 123 was protected and subjected to the 
bromination/ nucleophilic sulfur displacement to give bis–thioacetate 124. Removal of the 
acetate protecting groups and formation of the dithioacetal produced 30. Addition of n-BuLi in 
the presence of BOMCl gave bis–alkylated product 125, which was deprotected to give disulfide 
126. Conversion to bis–thiomethyl ether 127 proceeded uneventfully. Unfortunately, the 
conversion of bis–thiomethyl ether 127 to diselenide 128 did not proceed. This reaction was 
only attempted once and warrants further investigation; however at this time I turned my 
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(20% yield two steps)
1) HCl, MeOH
2) p-anisaldehyde
    BF3•Et2O, CH2Cl2
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The Tetrapetalones  
 
Tetrapetalone A was isolated in 2003 by Hirota and coworkers from a culture filtrate of 
Streptomyces sp. USF-4727.1 In 2004 the structurally related tetrapetalones B, C, and D were 
isolated from the same Streptomyces strain.2 The tetrapetalones have shown inhibitory activity 
against soybean lipoxygenase (SBL), which is similar to human lipoxygenase and 
cyclooxygenase, which have relevance in a variety of human diseases. We became interested 
in the tetrapetalones due to their interesting structural features and the synthetic challenge they 
present.  
6.1 Isolation and Structure Determination 
 
During their quest to discover new lipoxygenase inhibitors, Hirota and coworkers, while 
screening soil Streptomyces sp. strains using a well-known SBL assay, discovered the novel 
soybean lipoxygenase inhibitor tetrapetalone A from a culture filtrate of Streptomyces sp. USF-
4727 in 2003.1a This particular soil sample was taken from Yada, Shizuoka City, Japan. 
Tetrapetalone A was isolated as a pale yellow amorphous powder with a melting point of 190 °C 
and a molecular formula of C26H33NO7. Through extensive NMR studies including 1H, 13C, 
DEPT, 1H–1H COSY, HMQC, HMBC and 2D–INADEQUATE experiments they proposed 
structure 129 as the structure of tetrapetalone A (Figure 6.1). The relative stereochemistry of 
129 was determined through analogy of the sugar moiety to β-rhodinose and through NOESY 
correlations. The absolute stereochemistry of 129 was determined by analysis employing the 
modified Mosher’s method to the oxygens attached to C(4’) and C(9). The latter analysis 
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following hydrolysis of the appended deoxy sugar. The stereochemistry at C(4) and C(15) were 
not reported in the initial publication.    
 
Figure 6.1. Initially proposed structure of tetrapetalone A. 
 
In 2003, in an attempt to confirm the position and type of nitrogen atom in tetrapetalone 
A, Hirota and coworkers performed a 1H–15N HMBC experiment and found the data was 
inconsistent with their initially proposed structure. Specifically they noted a long range coupling 
between the nitrogen and the proton on the ethyl group, which is not possible in structure 129. 
Therefore they revised the structure of tetrapetalone A to be 130.1b Additionally they were able 
to assign the absolute stereochemistry of 130 from the data already reported and extensive 
NOESY studies of 130 and methylated derivative 131 (Scheme 6.1). This included the 
previously unassigned C(4) and C(15) and revise the stereochemistry of C(8).   
 
Scheme 6.1. Revised structure of tetrapetalone A (130) and conversion to tetrapetalone A-Me2 
(131). 
 
In 2004, after further investigations of the culture filtrate of Streptomyces sp. USF-4727, 














































C (133), and D (134) (Figure 6.2).2 These compounds are structurally related to tetrapetalone A 
and only differ in oxidation of the ethyl group (132), oxidation of the tetramic acid moiety (133), 
or oxidation at both the ethyl group and the tetramic acid (134). The structures of 132 – 134 
were assigned through various NMR studies and through analogy to 130.  
 
Figure 6.2. Tetrapetalones B (132), C (133), and D (134). 
 
In 2008, Hirota and coworkers identified ansaetherone (135) from the same 
Streptomyces strain as the tetrapetalones while screening with a radical scavenging assay 
(Figure 6.3).3 Ansaetherone was isolated as a colorless amorphous powder and found to have a 
molecular formula of C26H33NO7. The structure was elucidated utilizing 1H, 13C, DEPT, 1H–1H 
COSY, HMQC, and HMBC NMR experiments. The relative stereochemistry of 135 was 
assigned through NOE correlations and the absolute stereochemistry through analogy to the 
tetrapetalones, however the stereochemistry at C(2) and C(17) could not be assigned. Given 
the structural similarities, Hirota and coworkers proposed ansaetherone to be a biosynthetic 







































Figure 6.3. Structure of ansaetherone (135). 
6.2 Biosynthesis 
 
As noted above the Hirota group proposed that ansaetherone was a biosynthetic 
precursor to the tetrapetalones.3 However, as they had isolated both the tetrapetalones and 
ansaetherone from the same Streptomyces strain, they were interested in further exploring the 
biosynthetic origins of these compounds. Through feeding studies of isotopically labeled 
precursors it was determined that the tetrapetalone core was derived from three molecules of 
propionate (136), one butyrate (137), one glucose (138), and one 3-amino-5-hydroxybenzoic 
acid (AHBA, 139).4 Thus, it was proposed that tetrapetalone A was biosynthesized by a 
polyketide synthase using 139 as a starter unit, and proceeding with ansaetherone as an 



























































































































Chapter Seven  
Previous Synthetic Efforts 
 
Although there have been no completed syntheses of any members of the 
tetrapetalones, there has been significant interest in the family. There are published reports in 
the literature from the Porco,5 Sarpong,6 and Hong7 groups that outline progress towards the 
total synthesis of tetrapetalone A (130). There is also a single report from Yang et al. that 
outlines the syntheses of (+)-Q-1047H-A-A (140) and (+)-Q-1047H-R-A (141) (Figure 7.1),8 
which they propose could possibly be converted to tetrapetalone A. However, given the limited 
similarity to 130, including the presence of a methyl group at C(4) instead of an ethyl and no 
clear way to form the C(4)–N or C(7)–C(15) bonds, further discussion of this report is omitted. If 
you search tetrapetalone in SciFinder you can find abstracts of posters presented at ACS 
meetings from the Frontier, Pettus, and Kobayashi groups. However, as these posters cannot 
be accessed their work will not be discussed here.  
 





























7.1  Porco’s Efforts Towards Tetrapetalone A 
 
Porco and coworkers envisioned constructing tetrapetalone A (130) through a late stage 
transannular [4+3] cyclization process (Scheme 7.1).5a They believed this could proceed via one 
of two pathways. Utilizing quinone 143 under UV irradiation would form intermediate 142 
through an excited-state intramolecular proton transfer, which could undergo a formal [4+3] 
process.  Conversely, hydroquinone 145 could be oxidized to oxonium 144 and undergo a 
formal [4+3] cycloaddition. Hydroquinone 145 would be formed from triene 146 by a ring–
closing metathesis, and 146 would arise from an amidation of amide 148 with acid 147.  
  













































































To explore this [4+3] cyclization process, Porco and coworkers set out to form protected 
hydroquinone 146 (Scheme 7.2). To accomplish this aniline 148, available in three steps from 
known materials, was added to the in situ generated acid chloride of carboxylic acid 147, which 
was available in three steps from known materials. Unfortunately, subjecting triene 146 under
ring–closing metathesis conditions lead to no desired product. The authors believe that the 
catalyst was able to react with the monosubsitituted olefin, but not the 1,1–disubstituted olefin. 
Furthermore, due to the meta relationship of the two pieces and the presence of the ortho–
subsituted methoxy group, it was speculated that considerable conformational strain prohibited
proper overlap of the two double bond containing side chains.  
Scheme 7.2. Porco’s attempted ring-closing metathesis of triene 146. 
Having failed at ring-closing metathesis, the Porco group next explored a pathway where 
hydroquinone 145 would derive from nitrobenzene 151 via reduction and acyl migration. This 
macrocycle would be formed from O–acylation followed by ring–closing metathesis, and would 
















































Scheme 7.3. Porco’s revised retrosynthetic analysis of intermediate 145. 
 
In the event, benzylic alcohol 154, available in three steps from known materials, 
underwent a silyl migration to form intermediate alkoxide 155, which could be reacted with acid 
chloride 153 to give ester 156. Ring–closing metathesis followed by deprotection gave 
macrocycle 151, which could be converted to the desired hydroquinone (145) following 
reduction of the nitro group and exposure to silica gel. Hydroquinone 145 was unstable and was 
therefore used directly in the next step.   
 
Scheme 7.4. Porco’s synthesis of hydroquinone 145. 
 
With access to hydroquinone 145, the Porco group next explored their key transannular 























































1)     Grubbs II
    benzene, 80 °C
2) TBAF, HOAc







































reporting tetracycle 157 was formed, did not obtain any of the desired product, instead isolating
quinone 158 as the only product. This error was disclosed in a revision to the original 
manuscript (Scheme 7.5).5b  
 
Scheme 7.5. Porco’s attempted synthesis of tetracycle 157. 
7.2 Sarpong’s Efforts Towards Tetrapetalone A 
Sarpong and coworkers believed tetrapetalone A (130) could arise from late stage 
phenolic oxidation and glycosylation of tetracycle 159.6b The tetramic acid moiety would be 
assembled from a corresponding pyrrole while the olefin in the seven membered ring would 
derive from the ketone in 160. Pyrrole 160 would ultimately arrive from aryl bromide 161 in a 
number of steps including a key Nazarov cyclization.    
Scheme 7.6. Sarpong’s retrosynthetic analysis of tetrapetalone A (130). 
Beginning with dibromide 162, Sarpong and coworkers formed aryl ketone 161 after 


































































proceded in the presence of AlCl3, however gave a 9:1 mixture of the undesired cis–diasteromer
of the product. Exposure of the undesired isomer to potassium carbonate in warm dioxane 
induced epimerization and furnished the desired trans–diastereomer 164 in a 4:1 diastereomeric 
ratio. Reduction and protection of the ketone followed by conversion of the aryl bromide to an 
aryl azide provided intermediate 165. This could be converted to the desired aryl pyrrole 166
through reduction of the azide and condensation of the resultant aniline with 2,5–
dimethoxytetrahydrofuran (167) (Scheme 7.7). 
 
Scheme 7.7. Sarpong’s synthesis of intermediate 166. 
The seven–membered ring of tetrapetalone A (130) was formed in an interesting two 
step protocol that began with a hydroboration–oxidation sequence applied to aryl pyrrole 166 to 
provide primary alcohol 168 and concluded with an oxidation that employed the Dess–Martin 
periodinane. The seven-membered ketone 160 was formed presumably after initial oxidation 
produced aldehyde 169, which in turn underwent a Friedel–Crafts type reaction, possibly with 
the aid of an iodine Lewis Acid or hydronium ion, to give secondary alcohol 170. This alcohol 
could then be oxidized a second time to generate the observed product. Reduction of the 
derived pyrrole and installation of the requisite ethyl group to furnish 171 was accomplished via 


















2)       K2CO3
    dioxane, 80 °C(88% yield)









1) NaBH4, MeOH, 0 °C
2) TBSCl, imid., DMF, 80 °C
3) t-BuLi, THF, -78 °C
          then Ts-N3







1) LiAlH4, THF, 0 °C
2)  167, AcOH
    CH2Cl2, H2O






Mn(OAc)3•2H2O produced lactam 172, which could be converted to the desired tetramic acid 
(173) in a four step sequence (Scheme 7.8). Tetracycle 173 is the most elaborated compound 
reported by Sarpong and coworkers. Major challenges left in their synthesis include conversion 
of the ketone in the seven–membered ring to an olefin, removal of the TBS group from the 
benzylic alcohol followed by inversion of that alcohol stereocenter, introduction of the sugar 
moiety, and phenolic oxidation. 
Scheme 7.8. Sarpong’s synthesis of tetracycle 173. 
7.3 Hong’s Synthetic Studies Towards the Core of Tetrapetalone A 
In 2009, Hong and coworkers published a report detailing synthetic studies on the 
















































































2)    B2Pin2, CuCl
    NaOtBu, 172, THF
3) NaBO3, THF, H2O
4) (COCl)2, DMSO
    Et3N, CH2Cl2, -78 °C






(130). Their strategy includes a key Speckamp cyclization, which involves formation of an N-
acyl iminium ion (176) that can be trapped with the pendant olefin forming a secondary 
carbocation (177) that can be quenched with a nucleophile to form the six–seven–five system 
as seen in 178 (Scheme 7.9).  
 
Scheme 7.9. Hong’s proposed synthesis of the six–seven–five skeleton of tetrapetalone A. 
 
Their synthesis began with allylic alcohol 179. Johnson–Claisen rearrangement followed 
by reduction of the resultant ester to the primary alcohol and protection as the benzyl ether gave 
180. Reduction and condensation with succinic anhydride gave imide 181, which could be 
monoreduced to give hydroxylactam 182. Upon exposure to iron trichloride, hydroxylactam 182 
underwent the key Speckamp cyclization giving a mixture of diastereomeric tetracycles 183 and 
184 (Scheme 7.10).  
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(36% yield) (47% yield)
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The major diastereomer from the Speckamp cyclization (184) was oxidized to give 
lactone 185. Exposure to polyphosphoric acid led to a Friedel–Crafts/ dehydration sequence 
that furnished tetracycle 186. Although tetracycle 186 contains the carboskeleton required for 
tetrapetalone A, it lacks most of the functionality of the natural product. Although there are 
several interesting steps in the Hong synthesis, considerable effort remains for conversion of 
their most advanced intermediate to 130. 
 



































Chapter Eight  
Previous Approaches in the Wood Group 
 
Prior to my taking over the tetrapetalone project a previous student, Dr. Jennifer Howell, 
had explored several strategies for incorporating various requisite functional groups. As my 
work was inspired by Dr. Howell’s effort, it will be summarized here.9 
The first synthetic route studied in our group is outlined in Scheme 8.1. In that scenario 
tetrapetalone A (130) was envisioned as arising from late stage glycosylation and deprotection 
of tetracycle 187. A key disconnect in this route was a ring–closing metathesis to form the seven 
membered ring employing diene 188 as a substrate. The two required olefin components would 
be installed via a Buchwald–Hartwig coupling of vinyl halide 189 and amide 190.  
 
Scheme 8.1. Initial retrosynthetic analysis of tetrapetalone A (130). 
 
In order to explore the desired Buchwald-Hartwig coupling, initial efforts focused on the 
synthesis of vinyl halide 189. To access this intermediate it was envisioned that ketone 191 
would be reduced and protected. Ketone 191 would arise from an intramolecular Stetter 











































193. Ester 193 was seen as arising via a Claisen rearrangement applied to allylic alcohol 194, 
the product of a Wittig olefination of benzaldehyde 195 (Scheme 8.2).   
 
Scheme 8.2. Retrosynthetic analysis of vinyl halide 189. 
 
In accord with our retrosynthetic plan the synthesis began with a known two step 
sequence to form aldehyde 197 from phenol 196.10 Aldehyde 197 was then transformed in three 
steps to allylic alcohol 198. Although subjecting 198 to a Johnson–Claisen rearrangement 
provided a rearranged product, it preferentially gave the undesired syn–diastereomer 199 in a 
20:1 ratio over the desired anti–diastereomer (Scheme 8.3)   
 
Scheme 8.3. Synthesis of undesired syn diastereomer 199. 
 
After extensive research, it was found that allylic ester 201 could be formed in five steps 




















































two steps three steps
CEt(OEt)3
EtCO2H




that furnishes the desired anti–product 202.11 The latter was readily transformed into phenolic 
oxidation product 203 in five steps, however, efforts to employ 203 as a substrate in a Stetter 
reaction failed, presumably due to the sensitivity of this transformation to subtle changes in 
sterics (Scheme 8.4) 
 
Scheme 8.4. Unsuccessful attempts of the Stetter reaction to form 204. 
 
Due to the difficulties encountered with the Stetter reaction, a new strategy was devised. 
Ultimately tetracyclic intermediate 187 would be formed from aryl bromide 206 and tetramic acid 
190. The key difference in this route is the aryl–amidation and the Stetter reaction would be 
performed in reverse order, and therefore the Buchwald–Hartwig coupling would occur between 
206 and 190 (Scheme 8.5). 
 

















five steps LiHMDS, Et3N
toluene
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In accordance with this strategy, the requisite tetramic acid 210 was prepared from the 
corresponding amino acid derivative 208, which was in turn available in eight steps from serine 
methyl ester hydrochloride (207). In the key step for the formation of tetramic acid 210, a 
Dieckmann cyclization of 208 provided protected tetramic acid 209, which could be converted to 
the desired tetramic acid 210 in two steps. However, all attempts to couple 210 with aryl 
bromide 211 or derivatives of 211 were unproductive (Scheme 8.6).  
 
Scheme 8.6. Attempted Buchwald–Hartwig coupling to form 212. 
 
In order to circumvent this unsuccessful Buchwald–Hartwig coupling, the coupling 
partners were simplified (Scheme 8.7). In that regard, aryl bromide 213 and allyl amine were 
found to successfully form aryl amine 214 under palladium–catalyzed conditions. Conversion of 
214 to allylic ester 216 via a two step sequence set the stage for a lithium enolate Claisen 
rearrangement analogous to that employed previously. Methylation of the derived product 
produced the RCM substrate 217. Unfortunately, exhaustive efforts to implement the ring–






































Scheme 8.7. Unsuccessful attempts at ring–closing metathesis. 
After the unsuccessfull attempts to perform a Buchwald–Hartwig coupling and 
subsequent ring–closing metathesis, Dr. Howell attempted to simply reverse the order of these 
steps (Scheme 8.8). Specifically, tetracyclic intermediate 187 was now seen as arising from an 
intramolecular Buchwald–Hartwig coupling of 219, which itself would be the product of 
saponification of eight–membered lactone 220. Lactone 220 would come from a ring–closing 
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Scheme 8.8. Revised retrosynthetic analysis. 
 
To explore the viability of this route for delivering tetrapetalone A (130), carboxylic acid 
222 and tetramic acid 223 were coupled together to form lactone 221. Unfortunately, the ring 
closing metathesis of 221 was unsuccessful and did not lead to any of the desired eight–
membered lactone 220 (Scheme 8.9). Many variants of 221 were explored, including 
compounds bearing other tethers and compounds set up for relay ring–closing metathesis; 



















































Scheme 8.9. Attempted ring–closing metathesis to form lactone 220. 
 
As outline in Scheme 8.10, a new route for the synthesis of tetrapetalone A (130) was 
designed wherein intermediate 187 was seen as arising from diene 224 via a sequence that 
would involve an RCM reaction to construct the seven–membered ring and a Dieckmann 
condensation to complete the tetramic acid. It was postulated that performing the ring–closing 
metathesis prior to Dieckmann condensation would be beneficial due to increased 
conformational flexibility in the substrate. Key intermediate 224 would be formed from a 
Buchwald–Hartwig coupling of aryl halide 225 and amino acid derivative 226.  
 
Scheme 8.10. Revised retrosynthetic analysis of intermediate 187. 
 
Efforts to implement this latest strategy began with the preparation of aryl chloride 229. 
































































Subjecting silyl enol ether 228 to an intramolecular Tsuji–Trost allylation furnished 229 in 
moderate yield. To test the viability of the required aryl–amidation reaction, aryl chloride 229
was reacted with allyl amine to give aniline 230. Although the yield is low, it shows that this 
route may be viable in a synthesis of tetrapetalone A (130). This however, is where Dr. Jennifer 
Howell’s work towards 130 ended. 
 












































Formation of the Seven–Membered Ring Utilizing the Aromatic Ring as a 
Nucleophile 
 
Although Dr. Jennifer Howell left a route in place towards tetrapetalone A (130) that was 
beginning to show some promise, concern over the limitation in scope of the requisite aryl–
amidation reaction and numerous low yielding steps led us to consider a different approach.  
9.1 Cascade Friedel–Crafts Approach 
 
As illustrated in retrosynthetic fashion, our initial efforts to redesign the synthesis 
focused on a plan wherein a key cascade Friedel–Crafts reaction would furnish the tetracyclic 
core of 130. Specifically, 130 was seen as arising from tetracycle 232 via a sequence involving 
phenolic oxidation, glycosylation, and decarboxylation (Scheme 9.1). Tetracycle 232 would, in 
turn, arise from the key cascade Friedel–Crafts sequence in which both the five– and seven–
membered rings would be formed. To access 233, tetramic acid 234 would be employed in a 
1,4–addition followed by a Horner–Wadsworth–Emmons olefination. Tetramic acid 234 would 
be formed rapidly from simple precusors 235 and 236. 
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Scheme 9.1. Retrosynthetic analysis of tetrapetalone A (130). 
 
In putting our plan into practice, commercially available 3–aminophenol (233) was 
alkylated with α–bromo ketone 236 to give aniline 237. Exposure to acetic acid in toluene 
provided the corresponding lactam, which was subsequently protected to give 234. Ketone 234 
could be successfully deprotonated; however subjecting the derived enolate to aldehyde 238 
gave a complex mixture of products including the presence of a 1,2–addition product and the 


















































Scheme 9.2. Attempted synthesis of 1,4–adduct 239. 
 
Given the presence of a 1,2–addition product in our previous attempt, we sought a 
method to eliminate this possibility and favor the desired 1,4–adduct 239. Upon searching the 
literature we became inspired by a report from Yamamoto and coworkers that detailed the use 
of a bulky Lewis acid (241) to help favor 1,4– and 1,6–addition to aldehydes such as 240 over 
the corresponding 1,2–addition product (Scheme 9.3).12 They found that by initially forming the 
bulky Lewis acid–aldehyde complex 242, then adding a nucleophile such as t–butyl magnesium 
chloride, they could obtain a >99:1 ratio of the desired 1,4–product 243 over 1,2–product 244. 
Delightfully, applying this bulky Lewis acid led, presumably, to the preformed aldehyde complex 
(245) which, upon addition of the enolate derived from ketone 234 furnished exclusively the 1,4–
addition product 239 in good yield. This could be further elaborated to acid 247 through a 
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Scheme 9.3. Yamamoto’s bulky Lewis acid. 
 
 
Scheme 9.4. Synthesis of acid 247. 
 
With acid 247 in hand we were next ready to investigate the key cascade Friedel–Crafts 
reaction. This reaction is imagined to proceed via the pathway outlined in Scheme 9.5. Exposing 
acid chloride 233 to a Lewis acid would activate the leaving group, forming acylium ion 248. 
Exposure to light would promote a sequence wherein the undesired E–olefin could isomerize to 
the requisite Z–olefin (i.e. 248 to 251). Oxonium 251 could be quenched via a Friedel–Crafts 
1,4–addition from the electron rich aromatic ring forming ketene 252 and the seven–membered 
ring of tetrapetalone A. Nucleophilic attack from the aromatic ring towards the electrophilic 
ketene would eventually lead to tetracycle 253. Although we recognized this was an ambitious 
sequence to propose, we were inspired by work from Wasserman and coworkers that showed in 
enone 254 they could effect an olefin isomerization in the presence of light before effecting a 
conjugate addition to form β–amino ketone 256 (Scheme 9.6.a).13 Furthermore we had 


































































on a number of reports including the formation of ketone 258 from carboxylic acid 257 (Scheme 
9.6.b).14  
 
Scheme 9.5. Proposed cascade Friedel–Crafts to form tetracycle 253 from acid chloride 233. 
 
 
Scheme 9.6. Literature precedent showing a) an olefin isomerization before conjugate addition 














































































































In accordance with the above strategy carboxylic acid 245 was converted to acid 
chloride 233 and subjected to various conditions to perform the desired cascade Friedel–Crafts 
reaction (Scheme 9.7). Unfortunately, under none of the screened conditions was the desired 
product 253 obtained. To test the reactivity of acid chloride 233 in a Friedel–Crafts reaction, it 
was reacted with anisole and ketone 259 was obtained (Scheme 9.8). Thus it appeared the 
isomerization of the double bond was not occurring and a new strategy was devised. 
  
Scheme 9.7. Attempts at cascade Friedel–Crafts pathway. 
 
 
Scheme 9.8. Successful Friedel–Crafts with anisole. 
 
9.2 Intramolecular π-Allyl Approach 
 
Given the difficulties that occurred in the isomerization event in the cascade Friedel–
Crafts strategy, we became interested in other bond forming strategies that could both facilitate 































































ring. We believed that a palladium π-allyl species offered a nice solution due to the fact that 
palladium π-allyls can exist in both η1 and η3 binding modes, and the presence of an η1-π-allyl 
would allow for bond rotation and olefin isomerization (Scheme 9.9). In that regard previously 
synthesized aldehyde 239 would be converted to allylic carbonate 260 by Grignard addition and 
trapping the resultant alkoxide with methyl chloroformate. Exposing allylic carbonate 260 to 
palladium(0) would form palladium π-allyl 261, which could undergo an olefin isomerization 
event through an η1-π-allyl intermediate 262 to form π-allyl 263. Attack from the aromatic ring 
would construct the requisite seven–membered ring giving intermediate 264. 
   
Scheme 9.9. Proposed π-allyl pathway to form the seven–membered ring (264). 
 
To test the viability of the palladium π-allyl reaction, aldehyde 239 was reacted with 
methyl Grignard followed by methyl chloroformate to give allylic carbonate 265. Subjecting 265 
to palladium(0) resulted only in starting material and none of desired product 266. In order to 
help promote this reaction, specifically to help with the oxidative addition, bisallyl carbonate 268 
was synthesized in a similar fashion to 265. Subjecting 268 to palladium(0) at 110 °C resulted in 































































structure of 269 was obtained to verify its structure. A potential mechanism for the formation of 
this interesting compound is depicted in Scheme 9.11. Initial oxidative addition of allylic 
carbonate 268 forms η3-π-allyl 271. Migration to η1-π-allyl 272 allows for bond rotation and 
subsequent formation of η3-π-allyl 273. It is important to note that the olefin isomerization 
observed in this product is precisely what we desired in our planned reaction, and η3-π-allyl 273 
is the intermediate we hoped to access. However at this point the reaction deviates from our 
plan. Instead of the aromatic ring acting as a nucleophile, we are observing nucleophilic attack 
from the ketone towards the π-allyl forming oxocarbenium 274. A transannular Prins–type 
reaction then leads to observed fused tricycle 269, the product of a formal [3+2] cycloaddition. 
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Scheme 9.11. Proposed mechanism for the formation of fused tricycle 269. 
 
In considering the mechanism leading to the production of 269 we became curious as to 
what effect removing the terminal methyl group would have on the course of the reaction.  
Elimination of a proton from this methyl group furnishes the exomethylene and was seen as 
potentially facilitating the observed Prins–type reaction. We hypothesized that removal of this 
methyl group entirely could potentially eliminate this undesired pathway thereby leading to 
reformation of palladium π–allyl species 273 and potentially the desired product. Gratifyingly, by 
utilizing the compound lacking the methyl group (275) none of this undesired formal [3+2] 
product was obtained. It also however, did not give the desired seven–membered product, 
instead giving undesired five–membered product 276 (Scheme 9.12). Although this mode of 
cyclization was a concern, we were uncertain to what extent ring strain and sterics would govern 
the 5– vs. 7–membered ring formation. Clearly this experiment establishes the regiochemical 
preference; however, more importantly it demonstrated that a π–allyl species could be formed 
and trapped with the aromatic nucleophile in our system. Thus we sought a way to bias the 
























































































































Chapter Ten  
A Transannular π-Allyl Approach 
 
Although in the previous approach we were unable to form our desired product, we 
established that a palladium π–allyl species could be formed and would undergo E–to–Z 
isomerization to furnish a π–allyl intermediate capable of undergoing nucleophilic attack by the 
pendant aromatic ring. Encouraged by these results we initiated an effort to adjust the 
regiochemical outcome so as to favor the formation of the desired seven–membered ring. 
10.1 A Transannular π-Allyl Approach 
 
In order to control the regiochemistry, we envisioned starting with a ten–membered ring 
and forming the desired 5,7–ring system through a transannular attack from the aromatic ring 
onto a palladium π–allyl species. In accordance with this strategy tetrapetalone A (130) would 
ultimately arise from hydroboration, glycosylation, phenolic oxidation, and decarboxylation of 
277. Tetracycle 277 would be the product of the key transannular palladium π–allyl reaction, 
which would utilize allylic carbonate 278 as a starting point. It is important to note that while in 
this route we are choosing to start with the allylic carbonate shown, this reaction could be 
initiated from a regioisomeric allylic carbonate, and thus gives us flexibility in our synthetic 
approach. Nevertheless, allylic carbonate 278 would arise from triene 279 through a ring–
closing metathesis. Although previous routes toward 130 employing a ring–closing metathesis 
have failed, we believed this particular substrate had advantages relative to the other 
approaches. The monosubstituted olefin is more remote to the fully substituted carbon rather 
than being neopentyl as in other approaches in our group (cf. Chapter 8). In comparison to 
Porco’s failed ring–closing metathesis, wherein the substrate contained a meta–substituted 
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aromatic ring, there is only a proton in the ortho position compared to the bulkier methoxy group 
in their case (cf. 146 to 149, Scheme 7.2). Triene 279 would come from ketone 280 after a 1,4–
addition/ elimination followed by Wittig sequence and a Grignard addition into the methyl ester, 
and ketone 280 would be formed from aniline 281 and alkyl bromide 238 (Scheme 10.1). 
 
Scheme 10.1. Retrosynthetic analysis of 130 utilizing a transannular π-allyl reaction. 
 
A more detailed mechanistic pathway for the proposed transannular palladium π–allyl 
reaction is outlined in Scheme 10.2. As illustrated, it was envisioned that initial oxidative addition 
to allylic carbonate 278 would provide η3-π-allyl 282. By inspecting molecular models, it does 
not appear this palladium π–allyl species is accessible by the aromatic ring with the neighboring 
olefin in the E orientation. However, migration to η1-π-allyl 283 would allow for bond rotation and 
migration to give η1-π-allyl 285, which now contains the requisite Z–double bond and appears to 
be conformationally accessible to undergo nucleophilic attack from the aromatic ring to lead to 




























































Scheme 10.2. Proposed transannular palladium π-allyl reaction. 
 
To explore the plan outlined above, we initially set out to prepare triene 279. Ester 28115 
was chosen as a departure point due to the fact it was a known compound and we believed the 
presence of the methyl ester would be a good precursor to the allylic alcohol we eventually 
wanted to synthesize (i.e 279, Scheme 10.1). With that in mind, ester 281 was alkylated with 
alkyl bromide 238 under the same conditions as used previously (see: 236 to 237 Scheme 9.2). 
Unfortunately, the presence of the electron withdrawing ester lessened the reactivity of the 
aniline and 286 was only formed in 17% yield. Efforts to increase this yield by changing the 
iodide source, adding base, or adding silver did not lead to improvement, only to similar yields in 
the best case or more decomposition in the worst. Although the yield was low we decided to 
move forward and explore the subsequent chemistry. Aniline 286 could be converted cleanly to 
tetramic acid 280 after ring–closure and TIPS protection. The requisite diene was installed with 
the 1,4–addition/ elimination sequence utilizing the bulky Lewis acid developed by Yamamoto 
and coworkers, and the resultant aldehyde olefinated under Wittig conditions. At this point the 
ester needed to be converted to the allylic carbonate, however this ester once again proved 




















































only giving trace product (Scheme 10.3). Given the deleterious influences of the methyl ester, 
we began to consider alternative routes wherein the ester has been removed. 
 
Scheme 10.3. Synthesis of unreactive ester 287. 
 
10.2 Implementation of Hartwig’s Borylation Conditions 
 
Given the difficulties with the ester we decided to return to the original method of building 
the tetramic acid by employing 3–aminophenol (235) as the aromatic precursor (cf. 235 to 234, 
Scheme 9.2). Although removing the ester is advantageous for the production of 234, it creates 
a new problem in that we have an unreactive C–H bond in 234 where we eventually need an 
allylic alcohol (Scheme 10.4.a). Therefore we sought a method to selectively functionalize this 
position to form an intermediate (290), which contains functionality that could eventually be 
transformed into allylic alcohol 279. Due to the presence of the electron donating methoxy 
group, we believed classical electrophilic aromatic substitution would not be compatible with the 









































          80 °C
2) TIPSCl, imid.
       CH2Cl2





















(14% yield, two steps)
1) NaHMDS
    THF, toluene
2) KHDMS,





coworkers, who described that by employing a catalyst system based on [Ir(OMe)(cod)]2 and 
dtbpy as a ligand in the presence of B2Pin2, they could functionalize aromatic C–H bonds and 
obtain aryl boronic esters such as 292 as products (Scheme 10.4.b).16 Furthermore they found 
that when the starting arene contained two substituents in a 1,3–orientation (i.e. 291) they could 
exclusively obtain the 1,3,5–substituted product 292. They propose that steric effects 
predominate in determining the observed regioselectivity in this reaction, and in fact they could 
utilize compounds bearing both electron donating and withdrawing groups successfully.  
 
Scheme 10.4. Hartwig’s iridium–catalyzed borylation. 
 
Excited by the possibilities this transformation could provide, TIPS–protected phenol 234 
was subjected to the standard borylation conditions developed by Hartwig and coworkers. 
Unfortunately only starting material was obtained (Scheme 10.5.a). Although the Hartwig group 
was successful using one bulky group such as –OTIPS, they did not report any substrates 
possessing two bulky groups such as the –OTIPS and tetramic acid moieties in our substrate 
(234). In an effort to minimize the steric demand in our substrate, we opted to switch our TIPS 
protecting group to the sterically less demanding methyl, and therefore 295 was prepared in one 
PinBH
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step from phenol 294. Gratifyingly, subjecting methyl–protected phenol 295 to the borylation 
conditions delivered aryl boronic ester 296 in good yield (Scheme 10.5.b).  
 
Scheme 10.5. a) Unsuccessful borylation of 234 and b) successful borylation of 295. 
 
With aryl boronic ester 296 in hand, we next explored methods to further elaborate this 
compound (Scheme 10.6). Our initial thoughts were to utilize boronic ester 296 directly in a 
Suzuki coupling. In accordance with this, aryl boronic ester 296 was coupled with 2–butenyl 
bromide to give styrene 297. Exposure to a one–pot dihydroxylation/ oxidative cleavage 
furnished aryl ketone 298. We hoped that we could selectively functionalize the kinetically more 
accessible aryl ketone by converting it to silyl enol ether 299 or enone 300. However, this was 
























































Scheme 10.6. Synthesis of bisketone 298. 
 
While we were exploring the reactivity of aryl ketone 298, we also were investigating 
other routes to enone 300. Given the two–step procedure we were utilizing for the production of 
298 plus at least one more step for the installation of the exomethylene, we believed a more 
direct route could be realized. Specifically we imagined enone 300 could be formed directly from 
aryl bromide 301 through a carbonylative Stille reaction (Scheme 10.7).17 Although we would 
have to access aryl bromide 301 from aryl boronic ester 296, Hartwig and coworkers have 
shown that their iridium–catalyzed borylation products can be converted to aryl bromides by 
simply removing the solvent from the first step and, in the same pot, exposing the mixture to 
copper (II) bromide.18  
 

























































































Thus protected phenol 295 could be subjected to the previously employed borylation 
conditions, and after simple removal of solvent, could be subjected to copper (II) bromide to 
form aryl bromide 301 in good yield and only one purification step. Aryl bromide 301 proved to 
be a valuable synthetic intermediate, as it was a competent cross–coupling partner. In the 
presence of vinyl stannane 302 and carbon monoxide carbonylative Stille product 300 was 
produced from 301 albeit in low and variable yields. Nevertheless, ketone 300 could participate 
in the 1,4–addition/ elimination followed by Wittig sequence to furnish triene 303. Reduction of 
the enone under Luche conditions provided allylic alcohol 304. With this synthetic route we were 
able to access two possible ring–closing metathesis precursors, 303 and 304. 
 
Scheme 10.8. Succesful synthesis of ring–closing metathesis precursors 303 and 304. 
 
With trienes 303 and 304 in hand, we next explored the ring–closing metathesis.19 We 
recognized this was going to be a difficult ring–closing metathesis from the outset. We are 
attempting to form a ten–membered ring, and while medium sized rings such as this are both 
enthalpically and entropically unfavored, others have had success forming these ring systems 
via ring–closing metathesis.20 Although ten–membered rings have been formed via ring–closing 
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is embedded in that ring. There are, however, examples of forming larger rings embedded with 
meta–substituted aromatic rings21 and thirteen–membered rings containing a para–substituted 
aromatic ring.22 Additionally by inspecting molecular models of our system, it appeared a 
conformation was accessible where there was significant overlap of the two double bonds. Our 
system also contained a 1,1–disubstituted double bond, which is known to be less reactive 
towards ring–closing metathesis.23 However, we were hopeful that the process could initiate at 
the terminal olefin, making the reaction with the 1,1–disubstituted double bond intramolecular, 
and hopefully more facile. Unfortunately, exposing enone 303 to Grubbs II (150), Hoveyda–
Grubbs II (306), or the less sterically encumbered variant 30724 lead only to recovered starting 
material (Scheme 10.9). Allylic alcohol 304, while only being subjected to catalyst 307, also 
displayed no reactivity to the ring–closing metathesis (Scheme 10.10). The fact that only starting 
material was obtained and no dimeric products were observed suggests that catalyst could not 
initiate at either olefin. Although there are many catalysts and variants of ring–closing 
metatheses that we could try, we decided that our time would be best spent exploring other 
routes to our desired ten–membered ring. 
 


























































Scheme 10.10. Attempted ring–closing metathesis of allylic alcohol 304. 
 
10.3 A Nozaki–Hiyama–Kishi Approach to the Desired Ten–Membered Ring 
 
 After unsuccessfully attempting to form the desired ten–membered ring needed for the 
transannular palladium π–allyl reaction through a ring–closing metathesis strategy, we opted to 
explore other routes. Specifically we believed that tetrapetalone A (130) could still arise from 
tetracycle 309, which would be the product of the same type of transannular palladium π–allyl 
reaction as outlined in Scheme 10.2. The precursor in this instance, 310, would be 
regioisomeric to the allylic carbonate previously targeted (cf. 278 Scheme 10.2). By transposing 
the allylic carbonate, 310 could be generated from a Nozaki–Hiyama–Kishi (NHK) reaction of 
vinyl iodide 311, which would be the product of a modified Wittig–olefination and the 1,4–
addition/ elimination sequence applied to aldehyde 312. Aldehyde 312 would arise from 
























Scheme 10.11. Revised retrosynthetic analysis of tetrapetalone A (130). 
 
To access benzaldehyde 312, direct formylation of aryl bromide 301 was explored 
(Table 10.1). Subjecting 301 to palladium–catalyzed formylation conditions in the presence of 
carbon monoxide and a reductant unfortunately gave no product (entries 1 – 3). Lithium–
halogen exchange followed by quenching with DMF only led to decomposition (entry 4). 
Although the direct formylation warrants further exploration, concurrent to these investigations 
the two–step procedure described in Scheme 10.12 was successfully implemented. In that 
sequence aryl bromide 301 was first converted to styrene 313 through a Stille coupling and 
benzaldehyde 312 was formed after a one–pot dihydroxylation/ oxidative cleavage. Although a 
direct formylation would be a more efficient route, this two step process provided enough 




























































Scheme 10.12. Synthesis of aldehyde 312. 
 
With benzaldehyde 312 in hand we looked to elaborate this compound to the desired 
NHK precursor 311. Thus 312 was subjected to modified Wittig conditions to install the desired 
vinyl iodide giving 314, albeit in low yield.26 While attempting to install the α,β–unsaturated 
aldehyde applying our standard 1,4–addition/ elimination sequence, we observed none of the 
desired product 311. We instead isolated a product (315) where the desired α,β–unsaturated 
aldehyde was incorporated, however, the vinyl iodide also eliminated to form an alkyne. 
Unfortunately we were unable to attempt the Nozaki–Hiyama–Kishi reaction due to inability to 






















PdCl2(PPh3)2, Na2CO3, Et3SiH, DMF, CO, 90 °C
PdCl2(PPh3)2, NaCO2H, DMF, CO, 80 °C
PdCl2(PPh3)2, Bu3SnH, DMF, CO, 80 °C



































Scheme 10.13. Attempted synthesis of NHK precursor 311. 
Although we were unable to try the NHK reaction, we were intrigued by this alkyne 
byproduct. Specifically we became interested in utilizing this intermediate in a nickel–catalyzed
reductive alkyne–aldehyde coupling.27 We were intrigued by this reaction due to its use both to 
form medium to large ring systems, and in complex natural products synthesis. Montgomery 
and coworkers utilized this reaction in the late stages of their aigialoymycin (318) synthesis, 
forming protected allylic alcohol 317 from ynal 316 (Scheme 10.14).28 





















































































Before we explored this chemistry we sought a more direct route to ynal 315. To 
accomplish this, aryl bromide 301 was subjected to a Sonogashira coupling to install the alkyne 
and the α,β–unsaturated aldehyde was installed in the usual fashion to give 315. Unfortunately, 
subjecting this ynal to standard nickel catalyzed conditions provided none of the desired 
product, only giving recovered starting material (Scheme 10.15). This result is most likely due to 
the aldehyde and the alkyne not being able to adopt a conformation wherein the two reactive 
species are in close enough proximity to react.  
 
Scheme 10.15. Attempted nickel–catalyzed alkyne–aldehyde coupling. 
 
At this point we had attempted multiple routes towards a transannular palladium π–allyl 
precursor and although we believed this is still an interesting and potentially useful synthetic 
transformation, we decided to explore other synthetic strategies towards tetrapetalone A due to 
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Chapter Eleven  
Revisiting the Previous π–Allyl Strategy 
 
After unsuccessfully attempting a transannular palladium π–allyl approach to form the 
tetracyclic core of tetrapetalone A (130), we decided to take a step back and devise a new 
strategy. While we were still interested in forming the seven–membered ring of 130 through 
attack of the aromatic ring onto a palladium π–allyl species, we needed a way to bias the attack 
towards formation of the seven–membered ring. Recall that when allylic carbonate 275 was 
utilized in this reaction, none of the desired product was obtained, instead producing the 
undesired five–membered ring 276 (Scheme 11.1). This was due to intial formation of palladium 
π–allyl 320, which we had hoped to access due to the need to isomerize that double bond. In 
intermediate 320, there are two possible ways the aromatic ring could attack the palladium π–
allyl species, either by forming the desired seven–membered ring (path a) or the undesired five–
membered ring (path b). If we were to remove the double bond α to the tetramic acid moiety, we 
now only have access to palladium π–allyl 322, which cannot access a five–membered product, 
instead the attack can only occur to form an undesired nine–membered ring (path a) or the 









Scheme 11.2. Revised palladium π-allyl strategy. 
 
11.1 Testing a New Palladium π-Allyl Approach 
 
To test this new strategy, allylic carbonate 321 was synthesized in two steps. First 
ketone 295 was subjected to 1,4–addition conditions utilizing precoordinated methacrolein as 
the electrophile to furnish saturated aldehyde 325. Then 325 was exposed to vinyl magnesium 
bromide followed by methyl chloroformate to provide allylic carbonate 321. When heated to 80 
°C in the presence of palladium(0) 321 only delivered recovered starting material. Raising the 
temperature did not help, and only led to decomposition of the starting material (Scheme 11.3). 
















































































given that in our previous system (cf. 275 to 276) a doubly allylic carbonate was required for the 
oxidative addition to proceed.  
 
Scheme 11.3. Attempted palladium π-allyl reaction on substrate lacking double bond. 
 
Concurrent to our investigations of allylic carbonate 321, we also were interested in an 
allylic epoxide as the precursor for the palladium π–allyl reaction (Scheme 11.4). This was 
appealing due to the fact that the product (328) would contain an alcohol that could later be 
eliminated to form the double bond present in the natural product (i.e. 329).  
 



























































































To access the required epoxide 327, acrolein was reacted with known ylide 33129 to form 
ester 332, which was then reduced to give allylic alcohol 333. The allylic double bond was 
selectively epoxidized in the presence of a vanadium catalyst to furnish 334.30 Alcohol 334 was 
then converted to bromide 335 and tosylate 336 under standard conditions (Scheme 11.5.a). 
We looked to incorporate this epoxide–containing piece into our system, however subjecting the 
enolate derived from ketone 295 with either 335 or 336 lead only to decomposition (Scheme 
11.5.b).    
 
Scheme 11.5. a) Synthesis of epoxide 335 and 336 and b) attempts to form allylic epoxide 327. 
 
11.2 Revisiting the Friedel–Crafts Approach 
 
While we were encountering difficulties in the palladium π–allyl approach, we began to 


































































had aldehyde 325 in hand, we envisioned that ketone 339 could be accessed in quick fashion 
through a Friedel–Crafts acylation of acid chloride 338 (Scheme 11.6).14 Since 338 lacked the 
olefin α to the tetramic acid moiety, we believed this substrate was better suited for a Friedel–
Crafts reaction compared to our previous approach (cf. Section 9.1).  
 
Scheme 11.6. Proposed Friedel–Crafts pathway to ketone 339. 
 
Carboxylic acid 337 was thus formed through a Pinnick oxidation of aldehyde 325. We 
were delighted to find that by first converting 337 to the acid chloride and subjecting the crude 
material to aluminum trichloride in dichloroethane at 65 °C the desired seven–membered ketone 
(339) was obtained in good yield (Scheme 11.7). As we ultimately wanted a double bond in the 
seven–memebered ring, we next explored oxidizing ketone 339 (Table 11.1). Although various 
conditions were attempted to form enone 340, none of the desired product was obtained, 
instead returning recovered starting material in most cases.  
 





































































MeCN, H2O, 0 °C
(95% yield)
1) (COCl)2, DMF
         CH2Cl2
2) AlCl3, DCE, 65 °C
(70% yield, two steps)
 104 
Table 11.1. Attempted oxidation of ketone 339 to enone 340. 
 
 
To circumvent the difficulties encountered in the oxidation to enone 340, we looked to 
install a synthetic handle that could be eliminated after the Friedel–Crafts reaction. This was 
realized by subjecting ketone 295 to the same 1,4–addition conditions as before employing 
methacrolein precoordinated to the bulky Lewis acid developed by Yamamoto and coworkers 
followed by quenching the intermediate enolate (341) with bromine, to furnish α–bromo 
aldehyde 342. Gratifyingly 342 could undergo oxidation to carboxylic acid 343 followed by 
conversion to the acid chloride and Friedel–Crafts acylation to provide seven–membered ketone 





















IBX, DMSO, 60 °C
Br2, CCl4 then DBU
NBS, CCl4 then DBU
NaHMDS, PhSeBr then mCPBA









Scheme 11.8. Formation of α–bromo ketone 344. 
 
With α–bromo ketone 344 in hand, we next looked to eliminate the bromide to form 
enone 345, which was realized upon addition of DBU. To test the reactivity of enone 345, 
isopropenyl magnesium bromide (267) was added and allylic alcohol 346 was formed. 
Furthermore, exposure of 346 to BF3•OEt2 allowed access to tetracycle 347, a compound that 
contains all the carbons present in the tetrapetalone A core. Although we were excited to 
access 347, this compound would require significant functional group manipulations to access 
the natural product and thus we sought an alternate strategy to form this five–membered ring, 









































         CH2Cl2
2) AlCl3, DCE, 65 °C

























Scheme 11.9. Elimination of α–bromo ketone 344 to form enone 345 and elaboration to 
tetracycle 347. 
 
11.3 A New Strategy Towards Tetrapetalone A Utilizing the Friedel–Crafts Acylation 
 
At this point we had developed an effective method to form the desired seven–
membered ring, however the product we had obtained thus far (i.e. 345) lacked the functionality 
necessary to access the natural product. We believed that by targeting tetracycle 348 as a late 
stage intermediate, we would be in good position to finish the natural product (Scheme 11.10). 
In the final steps of this scenario, tetracycle 348 would be subjected to a hydroboration/ 
oxidation sequence followed by decarboxylation to furnish the natural product (130). Tetracycle 
348 would in turn be derived from styrene 349 or vinyl stannane 350 through a palladium 
catalyzed opening of the allylic epoxide, which would both form the five–membered ring and 
deliver the C(15)–O bond present in the natural product. Both 349 and 350 could be produced 
from alkyne 351, which would be derived from aldehyde 352 through Friedel–Crafts acylation 















































Scheme 11.10. Revised retrosynthetic analysis of tetrapetalone A (130). 
 
An alternate strategy to tetrapetalone A (130) is outlined in Scheme 11.11 and differs 
from the approach in Scheme 11.10 in that the tetracyclic core of tetrapetalone (i.e. 353) would 
be formed from intramolecular nucleophilic attack of ketone 354 onto the pendant epoxide with 
the aid of a Lewis acid or palladium. Ketone 354 would be derived by hydrolysis of alkyne 351, 
which would prove to be a valuable departure point to explore the different strategies outlined in 
both Scheme 11.10 and Scheme 11.11. 
  















































R = Me R' = SnBu3























































With a synthetic plan in place, we first looked to target alkyne 351. As we had bromide 
301 in hand from a previous route (cf. Scheme 10.8), we choose to first explore the Friedel–
Crafts reaction on the compound with the bromide in place. To simplify the Friedel–Crafts 
reaction in our initial explorations, we choose to leave out the bromine quench and instead 
target aldehyde 355, which was formed by subjecting aryl bromide 301 to the 1,4–addition 
sequence. Oxidation of 355 under Pinnick conditions provided carboxylic acid 356. 
Unfortunately Friedel–Crafts acylation on the acid chloride derived from 356 only resulted in 
recovered acid chloride. Thus the Friedel–Crafts acylation was not compatible with the aryl 
bromide already in place (Scheme 11.12). 
 
Scheme 11.12. Attempted Friedel–Crafts acylation of aryl bromide 356. 
 
To further investigate the Friedel–Crafts reaction with additional functionality, we choose 
to install the alkyne first. Coupling aryl bromide 301 with propyne proceeded uneventfully to 
provide aryl alkyne 358, which could react with precoordinated methacrolein (324) to furnish 
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converted to the acid chloride, was subjected to aluminum trichloride. Unfortunately this also led 
to no desired product, in this case only giving decomposition (Scheme 11.13).  
 
Scheme 11.13. Attempted Friedel–Crafts acylation of aryl alkyne 360. 
 
11.4 Installation of the Alkyne After the Friedel–Crafts Reaction 
 
It seemed that the presence of an additional substituent on the aromatic ring completely 
shut down the Friedel–Crafts reaction. Therefore we decided that instead of starting with a 
substituent in place, we would look to install the desired functionality after the seven–membered 
ring had been formed (Scheme 11.14.a). However, in that case we would need to find a way to 
selectively functionalize the C–H bond ortho to the ketone. Around the time we were thinking 
about this transformation a paper by Dong and coworkers was published in the literature which 
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Scheme 11.14. a) The desired functionalization of enone 345 and b) Dong’s selective C–
H oxidation utilizing a ketone as a directing group. 
 
Gratifyingly we found that by exposing ketone 345 to the conditions developed by Dong 
and coworkers, we could obtain phenol 365 in good yield (Scheme 11.15). Furthermore the 
phenol could be elaborated to aryl triflate 366, which proved to be competent in the Sonogashira 
coupling with propyne to deliver alkyne 351. By utilizing Dong’s C–H functionalization procedure 
we were able to circumvent the problems that arose in the Friedel–Crafts reaction when that 
position was prefunctionalized.  
 













































































Chapter Twelve  
Exploring the Phenolic Oxidation 
 
While we were exploring ways to install the desired alkyne to form intermediate 351, we 
also were investigating the phenolic oxidation to form the desired allylic epoxide. 
12.1 Deprotection Problems 
 
In order to test the viability of the phenolic oxidation to form an allylic alcohol, the 
sequence starting with ketone 345 was initially explored (Scheme 12.1). To access phenolic 
oxidation precursor 368, ketone 345 was reduced under Luche conditions to give allylic alcohol 
367. Interestingly it appeared that the ketone was being selectively reduced, which we 
hypothesized was based on the shape of the molecule, however at this point we were unsure 
which diastereomer was being favored. Nevertheless, 367 was subjected to conditions to 
remove the methyl protecting group; however this reaction was met with no success.  
 
Scheme 12.1. Attempted removal of methyl protecting group. 
 
Due to the difficulties encountered in methyl removal, we felt the best course of action 
was to explore other protecting groups. Recall we were initially utilizing a TIPS protecting group 
on the phenol and the only reason we had switched to the –OMe ether was to facilitate the 










































featured that transformation, we believed returning to the TIPS group would be worthwhile. 
Additionally, as we had previously utilized this protecting group, we were confident it would be 
compatible with our current chemistry, including the 1,4–addition, and be readily removed. The 
biggest question mark we had with the TIPS group was how it would fare in the Friedel–Crafts 
reaction.  
In that regard, previously accessed ketone 234 was convered to α–bromo aldehyde 370 
under the now standard conditions. Pinnick oxidation and conversion to the acid chloride 
proceeded smoothly, however exposure to the previously employed Friedel–Crafts conditions 
only provided 372 in a 25% yield, with a significant amount of TIPS removal observed. After a 
screen of Lewis acids it was found that tin tetrachloride was competent at promoting this 
reaction and a 61% yield of α–bromo ketone 372 was obtained. Elimination of the bromide 
reliably produced enone 373 (Scheme 12.2).  
 
Scheme 12.2. Synthesis of TIPS protected ketone 373. 
 
Although attempts to functionalize alkyne 376 will be discussed in later sections, we 
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2) Lewis acid




























series. Therefore, ketone 373 was selectively oxidized to provide phenol 374, which was 
converted to triflate 375. Coupling with propyne under Sonogashira conditions delivered alkyne 
376 in good yield (Scheme 12.3).  
 
Scheme 12.3. Synthesis of TIPS protected alkyne 376. 
 
12.2 Phenolic Oxidation Attempts 
 
With enone 373 in hand, we once again set out to explore the phenolic oxidation 
pathway to form allylic epoxide 369. To that end, 373 was reduced under Luche conditions, 
which delivered allylic alcohol 377. Gratifyingly, the TIPS protecting group could be removed 
upon exposure to TBAF. With a successful synthesis of phenolic oxidation precursor 368, we 
looked to explore this transformation. Subjecting 368 to hypervalent iodine led to a complex 
mixture of products, with none of the desired product obtained (Scheme 12.4).32 During the time 
we were exploring this reaction, in an effort to assign the stereochemical outcome of the Luche 
reduction, we were able to obtain a crystal structure of methyl protected allylic alcohol 367 
















































product shown; however this compound is racemic so the only important sterochemical 
information that can be obtained from this crystal structure is in the relative sense. 
Nevertheless, by inspecting the crystal structure, the relative stereochemistry of the newly 
formed allylic alcohol was found to be in the desired syn orientation to the ethyl group of the 
tetrasubstituted carbon. However, the allylic alcohol also appeared to be completely in the plane 
of the aromatic ring. This observation suggested to us that the phenolic oxidation that we were 
currently exploring was likely unable to proceed due to an inability to have significant overlap 
with the generated carbocation. 
 
Scheme 12.4. Attempted phenolic oxidation to form epoxide 369. 
 
 





















































Although spiroepxoide 369 appeared to be inaccessible, we were not deterred. To 
circumvent this conformational incompatibility, we opted to target cyclic carbonate 381 as a 
palladium π–allyl precursor instead. We believed that by exposing Boc–protected alcohol 379 to 
phenolic oxidation conditions we would access carbocation 380. The Boc group should have 
sufficient flexibility that it can access a conformation (i.e. 380), where the carbonyl can interact 
with the carbocation to form cyclic carbonate 381 (Scheme 12.5). Although to the best of our 
knowledge that are no reports of forming cyclic carbonates through this pathway, we were 
inspired by a recent report by Sarpong and coworkers outlining the synthesis of cyclic 
carbamate 384, which they formed from phenol 382 through a similar intermediate (383) to the 
one we are proposing. They utilized intermediate 384 in their synthesis of the core structure 
(385) of the hetidine natural products.33 Although we recognized that carbamates are better 
nucleophiles than carbonates, we believed this difference was minor and that our proposed 
transformation was feasible.     
 


















































Scheme 12.6. Sarpong’s synthesis of 384. 
 
In accordance with this strategy, allylic alcohol 377 was protected with Boc2O to give 
allylic carbonate 378. With the requisite carbonate formed, we next explored methods to remove 
the TIPS group. Unfortunately, thus far we have been unable to remove the TIPS protecting 
group under a variety of fluoride–mediated conditions (Scheme 12.7). We are hesitant to 
expose 378 to strongly acidic conditions due to the presence of the acid sensitive carbonate. 
Although we have been unable to access phenol 379 thus far, we are still in the process of 
exploring methods to access this enticing intermediate.  
 



































































Chapter Thirteen  
Elaboration of the Alkyne 
 
To ultimately gain access to tetrapetalone A (130), we sought a method to form the final 
five–membered ring. We hoped to form this ring by elaborating alkyne 351 into a suitable 
nucleophile (cf. Schemes 11.10 and 11.11). We believed that vinyl stannanes, olefins, ketones, 
and silyl enol ethers would all be viable nucleophiles in this approach. Thus syntheses of these 
compounds were explored.  
13.1 Attempts to Form a Vinyl Stannane 
 
We first targeted a vinyl stannane, as vinyl stannanes have been reported in the 
literature to react intramolecularly with palladium π–allyl species.34 Therefore our planned 
reaction pathway is outlined in Scheme 13.1. Oxidative addition into allylic carbonate 386 would, 
after loss of CO2, form palladium π–allyl 387, which is represented as the η1-π-allyl. 
Transmetallation from the vinyl stannane would form palladium intermediate 388, which could 
undergo reductive elimination to form tetracycle 348.  
 118 
 
Scheme 13.1. Proposed synthesis of tetracycle 348 from vinyl stannane 386. 
   
We hoped to install the requisite vinyl stannane by hydrostannylation of alkyne 389. 
Because we hoped to acces the anti–hydrostannylated product 390, we were attracted to 
radical conditions to perform this transformation.35 Initial experiments on alkyne 389 included 
the use of a trialkyl tin hydride and a radical initiator; however, none of the desired product was 
obtained (Table 13.1). We are currently in the process of screening other tin hydride species 
and radical initiators. 


















































































13.2 Attempts to Form an Aryl Ketone 
 
The most studied of the three nucleophiles that we want to approach is aryl ketone 391, 
which would be formed from hydrolysis of the triple bond. The ketone could be utilized in our 
desired reaction as a nucleophile by transforming it to either enolate 392 upon reaction with a 
strong base such as LDA or silyl enol ether 393. In either case a palladium π–allyl species (394) 
could be formed after oxidative addition into the allylic carbonate. Attack from the enolate onto 
the palladium π–allyl would then form tetracycle 395 (Scheme 13.2).  
 
Scheme 13.2. Proposed synthesis of tetracycle 395 from ketone 391. 
 
The attempts to form ketone 391 are outlined in Table 13.2. In our screening we initially 
attempted hydroboration/ oxidation (entry 1) and acid hydrolysis (entry 2). After those failed we 
moved to metal mediated hydrolysis including: palladium (entry 3), silver (entry 4), and gold 
(entries 5, 6, and 7).36 Unfortunately in all these attempts none of the desired product 396 was 
































































Table 13.2. Attempts to form ketone 396. 
 
13.3 Attempts to Reduce the Alkyne to an Olefin 
 
The last nucleophile we are interested in approaching is an olefin, which would be able 
to participate in a tandem palladium π–allyl/ Heck reaction. The reaction would be initiated by 
initial oxidative addition into allylic carbonate 397 to form palladium π–allyl 398. Migratory 
insertion into the nearby double bond would provide 399, which could undergo β–hydride 
elimination to give tetracycle 348. One important consideration is in the β–hydride elimination 
the palladium and hydride must be syn to each other, therefore to undergo this desired reaction 
we must start with the cis–olefin shown (Scheme 13.3). While subsequent complexation and 
migratory insetion of olefins (i.e. Heck chemistry) has not been demonstrated for π–allyls, they 






















Me BH3•SMe2, I2, CH2Cl2then NaOH, H2O2, MeOH
Me pTsOH, EtOH, 60 °C
Pd(PhCN)2Cl2






















Scheme 13.3. Proposed synthesis of tetracycle 348 from styrene 397. 
 
This transformation is in the most preliminary stages, as only one condition has been 
attempted. In the presence of hydrogen and Lindlar’s catalyst, only starting material was 
obtained (Scheme 13.4). We are currently investigating this route further. 
 
Scheme 13.4. Attempted reduction of alkyne 389. 
 
13.4 Conclusion and Future Work 
 
At this point we have access to an alkyne that we are hopeful can be transformed into an 
appropriate nucleophile to react with a palladium π–allyl species that will be derived from an 
allylic carbonate. We have outlined three strategies in this chapter to functionalize the alkyne, all 






































































thus far, we have devised two routes starting from aryl triflate 375. Direct Stille coupling of 375 
with a vinyl stannane would deliver styrene 400, the same product we are targeting through 
reduction of the alkyne (13.5.a). If instead the Stille reaction is performed in the presence of 
carbon monoxide, enone 401 could be accessed. After elaboration to cylic carbonate 402, 
conjugate reduction would provide enolate 392, which could interact with the allylic carbonate 
either directly or with the aid of palladium or a Lewis acid (Scheme 13.5.b). 
  
Scheme 13.5. Proposed reaction to form a) styrene 400 through a Stille coupling and b) 




















































































Chapter Fourteen  
Ansaetherone 
 
Concurrent to our studies toward the tetrapetalones, we also became interested in 
ansaetherone (135). This interest stemmed from the proposed biosynthetic pathway of the 
tetrapetalones, which included ansaetherone as an intermediate (cf. Scheme 6.2).3 Thus if we 
could gain access to 135, it may be possible to convert it to one of the tetrapetalones in a 
biomimetic fashion (Scheme 14.1). 
      
Scheme 14.1. Relationship between ansaetherone (135) and the tetrapetalones. 
 
14.1 Proposed Conversion of Ansaetherone to the Tetrapetalones 
 
The main challenges associated with the conversion of ansaetherone (135) to the 
tetrapetalones are the contraction of the six to a five–membered ring and formation of the 
seven–five ring system, which can only take place after trans/cis–isomerization of the olefin in 
the eleven–membered ring. To address the olefin isomerization and formation of the five–
membered tetramic acid moiety we envisioned utilizing allylic epoxide 404 as a substrate in a 
palladium–mediated transannular allylic amidation (Scheme 14.2). In the event ansaetherone 
derivative 403 would be selectively epoxidized under nucleophilic conditions to give allylic 


























130, 132, 133 or 134
synthesis?
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which upon migration to the corresponding η1-π-allyl (406) can undergo olefin isomerization and 
eventually deliver η1-π-allyl 407. Ring closure by intramolecular attack of the amide nitrogen 
would furnish 408. Inspection of molecular models indicates that cyclization prior to olefin 
isomerization is unlikely and the formation of 408 would be preferred. Having installed the 
tetramic acid moiety and set the olefin geometry only ring contraction followed by acetylation, 
deprotection, and glycosylation remains to form tetrapetalone B (132). 
  
Scheme 14.2. Proposed conversion of ansaetherone (135) to tetrapetalone B (132). 
 
As depicted in Scheme 14.2 we envision the ring contraction to form the tetracyclic core 
of the tetrapetalones could proceed under Lewis acidic or basic conditions. A more detailed 
schematic showing how these processes are envisioned is outlined in Scheme 14.3. Exposure 
of dihydropyran 408 to Lewis acid would promote the formation of allylic cation 410, which could 




































































































of the phenol 408 to basic conditions would result in phenoxide 411, which could undergo a 
stereoselective 1,2–Wittig rearrangement of resonance structure 412 to deliver tetracycle 409. 
 
Scheme 14.3. Proposed synthesis of tetracycle 409 through a Lewis acidic or basic pathway. 
 
An alternate pathway to convert phenol 408 to tetrapetalone B (132) is depicted in 
Scheme 14.4. Phenolic oxidation would initially form oxocarbenium 413, which could eliminate 
to form para–quinone 414. Exposure of 414 to UV light would promote a Paternó–Büchi reaction 
to give an intermediate oxetane (415) that upon ring opening and loss of a proton would furnish 
tetracycle 416. Tetrapetalone B would then be completed by acetylation, deprotection, 
reduction, and glycosylation. This approach was inspired by George and coworkers’ synthesis 




























































Scheme 14.4. Proposed alternate synthesis of tetrapetalone B from phenol 408. 
 
 
Scheme 14.5. George’s Paternó–Büchi/ elimination route to tetracycle 419. 
 
14.2 A Phenolic Oxidation Pathway to Ansaetherone 
 
With a plan to convert ansaetherone (135) to tetrapetalone B (132) in place, we sought a 
method to access 135. In that regard we envisioned 135 would ultimately arise from 
deprotection and glycosylation of diene 420, the product of a tandem enyne/ cross metathesis 
starting from enyne 421. Given that the olefin geometry of the exocyclic double bond is 
unknown in the natural product, late stage formation of this double bond will potentially lend 
access to both E and Z isomers and thus help lead to structural elucidation. Nevertheless, 



























































































phenol 423 after a phenolic oxidation to form the dihydropyran and installation of the aniline 
nitrogen from the aryl bromide. Phenol 423 would ultimately arrive from dibromophenol 424 and 
aldehyde 425 (Scheme 14.6). 
 
Scheme 14.6. Retrosynthetic analysis of ansaetherone (135). 
 
The synthesis began with a known two–step sequence to access β–hydroxy ester 427 
from ethyl acetate (426) and methacrolein (330).39 Silyl protection followed by a two–step 
reduction/ oxidation sequence furnished aldehyde 425. Protected dibromophenol 428 was 
formed via TIPS protection of phenol 424 and then underwent mono lithium–halogen exchange 
and reaction with aldehyde 425.6b Removal of both silyl protecting groups provided phenolic 
oxidation precursor 429. Unfortunately, exposure of 429 to phenolic oxidation conditions led 




















































422 423 424 425
 128 
 
Scheme 14.7. Attempted phenolic oxidation of 429. 
 
Although difficulties were met with the phenolic oxidation of 429, we still believed the 
dihydropyran moiety could be formed through a phenolic oxidation. Inspired by the work of Kita 
and coworkers, who showed that 433 could be formed by exposure of alcohol 431 to 
bisacetoxyiodo benzene and MK10, presumably through the intermediacy of 432 (Scheme 
14.8),40 the synthetic strategy outlined in Scheme 14.9 was devised. Specifically, intermediate 
422 would now be formed from an alkyl migration/ elimination sequence from 
spirotetrahydrofuran 434, which itself would be formed in situ from a phenolic oxidation and 
intramolecular trapping of alcohol 435. Alcohol 435 would ultimately derive from known ketone 
436 and methacrolein (330). 
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Scheme 14.9. Revised retrosynthetic analysis of dihydropyran 422. 
 
In the event known acetophenone 436 underwent an aldol reaction with methacrolein 
(330) to provide β–hydroxy ketone 437. Although ketone 437 is lacking the required α–methyl 
group, we decided to explore the subsequent chemistry on the desmethyl compound. With that 
in mind, 437 was reduced to selectively give anti–diol 438 as essentially one diastereomer. 
Protected phenol 438 was then explored in the phenolic oxidation step. However none of the 
desired product was obtained utilizing the conditions developed by Kita and coworkers or with 
DDQ (Scheme 14.10).  
 
Scheme 14.10. Attempted synthesis of dihydropyran 439. 
 
We had utilized protected phenol 438 in this step because Kita and coworkers had used 
methyl protected phenols in their paper. However given our unsuccessful result we opted to look 
at the reaction with free phenol 441, which would proceed via an alternate mechanistic pathway 
(i.e. intermediate 442). To access free phenol 441, diol 438 was converted to acetal 440. 































































acetal to give phenolic oxidation precursor 441. Gratifyingly, exposing 441 to iodobenzene 
diacetate provided spirotetrahydrofuran 443 albeit in low yields. Excited by this phenolic 
oxidation product we next explored the alkyl shift to form tetrahydropyran 439. Subjecting 439 to 
the conditions developed by Kita and coworkers (i.e. MK10) resulted in no desired product 
formation, as did adding BF3•OEt2. Given the low yields of 443 and the inability to move it 
forward, we opted to explore other strategies toward ansaetherone (135). 
  
Scheme 14.11. Attempted synthesis of dihydropyran 439. 
 
14.3 Turning to a Fries Rearrangement 
 
Given the difficulties encountered in trying to form the aromatic C–O bond, we decided 
to alter our approach and begin with that bond already in place. Therefore ansaetherone (135) 
would still arise from enyne 421, which would be derived from aniline 422 as described in 
Scheme 14.6. However aniline 422 would come from reduction of nitrophenol 444, the product 






















































phenol 445 would be an anionic Fries rearrangement of the ester derived from acylation of 
phenol 446 with acid 447 (Scheme 14.12).42 
 
Scheme 14.12. Revised retrosynthetic analysis of ansaetherone (135). 
 
To investigate the proposed anionic Fries rearrangement, known ylide 331 was reacted 
with methacrolein (330) and the resultant ester (332) was saponified to give acid 447. 
Conversion to the acid chloride and addition of commercially available phenol 446 provided 
access to aryl ester 448 in moderate yield. Subjecting aryl bromide 448 to n-BuLi or t-BuLi 
provided the desired anionic Fries rearrangement product in very low yields. Furthermore the 
intramolecular oxy–Michael addition of phenol 445 did not provide any of the desired product 























































Scheme 14.13. Attempted synthesis of oxy–Michael product 444. 
Although we were able to obtain small amounts of anionic Fries product 444, it was clear 
this was not a viable route. We hypothesized that removal of the electron withdrawing nitro 
group may be beneficial for both the Fries rearrangement and the oxy–Michael addition. Thus 
we believed nitrobenzene 444 would be the product of the oxy–Michael addition followed by a 
nitration starting with phenol 449, which would be derived from phenol 450 and acid 447 through 
an acylation/ anionic Fries rearrangement sequence (Scheme 14.14). 
 
Scheme 14.14. Revised retrosynthetic analysis of nitrobenzene 444. 
Converting carboxylic acid 447 to the acid chloride then adding phenol 450 provided aryl 
ester 451 although in low yield once again. To help improve this acylation event, carboxylic acid 
447 was converted to anhydride 452, which proved to be a more effective acylating agent, 
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133 
anionic Fries rearrangement to give aryl ketone 449 albeit still in low yield (Scheme 14.15).
Employing other lithium or magnesium bases did not improve this reaction. Attempts to improve 
this rearrangement by utilizing Lewis acid–catalyzed Fries or photo Fries conditions were futile, 
leading either to recovered starting material or deacylated product (Scheme 14.15).  
Scheme 14.15. Synthesis of aryl ketone 449. 
Scheme 14.16. Attempts at Fries or photo Fries rearrangments. 
14.4 Forming an Oxy–Michael Precursor Through an Aldol Reaction 
Although we were able to obtain aryl ketone 449 through an anionic Fries 



















































































ways to obtain this required compound. In that regard dimethoxyphenol (454) was transformed 
to ketophenol 455 under known conditions.43 Subjecting 455 to aldol condensation conditions to 
give enone 449 directly only resulted only in recovered starting material, most likely due to a 
retro–aldol reaction occurring more readily than the desired dehydration. However, aldol adduct 
456 could be obtained by switching to irreversible conditions utilizing LDA (Scheme 14.17). 
 
Scheme 14.17. Aldol Attempts to form aryl ketone 449. 
 
With β–hydroxy ketone 456 in hand we next looked to eliminate to form enone 449. 
Direct elimination under a variety of conditions gave no desired product, instead in most cases 
giving retro–Aldol product. However 456 could be converted to bismesylate 457 and eliminated 
to give enone 458 (Scheme 14.18). Although the yield on this reaction is low, there has been no 
attempt to optimize this reaction as of yet. We believe the most direct pathway would involve 
subjecting 458 to two equivalents of LDA, which would both promote the elimination and 
removal of the phenolic mesylate in the same step.44 With phenol 449 in hand we will be able to 
investigate the remaining steps of the synthesis towards ansaetherone (135) and eventually the 






































Scheme 14.18. Synthesis of enone 458. 
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Preparation of  DKP 39 
 
To a solution of dipeptide 551 (1.287 g, 4.9 mmol) in CH2Cl2 (49 mL) at 0 °C was added 
TFA (2.29 mL, 29.7 mmol). The solution was allowed to warm to room temperature and stirred 
overnight. The solvent was removed in vacuo and the crude material was used directly in the 
next reaction.  
The crude TFA salt was dissolved in MeOH and refluxed. After two days the solvent was 
removed in vacuo and the crude material was purified by flash chromatography (5:1 
CH2Cl2:MeOH) to yield DKP 39 as a white solid (0.461 g, 73% yield). Spectral data for DKP 39 
was consistent with that published in the literature.1-2 
 
Preparation of  DKP 72 
 
n-BuLi (1.93 M, 0.192 mL, 0.37 mmol) was added to a solution of THF (7 mL) and 
DMSO (3 mL) at 0 °C. The reaction was allowed to stir for 20 min at 0 °C then 10 min at room 
temperature then cooled back to 0 °C at which point known DKP 713 (0.100 g, 0.34 mmol) in 
DMSO (3 mL) was added. The reaction was allowed to stir for 15 min at 0 °C then 15 min at 
room temperature. The reaction was cooled back to 0 °C and benzyl bromide (0.044 mL, 0.37 
mmol) was added. After 1 h the reaction was warmed back to room temperature and water (20 
mL) was added and extracted with EtOAc (3 × 20 mL). The combined organics were washed 

























vacuo. The crude material was purified by flash chromatography (6:1 CH2Cl2:Et2O) to yield DKP 
72 (0.074 g, 56% yield). 
1H-NMR (400 MHz; CDCl3): δ 7.36-7.25 (m, 8H), 7.19-7.13 (m, 3H), 7.06 (t, J = 7.6 Hz, 
2H), 6.96 (d, J = 7.4 Hz, 2H), 5.44 (d, J = 14.8 Hz, 1H), 4.42 (d, J = 14.3 Hz, 1H), 4.28 (d, J = 
14.3 Hz, 1H), 4.21 (t, J = 4.0 Hz, 1H), 3.92 (d, J = 14.8 Hz, 1H), 3.36 (d, J = 17.2 Hz, 1H), 3.22-
3.10 (m, 2H), 2.33 (d, J = 17.1 Hz, 1H); 13C-NMR (101 MHz, CDCl3): δ 165.80, 164.62, 135.33, 
134.64, 134.39, 129.86, 128.99, 128.96, 128.72, 128.58, 128.43, 128.16, 128.07, 127.60, 59.98, 
49.57, 48.49, 46.79, 36.74; FTIR (thin film): 3047, 3028, 2935, 1654, 1494, 1469, 1455, 1432, 
1422, 1332, 1321, 1242, 1228, 1181, 1171, 1080, 1030, 1002 cm-1; HRMS (ESI–APCI) m/z 
calc’d for C25H24N2O2  (M+H)+: 385.1916, found: 385.1916. 
 
Preparation of  DKP 76 
 
n-BuLi (1.93 M, 1.7 mL, 0.88 mmol) was added to a solution of DMSO (15 mL) and THF 
(35 mL) at 0 °C. After 35 min known DKP 743 (0.550 g, 1.55 mmol) in DMSO (15 mL) was 
added. After 25 min benzyl bromide 754 (0.558 g, 1.7 mmol) was added and allowed to stir for 2 
h at which point the solution was allowed to warm to room temperature and water (30 mL) was 
added and extracted with EtOAc (3 × 30 mL). The combined organics were washed with water 
(2 × 30 mL) and brine (40 mL), dried over Na2SO4, filtered and concentrated in vacuo. The 
crude material was purified by flash chromatography (4:1 CH2Cl2:Et2O) to give DKP 76 (0.322 g, 
35% yield). 
1H-NMR (300 MHz; CDCl3): δ 7.16-7.04 (m, 5H), 6.88-6.81 (m, 4H), 6.76-6.70 (m, 2H), 




















Hz, 1H), 3.90-3.89 (s, 3H), 3.83-3.79 (m, 6H), 3.67 (d, J = 17.1 Hz, 1H), 3.47-3.37 (m, 3H); 13C-
NMR (75 MHz, CDCl3): δ 166.01, 164.81, 159.67, 159.57, 158.62, 140.85, 130.19, 129.89, 
129.40, 127.85, 127.40, 123.53, 114.48, 109.89, 93.84, 59.90, 56.78, 55.52, 49.29, 47.93, 
42.58; FTIR (thin film): 3251, 2899, 2837, 1650, 1586, 1567, 1513, 1466, 1434, 1422, 1356, 
1269, 1247, 1174, 1096, 1039, 1010 cm-1; HRMS (ESI–APCI) m/z calc’d for C28H29IN2O5 
(M+H)+: 601.1199, found: 601.1195. 
 
Preparation of  protected amino acid 82 
 
KOtBu (0.484 g, 4.3 mmol) was suspended in THF (18 mL) and cooled to –78 °C. 
Known imine 815 (0.916 g, 3.6 mmol) in THF (18 mL) was added via cannula to the suspension 
and allowed to stir for 30 min at which point known benzyl bromide 754 (1.3 g, 3.97 mmol) in 
THF (18 mL) via cannula. After 5 h the reaction was warmed to room temperature and water (40 
mL) was added and the THF was removed in vacuo. The aqueous solution was extracted with 
CH2Cl2 (3 × 20 mL) and the combined organics were washed with brine (40 mL), dried with 
Na2SO4, filtered and concentrated in vacuo. The crude material was purified by flash 
chromatography (5% Et2O/benzene) to provide 82 as a white solid (1.299 g, 72% yield). 
1H-NMR (400 MHz; CDCl3): δ 7.57-7.55 (m, 2H), 7.34-7.19 (m, 6H), 7.09 (t, J = 7.8 Hz, 
1H), 6.79 (dd, J = 7.6, 1.2 Hz, 1H), 6.62-6.60 (m, 1H), 6.51-6.50 (m, 2H), 4.54 (dd, J = 10.0, 3.8 
Hz, 1H), 3.83 (s, 3H), 3.73 (s, 3H), 3.51 (dd, J = 13.3, 3.8 Hz, 1H), 3.32 (dd, J = 13.3, 10.0 Hz, 
1H); 13C-NMR (101 MHz, CDCl3): δ 172.26, 171.44, 158.27, 142.26, 139.52, 136.06, 130.45, 
129.05, 128.64, 128.33, 128.17, 127.84, 124.89, 109.09, 94.08, 64.53, 56.75, 52.49, 44.39; 




















1206, 1172, 1073, 1027, 1013 cm-1; HRMS (ESI–APCI) m/z calc’d for C24H22INO3 (M+H)+: 
500.0723, found: 500.0719.  
 
Preparation of  amino ester 79 
 
To a solution of imine 82 (4.82 g, 9.65 mmol) in THF (97 mL) was added a 10% solution 
of citric acid in water (32 mL) and allowed to stir for 16 h then the reaction was diluted with Et2O 
(40 mL) and extracted with 1 N HCl (2 × 30 mL). The acidic solution was washed with Et2O (2 × 
30 mL) and basified with solid K2CO3. The basic aqueous solution was extracted with EtOAc (3 
× 30 mL), washed with brine (50 mL), dried with MgSO4, filtered and concentrated in vacuo to 
yield crude 79 (3.0 g, 93% yield), which was used in the next step as is. 
1H-NMR (300 MHz; CDCl3): δ 7.27-7.21 (m, 1H), 6.85 (dd, J = 7.5, 1.2 Hz, 1H), 6.71 (dd, 
J = 8.2, 1.3 Hz, 1H), 3.89 (s, 3H), 3.72 (s, 3H), 3.33 (dd, J = 13.5, 5.5 Hz, 1H), 2.98 (dd, J = 
13.5, 8.9 Hz, 1H); 13C-NMR (75 MHz, CDCl3): δ 175.51, 158.55, 142.50, 129.15, 123.47, 
109.47, 93.53, 56.76, 54.75, 52.29, 51.41, 46.38. 
 
Preparation of  DKP 70 
 
To a solution of amine 79 (3.00 g, 8.95 mmol), Boc–sarcosine (78) (2.03 g, 10.7 mmol), 















































reaction was allowed to stir for 20 h after which the reaction was diluted with CH2Cl2 (20 mL) 
and washed with 10% HCl in water (20 mL) then sat. aq. NaHCO3 (2 × 20 mL). The combined 
aqueous washes were extracted with CH2Cl2 (2 × 20 mL) and the organics were combined and 
washed with brine (50 mL), dried over Na2SO4, filtered and concentrated in vacuo. The crude 
material was purified by flash chromatography (15:1 CH2Cl2:MeOH) to give dipeptide 83. 
1H-NMR (300 MHz; CDCl3): δ 7.22 (t, J = 7.9 Hz, 1H), 6.80 (dd, J = 7.6, 1.0 Hz, 1H), 
6.69 (dd, J = 8.2, 1.0 Hz, 1H), 4.94-4.86 (m, 1H), 3.89-3.84 (s, 3H), 3.84-3.75 (m, 1H), 3.75-3.72 
(s, 3H), 3.40 (dd, J = 14.0, 5.8 Hz, 1H), 3.25-3.18 (m, 1H), 2.83 (d, J = 5.1 Hz, 3H), 1.44-1.38 (s, 
9H); 13C-NMR (75 MHz, CDCl3): δ 171.91, 169.33, 158.52, 141.32, 129.35, 122.82, 109.66, 
56.73, 52.75, 52.62, 51.39, 42.94, 35.81, 28.50. 
Dipeptide 83 was dissolved in CH2Cl2 (90 mL) and TFA (4.1 mL, 53.7 mmol) was added. 
The reaction stirred overnight and the solvent was removed in vacuo. The crude material was 
purified by flash chromatography (12:1 CH2Cl2:MeOH). After column there was still a mixture of 
starting material and product, which was free based by dissolving in CH2Cl2 (20 mL) and Et3N 
(1.25 mL, 8.95 mmol) was added. After stirring for 20 min, water (20 mL) was added and the 
solution was extracted with CH2Cl2 (2 × 20 mL) and the combined organics were washed with 
brine (30 mL), dried over Na2SO4, filtered and concentrated in vacuo. The material was then 
used in the next step as is. 
The deprotected dipeptide (2.11 g, 5.2 mmol) was dissolved in MeOH (54 mL) and 
NH4OH (28% in water, 5.36 mL) was added. After 1 h the solvent was removed in vacuo. The 
crude material was purified by flash chromatography (12:1 CH2Cl2:MeOH) to provide DKP 70 
(1.761 g, 53% yield, three steps). 
1H-NMR (300 MHz; CDCl3): δ 7.67-7.64 (m, 1H), 7.23-7.18 (m, 1H), 6.84-6.82 (m, 1H), 
6.72-6.67 (m, 1H), 4.97-4.89 (m, 1H), 3.86 (s, 3H), 3.72-3.69 (s, 3H), 3.45-3.38 (m, 1H), 3.27-
3.19 (m, 1H), 3.19-3.12 (m, 2H), 2.33-2.29 (s, 3H); 13C-NMR (75 MHz, CDCl3): δ 172.26, 
171.72, 158.49, 141.61, 129.25, 122.81, 109.60, 109.47, 93.87, 56.74, 54.60, 52.65, 52.26, 
 146 
42.92, 36.87; FTIR (thin film): 3246, 2930, 1659, 1640, 1584, 1566, 1463, 1426, 1321, 1262, 
1200, 1184, 1100, 1064, 1025, 1013 cm-1; HRMS (ESI–APCI) m/z calc’d for C13H15IN2O3 
(M+H)+: 375.0206, found: 375.0199. 
 
Preparation of  DKP 84 
 
To aryl iodide 70 (1.542 g, 4.1 mmol), CuI (0.078 g, 0.41 mmol), and K3PO4 (1.741 g, 8.2 
mmol) were added toluene (41 mL) then DMEDA (87.2 µL, 0.82 mmol). The reaction was 
heated to 110 °C for 12 h then filtered and the solvent removed in vacuo. The crude material 
was filtered through a plug of silica gel (15:1 CH2Cl2:MeOH) to yield DKP 84 (0.574 g, 57% 
yield). 
1H-NMR (300 MHz; CDCl3): δ 7.16 (t, J = 7.9 Hz, 1H), 6.91-6.88 (m, 2H), 4.80 (d, J = 0.6 
Hz, 1H), 4.47-4.41 (m, 1H), 3.93-3.88 (m, 4H), 3.34 (d, J = 9.8 Hz, 2H), 3.06 (s, 3H); 13C-NMR 
(75 MHz, CDCl3): δ 165.79, 159.61, 150.43, 134.08, 129.94, 127.94, 117.29, 112.78, 62.76, 
56.68, 54.12, 35.50, 33.83; FTIR (thin film): 2937, 2838, 1653, 1606, 1486, 1464, 1461, 1418, 
1406, 1343, 1292, 1271, 1213, 1145, 1122, 1065 cm-1; HRMS (ESI–APCI) m/z calc’d for 
























Deuterium incorporation studies of DKP 84 
 
DKP 84 (0.010 g, 0.040 mmol) was dissolved in THF (1 mL) and added to the 
appropriate base (2.1 equiv.) in THF (1 mL) at the given temperature. The reaction stirred for 30 
min and was brought to 0 °C and D2O (1 mL) was added and stirred for 10 min. The solution 
was diluted with more D2O (5 mL) and extracted with EtOAc (3 × 5 mL). The combined organics 
were dried over MgSO4, filtered and concentrated in vacuo. The % deuterium incorporation was 
then found by integration of the relevant peaks in the crude NMR. 
 
Preparation of  indole 87 
 
Indole 87 was obtained as a side product in various attempts outlined in Table 3.5. An 
example is given here. DKP  (0.030 g, 0.12 mmol) in THF (4 mL) was added to a freshly 
prepared solution of LDA (prepared by adding n-BuLi (2.13 M, 0.169 mL, 0.36 mmol) to 
diisopropylamine (0.056 mL, 0.40 mmol) in THF (1.2 mL) at –78 °C and allowing it to stir for 30 
min) at –78 °C. After 1 h BnSSBn (0.098 g, 0.040 mmol) was added and stirred for 1 h 45 min 





















LDA -78 0 ~100
LDA 0 ~50 ~100





















with sat. aq. NH4Cl (5 mL) and extracted with EtOAc (3 × 5 mL). The combined organics were 
washed with brined (10 mL), dried over MgSO4, filtered and concentrated in vacuo. The crude 
material was purified by flash chromatography (100% EtOAc) to provide DKP 87. 
1H-NMR (300 MHz; CDCl3): δ 7.47 (s, 1H), 7.38-7.28 (m, 2H), 7.05-7.02 (m, 1H), 4.43 (s, 
2H), 4.02 (s, 3H), 3.17 (s, 3H). 
 
Preparation of  indole 89 
 
To a solution of DKP 84 (0.030 g, 0.122 mmol) in THF (1.2 mL) at 0 °C was added LDA 
(0.71 M, 0.38 mL, 0.268 mmol). After 1 h TBSCl (0.046 g, 0.305 mmol) in THF (1.2 mL) was 
added and the solution was allowed to warm to room temperature. After 3 h the reaction was 
quenched with sat. aq. NH4Cl (5 mL) and extracted with EtOAc (3 × 5 mL). The combined 
organics were washed with brine (10 mL), dried over MgSO4, filtered and concentrated in vacuo. 
The crude material was purified by column chromatography (100% EtOAc) to provide indole 89 
(0.009 g, 20% yield). 
1H-NMR (400 MHz; CDCl3): δ 7.39 (s, 1H), 7.32 (d, J = 8.0 Hz, 1H), 7.17 (t, J = 7.9 Hz, 





















Preparation of  DKP 90 and indole 87 
 
To a solution of DKP 84 (0.015 g, 0.061 mmol) in benzene (1 mL) was added Pb(OAc)4 
(0.054 g, 0.122 mmol). After 7.5 h the reaction was filtered through celite and the solvent was 
removed in vacuo. The crude material was purified by flash chromatography (100% EtOAc) to 
provide DKP 90 and indole 87. 
1H-NMR (300 MHz; CDCl3): δ 7.22 (t, J = 7.9 Hz, 1H), 6.94 (d, J = 7.8 Hz, 2H), 4.70 (d, J 
= 15.4 Hz, 1H), 3.90-3.85 (m, 4H), 3.45 (s, 2H), 3.03-3.02 (s, 3H), 2.00-1.99 (s, 3H). 
 
Preparation of  amide 91 
 
To a heterogeneous mixture of Acid 93 (11.0 g, 66.2 mmol) and CH2Cl2 (276 mL) at 0 °C 
was added oxalyl chloride (6.47 mL, 71.8 mmol) followed by dimethylformamide (0.21 mL, 2.76 
mmol). After 15 min the solution was allowed to warm to room temperature. After stirring for an 
additional 2.5 h the reaction was cooled back down to 0 °C and Aniline 92 (10.0 g, 55.2 mmol), 
Et3N (17.7 mL, 127 mmol) and CH2Cl2 (276 mL) were added slowly via an addition funnel. The 
solution was then allowed to warm to room temperature and stirred for 12 h. To the mixture was 
added 10% HCl (300 mL) and brine (100 mL) and the layers were separated. The aqueous 
layer was then extracted with CH2Cl2 (100 mL) and EtOAc (2 × 100 mL) and the organic layers 













































and the resulting oil was purified by flash chromatography (9:1→4:1 DCM:Et2O) to give 91 (9.8 
g, 54% yield) as a yellow oil which slowly solidified.  
1H-NMR (300 MHz, Toluene – d8, 105 °C) δ 8.14 (br s, 1H), 7.36 (d, J = 8.0 Hz, 1H), 
6.86 (t, J = 8.0 Hz, 1H), 6.65 (d, J = 8.2 Hz, 1H), 3.86 (s, 2H), 3.76 (s, 2H), 3.60 (s, 3H), 3.44 (s, 
3H), 2.77 (s, 3H); 13C-NMR (75 MHz, Toluene – d8, 105 °C) δ 166.9, 166.1, 154.0, 127.3, 127.1, 
125.6, 122.3, 115.5, 56.0, 53.1, 51.5, 41.0, 35.8; FTIR (thin film) 3288, 3005, 2950, 2840, 1723, 
1700, 1660, 1609, 1586, 1521, 1470, 1434, 1405, 1285, 1062, 751; HRMS (ESI–APCI) m/z 
calc’d for C14H17ClN2O5 (M+H)+: 329.0899, found: 329.0898; m.p. 97 – 100 °C. 
 
Preparation of  DKP 49 
 
A solution of Amide 91 (9.80 g, 29.8 mmol), potassium carbonate (4.94 g, 35.8 mmol), 
potassium iodide (1.24 g, 7.45 mmol) and MeOH (298 mL) was heated to 65 °C. After 1 h the 
reaction was allowed to cool to room temperature and the reaction mixture was filtered and the 
solvent removed in vacuo. The crude material was purified by flash chromatography (15:1 
DCM:MeOH) to give 3 (7.2 g, 83% yield). Spectral data for DKP 49 was consistent with that 




























Preparation of  bisselenobenzoate 103 
 
Known dibromide 4593 (0.030 g, 0.1 mmol) was dissolved in DMF (1 mL) and cooled to –
45 °C. KSeBz7 (0.2 g, 0.045 mmol) was added and the solution was stirred for 4.5 h. The 
reaction was allowed to warm to room temperature and water (5 mL) was added. The solution 
was extracted with EtOAc (3 × 5 mL) and the combined organics were washed with water (2 × 
10 mL) and brine (10 mL), dried over Na2SO4, filtered and concentrated in vacuo. The crude 
material was purified by flash chromatography (15%→30% EtOAc/hexanes) to yield 
bisselenobenzoate 103 (0.025 g, 49% yield). 
1H-NMR (300 MHz; CDCl3): δ 7.99-7.90 (m, 4H), 7.72-7.63 (m, 2H), 7.58-7.48 (m, 4H), 
6.06 (s, 2H), 3.10-2.96 (s, 6H); 13C-NMR (101 MHz, CDCl3): δ 191.03, 165.21, 137.12, 134.78, 
129.14, 127.94, 78.81, 60.87, 32.25; FTIR (thin film): 3061, 2927, 2854, 1729, 1677, 1447, 
1396, 1291, 1242, 1200, 1171, 1062, 1037, 1023 cm-1; HRMS (ESI–APCI) m/z calc’d for 
C20H18N2O4Se2 (M+H)+: 510.9675, found: 510.9666. 
 
Preparation of  bisselenobenzoate 104 
 
The same procedure for the preparation of bisselenobenzoate 103 was followed. DKP 
109 (0.384 g, 0.85 mmol) and KSeBz (0.386 g, 1.7 mmol) in DMF (8.5 mL) were used to 






























1H-NMR (400 MHz; CDCl3): δ 7.92-7.90 (m, 4H), 7.68-7.64 (m, 2H), 7.53-7.49 (m, 4H), 
7.37-7.29 (m, 10H), 6.10 (s, 2H), 5.12 (d, J = 14.7 Hz, 2H), 3.99 (d, J = 14.7 Hz, 2H); 13C-NMR 
(101 MHz, CDCl3): δ 165.26, 135.05, 134.71, 129.10, 128.80, 128.71, 128.18, 127.99, 58.62, 
47.99; FTIR (thin film): 3063, 3032, 2945, 1730, 1705, 1595, 1581, 1447, 1426, 1256, 1202, 
1174, 1065 cm-1; HRMS (ESI–APCI) m/z calc’d for C32H26N2O4Se2 (M+H)+: 663.0301, found: 
663.0299. 
 
Preparation of  bromide 112 
 
Amino acid 1118 (0.600 g, 2.8 mmol), NBS (0.548 g, 3.1 mmol), AIBN (5 mg, 0.028 
mmol) and CCl4 (28 mL) were added together and heated to 80 °C for 3 h at which point the 
reaction was cooled to room temperature, filtered and the solvent was removed in vacuo to give 
bromide 112 (0.723 g, 87% yield), which was used without further purification in the next step. 
 
Preparation of  diselenide 113 
 
Absolute ethanol (0.12 mL, 2 mmol) was added drop wise to a flask containing selenium 
powder (0.027 g, 0.034 mmol) and NaBH4 (0.026 g, 0.675 mmol). The solution turned reddish 
brown then grey and hydrogen gas evolved. After 10 min DMF (0.7 mL) was added and the 
solution turned dark brown. The dark brown color slowly dissipated until it was light brown in 
color. After stirring for 1 h, 95% ethanol (0.080 mL) then selenium powder (0.027 g, 0.338) was 


















DMF (0.3 mL) was added. After 30 min the solution was heated to 70 °C and kept there for 35 
min at which point the reaction was cooled to room temperature and water (10 mL) was added. 
The mixture was extracted with EtOAc (3 × 10 mL) and the combined organics were washed 
with brine (20 mL), dried over Na2SO4, filtered and concentrated in vacuo. The crude material 
was purified by flash chromatography (10% EtOAc/hexanes) to give diselenide 113 (0.078 g, 
39% yield). 
HRMS (ESI–APCI) m/z calc’d for (M+Na)+: 615.0700, found: 615.0711. 
 
Preparation of  diselenide 106 
 
Absolute ethanol (0.12 mL, 2 mmol) was added drop wise to a flask containing selenium 
powder (0.026 g, 0.33 mmol) and NaBH4 (0.025 g, 0.66 mmol). The solution turned reddish 
brown then white and hydrogen gas evolved. After 10 min DMF (0.66 mL) was added and the 
solution turned dark brown. The dark brown color slowly dissipated until the solution was 
colorless. After stirring for 1 h, 95% ethanol (0.077 mL) then selenium powder (0.026 g, 0.33 
mmol) was added and the solution turned dark brown. After stirring for 45 min the flask was put 
in a MeCN/dry ice bath and dibromide 109 (0.3 g, 0.66 mmol) in DMF (2 mL) was added. The 
solution stirred for 1.5 h then water (10 mL) was added and extracted with EtOAc (3 × 10 mL). 
The combined organics were washed with water (2 × 20 mL) and brine (20 mL), dried over 
Na2SO4, filtered and concentrated in vacuo to give a reddish brown solid. The solid was purified 
by flash chromatography (5:45:50 Et2O:hexanes:CH2Cl2) to yield diselenide 106 as an orange 

















1H-NMR (400 MHz, CDCl3) δ 7.24−7.38 (m, 10H), 5.42 (s, 2H), 4.93 (d, J = 14.9 Hz, 2H), 
4.41 (d, J = 14.9 Hz, 2H); 13C-NMR (100 MHz, CDCl3) δ 189.5, 164.4, 134.0, 129.2, 128.6, 58.3, 
47.6; 77Se-NMR (76 MHz, CDCl3) δ 561.9; FTIR (thin film) 3065, 2975, 1671, 1444, 1418 cm-1; 
Anal. calcd for C18H16N2O2Se2: C, 48.02; H 3.58; N, 6.22; found C, 48.22; H, 3.65; N, 6.27; m.p. 
164 °C (decomp.). 
 
Preparation of  dibromide 109 
 
To a solution of bisthiomethyl ether 116 (0.281 g, 0.73 mmol) in CH2Cl2 (7.3 mL) was 
added Br2 (0.082 mL, 1.6 mmol). After 20 min the solution was concentrated in vacuo to give 
the crude dibromide 109 (0.33 g, quant. yield) and due to instability was used crude in the next 
reaction. 
1H-NMR (400 MHz, CDCl3) δ 7.39−7.28 (m, 10H), 5.94 (s, 2H), 5.31 (d, J = 14.6 Hz, 2H), 
4.05 (d, J = 14.6 Hz, 2H); 13C-NMR (100 MHz, CDCl3) δ 161.5, 132.8, 129.3, 129.1, 129.0, 57.6, 
48.3.   
 
Preparation of  bisselenoether 120 
 
To a solution of diselenide 106 (0.128 g, 0.28 mmol) in MeOH (1.6 mL) was added 
pyridine (0.9 mL), MeI (0.6 mL) then NaBH4 (0.022 g, 0.57 mmol). After 1 h HCl (5 mL, 2 N in 


































with brine (10 mL), dried over Na2SO4, filtered and concentrated in vacuo to give the crude 
bisselenomethyl ether. The crude solid was purified by flash chromatography (15% 
EtOAc/hexanes) to give 120 as a white solid (0.091 g, 68% yield). 
1H-NMR (400 MHz, CDCl3) δ 7.19−7.30 (m, 10H), 5.25 (d, J = 14.7 Hz, 2H), 4.68 (s, 2H), 
4.01 (d, J = 14.7); 13C-NMR (100 MHz, CDCl3) δ 165.1, 134.7, 129.0, 128.6, 128.3, 54.3, 47.4, 
8.0; 77Se-NMR (76 MHz, CDCl3) δ 250.8; FTIR (thin film) 3063, 3029, 2926, 1672, 1446, 1426 
cm-1; Anal. calcd for C20H22N2O2Se2: C, 50.01; H, 4.62; N, 5.83; found C, 50.34; H, 4.75; N, 
5.75; m.p. 105−108 °C. 
 
Preparation of  dithioacetal 121 
 
To a solution of disulfide 115 (0.1 g, 0.28 mmol) in MeOH (1.5 mL) was added pyridine 
(1 mL), CH2I2 (0.6 mL) then NaBH4 (0.021 g, 0.56 mmol). After 10 min another portion of CH2I2 
(0.6 mL) was added. After stirring for 2 h, HCl (10 mL, 2 N in H2O) was added and extracted 
with EtOAc (3 × 10 mL). The combined organics were washed with brine (15 mL), dried over 
Na2SO4, filtered and concentrated in vacuo. The crude material was purified by flash 
chromatography (10%→30% EtOAc/hexanes) to give diketopiperazine 121 as a white solid 
(0.057 g, 55% yield). 
1H-NMR (400 MHz, CDCl3) δ 7.24−7.35 (m, 10H), 5.14 (d, J = 14.8, 2H), 4.85 (s, 2H), 
4.16 (d, J = 14.8, 2H), 3.86 (s, 2H); 13C-NMR (100 MHz, CDCl3) δ 189.5, 164.6, 134.1, 129.1, 
128.5, 60.3, 47.9, 29.3; FTIR (thin film) 3064, 3031, 2966, 1676, 1447, 1423 cm-1; HRMS 




















Preparation of  dithioacetal 125 
 
A solution of known dithioacetal 306a (1.7 g, 5.24 mmol) and BOMCl (7.3 mL, 52.4 mmol) 
in THF (210 mL) was cooled to –78°C. n-BuLi (2.6 M, 4.64 mL, 12.05 mmol) was added over 1 
h 15 min. After 40 min the reaction was allowed to warm to room temperature and stirred for 5 
h. The reaction was quenched with sat. aq. NH4Cl (150 mL) and extracted with EtOAc (3 × 100 
mL). The combined organics were washed with brine (200 mL), dried over MgSO4, filtered and 
concentrated in vacuo. The crude material was purified by flash chromatography (15%→30% 
EtOAc/hexanes then 1% Et2O/CH2Cl2) to give dithioacetal 125 (0.961 g, 32% yield). 
1H-NMR (300 MHz; CDCl3): δ 7.38-7.24 (m, 12H), 6.83-6.80 (m, 2H), 4.94 (s, 1H), 4.76-
4.66 (m, 2H), 4.55 (dd, J = 12.3 Hz, 2H), 4.44 (d, J = 10.6 Hz, 1H), 4.25 (d, J = 10.5 Hz, 1H), 
3.81-3.75 (m, 5H), 3.25-3.23 (s, 3H), 3.16 (s, 3H). 
 
Preparation of  disulfide 126 
 
Dithioacetal 125 (0.300 g, 0.53 mmol) was dissolved in CH2Cl2 (117 mL) and mCPBA 
(0.143 g, 0.83 mmol) was added. After stirring for 8 min DMS (0.050 mL, 0.64 mmol) and then 2 
min later a 5:1 mixture of MeOH:HClO4 (1.06 mL) was added. After stirring for 19 h sat. aq. 
NaHCO3 (5 mL) was added and extracted with EtOAc (3 × 5 mL). The combined organics were 















































material was purified by flash chromatography (10%→20% EtOAc/hexanes) to give pure 
disulfide 126 (0.145 g, 62% yield). 
1H-NMR (300 MHz; CDCl3): δ 7.39-7.29 (m, 10H), 4.77-4.67 (m, 4H), 4.29-4.21 (m, 4H), 
3.16-3.14 (m, 6H). 
 
Preparation of  bisthiomethyl ether 127 
 
Disulfide 126 (0.270 g, 0.61 mmol) was dissolved in MeOH (3.4 mL), pyridine (2 mL), 
and MeI (1.4 mL) and cooled to 0 °C. Solid NaBH4 (0.046 g, 1.2 mmol) was added and after 15 
min the reaction was allowed to warm to room temperature. After 3 h 15 min 1 N HCl (5 mL) 
was added and the mixture was extracted with EtOAc (3 × 5 mL). The combined organics were 
washed with brine (10 mL), dried over MgSO4, filtered and concentrated in vacuo. The crude 
material was purified by flash chromatography (30% EtOAc/hexanes) to give bisthiomethyl ether 
127 (0.211 g, 73% yield). 
1H-NMR (400 MHz; CDCl3): δ 7.34-7.19 (m, 10H), 4.45 (d, J = 12.2 Hz, 2H), 4.31 (d, J = 
12.2 Hz, 2H), 4.17 (d, J = 10.1 Hz, 2H), 3.71 (d, J = 10.1 Hz, 2H), 3.08 (s, 6H), 2.19 (s, 6H); 13C-
NMR (101 MHz, CDCl3): δ 165.00, 137.56, 128.31, 127.59, 126.92, 73.18, 70.90, 65.11, 65.08, 
29.66, 13.52; FTIR (thin film): 3467, 3062, 3029, 2923, 2866, 1496, 1453, 1425, 1381, 1244, 


























Preparation of  bromoketone 236 
 
NaH (60% in mineral oil, 7.0 g, 0.29 mol) was suspended in THF (265 mL) and cooled to 
0 °C. Malonate 460 (27.1 mL, 0.159 mol) was added portionwise over 50 min while H2 evolved. 
The reaction was warmed to room temperature, stirred at that temperature for 30 min, then was 
cooled back to 0 °C. Acid bromide 461 (21.1 mL, 0.175 mol) was added and the reaction was 
allowed to warm to room temperature. The solution became cloudy as NaBr crashed out and 
after stirring for 17 h was filtered through celite three times then silica gel once to provide 
bromoketone 236 as a yellow oil (51.9 g, quant. yield). 
1H-NMR (400 MHz; CDCl3): δ 4.68 (dd, J = 9.0, 4.9 Hz, 1H), 4.27-4.17 (m, 4H), 2.05-
1.99 (m, 2H), 1.67 (s, 3H), 1.26 (dt, J = 15.3, 7.1 Hz, 6H), 1.04 (t, J = 7.3 Hz, 3H); 13C-NMR 
(101 MHz, CDCl3): δ 195.86, 168.47, 167.59, 66.32, 62.73, 62.33, 51.17, 26.96, 18.03, 13.83, 
13.78, 11.81; FTIR (thin film): 2981, 2940, 2908, 2879, 1719, 1449, 1380, 1256, 1110, 1014 cm-
1; HRMS (ESI–APCI) m/z calc’d for C12H19BrO5 (M+H)+: 323.0494, found: 323.0493. 
 
Preparation of  aniline 237 
 
A solution of 3-aminophenol (235) (2.18 g, 20.0 mmol), alkyl bromide 236 (3.23 g, 10 
mmol), and KI (0.166 g, 1.0 mmol) was heated to 50 °C for 48 h. All volatiles were removed in 
vacuo and the crude mixture was purified via flash chromatography (30% EtOAc/hexanes) to 






































1H-NMR (500 MHz; CDCl3): δ 6.99 (t, J = 8.0 Hz, 1H), 6.21 (dd, J = 7.9, 1.7 Hz, 1H), 
6.17 (dd, J = 8.1, 1.6 Hz, 1H), 6.09 (t, J = 2.1 Hz, 1H), 5.29 (s, 1H), 4.40-4.34 (m, 2H), 4.22-4.14 
(m, 2H), 3.94-3.89 (m, 2H), 1.96 (ddd, J = 14.1, 7.3, 4.6 Hz, 1H), 1.72 (dt, J = 14.7, 6.3 Hz, 1H), 
1.65 (d, J = 22.3 Hz, 3H), 1.26 (q, J = 6.8 Hz, 3H), 1.14 (t, J = 7.1 Hz, 3H), 0.92 (t, J = 7.4 Hz, 
3H); 13C-NMR (126 MHz, CDCl3): δ 203.88, 168.78, 168.67, 156.78, 147.79, 130.15, 106.16, 
105.44, 100.30, 64.94, 62.41, 62.27, 61.15, 24.84, 19.25, 13.86, 13.73, 9.77; FTIR (thin film): 
3396, 2980, 2940, 2908, 2878, 1717, 1600, 1517, 1498, 1451, 1378, 1264, 1161, 1114, 1017 
cm-1; HRMS (ESI–APCI) m/z calc’d for C18H26NO6 (M+H)+: 352.1755, found: 352.1764. 
 
Preparation of  ketone 239 
 
A solution of aniline 237 (1.79 g, 5.08 mmol) and acetic acid (5.0 mL) in toluene (50 mL) 
was heated to 80 °C overnight. All volatiles were removed in vacuo and the crude mixture was 
purified via flash chromatography (30% EtOAc/hexanes) to yield phenol 287 (1.44 g, 93% yield) 
as a separable mixture of diastereomers. 
Higher Rf diastereomer: 1H-NMR (500 MHz; CDCl3): δ 7.26-7.23 (m, 1H), 7.03 (t, J = 2.1 
Hz, 1H), 6.83 (dd, J = 7.9, 1.2 Hz, 1H), 6.75 (s, 1H), 6.75-6.71 (m, 1H), 4.77 (dd, J = 5.6, 2.9 Hz, 
1H), 4.23-4.18 (m, 2H), 1.97 (ddt, J = 14.8, 7.4, 3.7 Hz, 1H), 1.81-1.75 (m, 1H), 1.63 (s, 3H), 
1.29-1.23 (m, 3H), 0.75 (t, J = 7.4 Hz, 2H); 13C-NMR (126 MHz, CDCl3): δ 204.90, 169.73, 
165.11, 157.10, 136.22, 130.15, 115.31, 114.87, 112.39, 68.24, 62.96, 59.76, 21.28, 14.96, 
13.90, 7.99; FTIR (thin film): 3331, 2972, 2939, 2881, 1778, 1747, 1683, 1608, 1596, 1492, 
1460, 1407, 1298, 1222, 1159, 1126, 1108, 1048, 1009; HRMS (ESI–APCI) m/z calc’d for 






























Lower Rf diastereomer: 1H-NMR (500 MHz; CDCl3): δ 7.28-7.25 (m, 1H), 7.11 (t, J = 2.2 
Hz, 1H), 6.82 (dt, J = 8.0, 0.9 Hz, 1H), 6.74 (ddd, J = 8.2, 2.4, 0.8 Hz, 1H), 6.35 (s, 1H), 4.52 
(dd, J = 7.2, 3.7 Hz, 1H), 4.27-4.19 (m, 2H), 1.98 (ddd, J = 14.5, 7.5, 3.7 Hz, 1H), 1.87 (dt, J = 
14.5, 7.3 Hz, 1H), 1.63 (s, 3H), 1.27-1.24 (m, 3H), 0.89 (t, J = 7.5 Hz, 3H); 13C-NMR (126 MHz, 
CDCl3): δ 204.61, 169.54, 165.35, 156.88, 136.28, 130.13, 114.97, 114.51, 112.16, 67.54, 
62.79, 59.66, 22.50, 17.19, 13.87, 8.67; FTIR (thin film): 3320, 2980, 2940, 2882, 1776, 1745, 
1682, 1596, 1492, 1460, 1407, 1297, 1215, 1158, 1106, 1046, 1011. 
To a solution of phenol 287 (0.811 g, 2.66 mmol) in CH2Cl2 (27 mL) was added 
imidazole (0.271 g, 3.98 mmol) and TIPSCl (0.739 mL, 3.45 mmol). The reaction mixture was 
stirred overnight at room temperature then quenched with water (30 mL). The phases were 
separated and the aqueous layer was extracted with CH2Cl2 (2 x 20 mL). The combined 
organics were dried over MgSO4, filtered and concentrated in vacuo. The crude material was 
purified via flash chromatography (10% EtOAc/hexanes) to yield ketone 234 (1.21 g, 99% yield) 
as a separable mixture of diastereomers as an off-white waxy solid. 
Higher Rf diastereomer: 1H-NMR (500 MHz; CDCl3): δ 7.27 (t, J = 8.0 Hz, 1H), 6.99 (t, J 
= 2.4 Hz, 2H), 6.82 (d, J = 8.1 Hz, 1H), 4.76 (dd, J = 5.2, 2.6 Hz, 1H), 4.19 (q, J = 7.1 Hz, 2H), 
1.97 (s, 1H), 1.78 (d, J = 6.8 Hz, 1H), 1.58 (d, J = 12.8 Hz, 3H), 1.26 (m, 6H), 1.10 (s, 18H), 
0.74 (t, J = 7.3 Hz, 3H); 13C-NMR (126 MHz, CDCl3): δ 205.41, 168.61, 165.17, 156.74, 136.74, 
129.81, 118.44, 116.63, 116.12, 67.78, 62.72, 59.58, 21.22, 17.86, 14.87, 13.86, 12.63, 7.89; 
FTIR (thin film): 2966, 2945, 2893, 2869, 1780, 1749, 1709, 1598, 1490, 1463, 1449, 1388, 
1297, 1221, 1183, 1158, 1126, 1107, 1073, 1048, 1005; HRMS (ESI–APCI) m/z calc’d for 
C25H40NO5Si (M+H)+: 462.2670, found: 462.2676. 
Lower Rf diastereomer: 1H-NMR (500 MHz; CDCl3): δ 7.28-7.25 (m, 1H), 7.01 (t, J = 2.1 
Hz, 1H), 6.98 (d, J = 8.0 Hz, 1H), 6.81-6.80 (m, 1H), 4.49 (dd, J = 7.2, 3.6 Hz, 1H), 4.25 (dd, J = 
7.1, 3.5 Hz, 2H), 1.87 (d, J = 7.3 Hz, 1H), 1.60 (s, 3H), 1.26 (dt, J = 14.3, 5.4 Hz, 6H), 1.11 (d, J 
= 7.3 Hz, 18H), 0.88 (t, J = 7.5 Hz, 3H); 13C-NMR (126 MHz, CDCl3): δ 205.14, 168.67, 165.52, 
 161 
156.70, 136.55, 129.79, 118.33, 116.27, 116.03, 67.24, 62.58, 22.46, 17.86, 17.17, 13.86, 
12.61, 8.64; FTIR (thin film): 2945, 2894, 2869, 1775, 1732, 1702, 1599, 1496, 1447, 1395, 
1306, 1255, 1232, 1160, 1127, 1107, 1052, 1005. 
 
Preparation of  enal 239 
 
To a  –78 °C solution of ketone 234 (3.63 g 7.86 mmol) in THF (80 mL) was added 
NaHMDS (8.65 mL, 1.0 M in THF, 8.65 mmol) and the reaction mixture was allowed to warm 
slowly to –50 °C then cooled to –78 °C. Meanwhile, the vinyl bromide (1.76 g, 11.8 mmol) was 
added slowly to a solution of the bulky Lewis acid (generated from slow addition of AlMe3 (7.03 
mL, 2.0 M in hexanes, 14.07 mmol) to a solution of 2,6-diphenylphenol (9.90 g, 40.2 mmol) in 
toluene (70 mL) at room temperature) at -78 °C and maintained for 20 min. The solution 
containing aldehyde complex 245 was then transferred via cannula to the sodium enolate of 
ketone 234. The reaction mixture was maintained at –78 °C for 1 h then allowed to warm slowly 
to room temperature over 3 h. The reaction mixture was quenched with sat. aq. Rochelle’s salt 
(100 mL), stirred vigorously overnight, and extracted with EtOAc (3 x 100 mL). The combined 
organics were dried over MgSO4, filtered and concentrated in vacuo. The crude material was 
purified via flash chromatography (5%→10% EtOAc/hexanes) to yield enal 239 (3.33 g, 80% 































1H-NMR (500 MHz; CDCl3): δ 9.40 (s, 1H), 7.25 (m, 1H), 6.97-6.95 (m, 1H), 6.92 (t, J = 
2.2 Hz, 1H), 6.84 (ddd, J = 8.2, 2.3, 0.7 Hz, 1H), 6.47 (d, J = 1.4 Hz, 1H), 4.28 (qd, J = 7.1, 3.0 
Hz, 2H), 2.42 (dd, J = 14.6, 7.3 Hz, 1H), 2.18 (dd, J = 14.6, 7.4 Hz, 1H), 1.89 (s, 3H), 1.62 (s, 
3H), 1.29 (t, J = 7.2 Hz, 3H), 1.25-1.18 (m, 3H), 1.10-1.04 (m, 18H), 0.83 (t, J = 7.4 Hz, 3H); 
13C-NMR (126 MHz, CDCl3): δ 203.07, 193.82, 169.39, 165.22, 156.64, 149.71, 142.03, 136.09, 
129.88, 119.22, 117.50, 116.66, 62.89, 58.82, 27.78, 17.79, 13.87, 12.57, 10.30, 8.06; FTIR 
(thin film): 2946, 2868, 1777, 1751, 1710, 1598, 1491, 1463, 1378, 1354, 1284, 1225, 1124, 
1004; HRMS (ESI–APCI) m/z calc’d for C29H44NO6Si (M+H)+: 530.2932, found: 530.2941. 
 
Preparation of  carboxylic acid 247 
 
To a –78 °C solution of phosphonate 246 (0.436 g 2.08 mmol) in THF (20 mL) was 
added n-BuLi (2.79 mL, 1.49 M, 4.15 mmol). After 40 min enal 239 (1.0 g, 1.89 mmol) in THF 
(5.0 mL) was added slowly. The reaction mixture was maintained at –78 °C for 1 h then allowed 
to warm slowly to 0 °C and quenched with sat. aq. NH4Cl (25 mL) and extracted with EtOAc (3 x 
25 mL). The combined organics were dried over MgSO4, filtered and concentrated in vacuo. The 
crude material was purified via flash chromatography (20%→30%→60% EtOAc/hexanes) to 
yield carboxylic acid 247 (0.515 g, 47% yield) as an inseparable mixture of diastereomers as a 
colorless oil and unreacted enal 239 (0.215 g, 22% yield). The major diastereomer of the 
product is characterized. 
1H-NMR (500 MHz; CDCl3): δ 7.26-7.22 (m, 1H), 7.15 (s, 1H), 7.01 (dd, J = 8.1, 1.1 Hz, 































2H), 2.26 (dd, J = 14.5, 7.3 Hz, 1H), 2.11 (dd, J = 14.5, 7.4 Hz, 1H), 1.93 (s, 3H), 1.92 (s, 3H), 
1.68 (s, 3H), 1.28 (t, J = 7.1 Hz, 3H), 1.26-1.18 (m, 3H), 1.08 (dd, J = 7.4, 1.6 Hz, 18H), 0.82 (q, 
J = 6.7 Hz, 3H); 13C-NMR (126 MHz, CDCl3): δ 204.02, 169.59, 165.58, 156.51, 143.80, 138.05, 
136.36, 132.22, 129.68, 119.11, 118.40, 117.38, 76.04, 62.76, 58.77, 50.69, 45.27, 28.84, 
28.28, 17.78, 13.86, 12.60, 8.07; FTIR (thin film): 2946, 2869, 2653, 2529, 2253, 1775, 1748, 
1714, 1635, 1598, 1489, 1463, 1379, 1285, 1122, 1004; HRMS (ESI–APCI) m/z calc’d for 
C32H48NO7Si (M+H)+: 586.3203, found: 586.3203. 
 
Preparation of  acid chloride 233 
 
To a solution of carboxylic acid 245 (0.100 g, 0.171 mmol) in acetonitrile (5 mL) was 
added oxalyl chloride (0.017 mL, 0.205 mmol) and DMF (1 drop). The reaction was vented with 
a needle until effervescence ceased, then maintained under a positive pressure of N2 overnight. 
All volatiles were removed under full vacuum to yield acid chloride 233 (0.105 mg) as a crude 

































Preparation of  ketone 259 
 
To a 0 °C solution of acid chloride 233 (20.6 mg, 0.0341 mmol) in CH2Cl2 (5.0 mL) was 
added AlCl3 (0.009 g, 0.0683 mmol) and anisole (0.050 mL, 0.460 mmol). The reaction mixture 
was allowed to warm to room temperature and maintained overnight. After addition of sat. aq. 
Rochelle’s salt (5 mL) the reaction was stirred vigorously for 2 h and the mixture was extracted 
with EtOAc (3 x 5 mL). The combined organics were dried over MgSO4, filtered and 
concentrated in vacuo. The crude material was purified by flash chromatography (20% 
EtOAc/hexanes) to yield ketone 259 (0.008 mg, 35% yield) as an inseparable mixture of 
diastereomers as a colorless oil. The major diastereomer of the product is characterized. 
1H-NMR (500 MHz; CDCl3): δ 7.70 (d, J = 8.8 Hz, 2H), 7.23 (d, J = 8.1 Hz, 1H), 7.02-
7.01 (m, 1H), 6.98 (d, J = 2.0 Hz, 1H), 6.93 (d, J = 8.8 Hz, 2H), 6.84-6.82 (m, 1H), 6.43 (s, 1H), 
5.58 (s, 1H), 4.27 (q, J = 7.1 Hz, 2H), 3.88-3.86 (s, 3H), 2.27 (dd, J = 14.5, 7.3 Hz, 1H), 2.13 
(dd, J = 14.5, 7.3 Hz, 1H), 2.04-2.02 (s, 3H), 1.90 (s, 3H), 1.69 (s, 3H), 1.29 (t, J = 7.1 Hz, 3H), 
1.27-1.18 (m, 3H), 1.11-1.04 (m, 18H), 0.82 (q, J = 6.7 Hz, 3H); 13C-NMR (126 MHz, CDCl3): δ 
204.18, 197.78, 169.58, 165.63, 162.92, 156.49, 142.04, 138.08, 136.90, 136.48, 131.80, 
131.10, 130.05, 129.63, 118.99, 118.22, 117.43, 113.55, 76.13, 62.75, 58.76, 55.44, 28.85, 
18.07, 17.82, 14.88, 13.87, 12.58, 8.10; FTIR (thin film): 2943, 2868, 1774, 1748, 1708, 1647, 
1599, 1509, 1490, 1461, 1376, 1354, 1283, 1254, 1173, 1149, 1111, 1005; HRMS (ESI–APCI) 






























Preparation of  allylic carbonate 265 
 
To a solution of enal 239 (0.222 g, 0.419 mmol) in THF (5 mL) cooled to –78 °C was 
added MeMgCl (0.210 mL, 3.0 M in THF, 0.630 mmol) and maintained for 1.5 h. Methyl 
chloroformate (0.097 mL, 1.26 mmol) was then added and the reaction mixture was allowed to 
warm slowly to room temperature then quenched with sat. aq. NaHCO3 (5 mL) and extracted 
with Et2O (3 x 5 mL). The combined organics were dried over MgSO4, filtered and concentrated 
in vacuo. The crude material was purified by flash chromatography (10%→30% 
EtOAc/hexanes) to yield allylic carbonate 265 (0.225 g, 89% yield) as an inseparable mixture of 
diastereomers as a colorless oil. 
1H-NMR (500 MHz; CDCl3): δ 7.21 (q, J = 8.4 Hz, 1H), 7.01 (dt, J = 15.8, 2.2 Hz, 1H), 
6.97-6.95 (m, 1H), 6.82-6.79 (m, 1H), 5.65 (d, J = 21.7 Hz, 1H), 4.99 (dd, J = 6.5, 3.4 Hz, 1H), 
4.26-4.22 (m, 2H), 3.74 (d, J = 3.1 Hz, 2H), 2.29-2.26 (m, 1H), 2.04 (td, J = 7.3, 3.4 Hz, 1H), 
1.76 (dd, J = 5.4, 1.1 Hz, 3H), 1.63-1.60 (m, 3H), 1.35-1.31 (m, 3H), 1.29-1.20 (m, 6H), 1.09-
1.04 (m, 18H), 0.74 (tt, J = 7.6, 3.9 Hz, 3H); 13C-NMR (126 MHz, CDCl3): δ 204.22, 204.02, 
169.63, 165.80, 165.78, 156.37, 154.78, 154.74, 140.99, 140.91, 136.49, 136.44, 129.51, 
129.45, 126.59, 125.89, 118.73, 118.69, 117.80, 117.54, 117.47, 79.09, 78.89, 76.02, 75.95, 
62.58, 62.56, 58.74, 58.67, 54.70, 27.80, 27.54, 19.15, 18.99, 17.83, 13.83, 13.63, 13.20, 12.57, 
8.08, 8.06; FTIR (thin film): 2946, 2869, 1775, 1750, 1598, 1490, 1445, 1378, 1355, 1268, 1112, 






























Preparation of  allylic carbonate 268 
 
To a solution of enal 239 (0.300 g, 0.566 mmol) in THF (6 mL) cooled to –78 °C was 
added 2-propenylMgCl (1.70 mL, 0.5 M in THF, 0.849 mmol) and maintained for 1.5 h. Methyl 
chloroformate (0.131 mL, 1.70 mmol) was then added and the reaction mixture was allowed to 
warm slowly to room temperature and quenched with sat. aq. NaHCO3 and extracted with Et2O 
(3 x 5 mL). The combined organics were dried over MgSO4, filtered and concentrated in vacuo. 
The crude material was purified via flash chromatography (15%→20% EtOAc/hexanes) to yield 
allylic carbonate 268 (0.280 g, 79% yield) as an inseparable mixture of diastereomers as a 
colorless oil.  
1H-NMR (500 MHz; CDCl3): δ 7.21 (q, J = 8.6 Hz, 1H), 7.04 (d, J = 11.0 Hz, 1H), 6.96 (t, 
J = 8.5 Hz, 1H), 6.82-6.80 (m, 1H), 5.73 (d, J = 9.6 Hz, 1H), 5.24 (s, 1H), 5.08 (s, 1H), 5.02 (s, 
1H), 4.25 (td, J = 6.6, 5.1 Hz, 2H), 3.80-3.77 (s, 3H), 2.32 (ddd, J = 14.5, 10.9, 7.3 Hz, 1H), 2.05 
(dd, J = 14.4, 7.1 Hz, 1H), 1.71 (s, 3H), 1.62 (m, 6H), 1.25 (m, 6H), 1.13-1.05 (m, 18H), 0.76 (t, 
J = 7.1 Hz, 3H); 13C-NMR (126 MHz, CDCl3): δ 204.21, 204.09, 169.60, 165.76, 165.74, 156.43, 
156.42, 154.62, 154.57, 139.97, 139.91, 137.92, 137.85, 136.50, 136.45, 129.51, 129.42, 
127.95, 127.39, 118.74, 118.66, 117.66, 117.62, 117.41, 114.96, 114.48, 84.84, 84.81, 76.20, 
62.58, 58.68, 58.62, 54.85, 27.98, 27.72, 18.42, 18.09, 17.84, 14.05, 13.84, 13.49, 12.60, 8.13; 
FTIR (thin film): 2946, 2869, 1775, 1751, 1709, 1651, 1598, 1490, 1444, 1377, 1355, 1269, 






























Preparation of  fused tricycle 269 
 
A flame dried vial was charged with methyl carbonate 268 (0.029 g, 0.0461 mmol), 
Pd2(dba)3 (4.2 mg, 0.00461 mmol), and DIPHOS (3.7 mg, 0.00922 mmol) and vacuum purged 
under N2. DMF (3 mL) was then added and the reaction mixture heated to 110 °C overnight. 
Volatiles were removed in vacuo and the crude mixture was purified by flash chromatography 
(5% EtOAc/hexanes) to yield fused tricycle 269 (15 mg, 59% yield) as a colorless crystalline 
solid. 
1H-NMR (500 MHz; CDCl3): δ 7.22 (t, J = 8.0 Hz, 1H), 6.85 (dd, J = 8.1, 1.1 Hz, 1H), 
6.80 (d, J = 7.8 Hz, 1H), 6.74 (s, 1H), 5.40 (s, 1H), 5.13 (d, J = 0.7 Hz, 1H), 5.07 (d, J = 1.0 Hz, 
1H), 4.47 (d, J = 12.7 Hz, 1H), 4.37-4.34 (m, 1H), 4.26 (q, J = 7.1 Hz, 2H), 3.83 (s, 1H), 2.17 
(dd, J = 14.5, 7.4 Hz, 1H), 1.82 (s, 3H), 1.77 (dd, J = 14.5, 7.7 Hz, 1H), 1.49 (s, 2H), 1.34 (t, J = 
7.1 Hz, 3H), 1.25 (dt, J = 15.0, 7.5 Hz, 3H), 1.10 (d, J = 7.4 Hz, 18H), 0.71 (t, J = 7.6 Hz, 3H); 
13C-NMR (126 MHz, CDCl3): δ 170.78, 170.31, 156.35, 146.44, 141.67, 138.07, 129.45, 129.40, 
128.28, 128.23, 128.19, 121.45, 121.41, 121.38, 121.35, 120.52, 120.44, 119.55, 106.29, 
106.25, 98.39, 79.18, 72.28, 61.34, 60.25, 57.30, 25.27, 17.86, 14.57, 13.96, 12.59, 9.53; FTIR 
(thin film): 2945, 2868, 1742, 1702, 1666, 1596, 1487, 1464, 1443, 1384, 1367, 1282, 1246, 
1197, 1155, 1133, 1081, 1006; HRMS (ESI–APCI) m/z calc’d for C32H48NO5Si (M+H)+: 





























Preparation of  allylic carbonate 275 
 
To a solution of enal 239 (0.112 g, 0.211 mmol) in THF (3 mL) cooled to –78 °C was 
added vinylMgCl (0.317 mL, 1.0 M in THF, 0.317 mmol) and maintained for 1.5 h. Methyl 
chloroformate (0.049 mL, 0.634 mmol) was then added and the reaction mixture was allowed to 
warm slowly to room temperature and quenched with sat. aq. NaHCO3 and extracted with 
EtOAc (3 x 5 mL). The combined organics were dried over MgSO4, filtered and concentrated in 
vacuo. The crude material was purified by flash chromatography (10% EtOAc/hexanes) to yield 
allylic carbonate 462 (0.096 g, 74% yield) as an inseparable mixture of diastereomers as a 
colorless oil.  
1H-NMR (500 MHz; CDCl3): δ 7.21 (q, J = 7.6 Hz, 1H), 7.00 (d, J = 14.1 Hz, 1H), 6.96 (d, 
J = 8.1 Hz, 1H), 6.81 (d, J = 8.2 Hz, 1H), 5.73 (dd, J = 13.5, 8.0 Hz, 2H), 5.35-5.27 (m, 3H), 
4.26-4.22 (m, 2H), 3.77 (s, 3H), 2.28 (dd, J = 14.5, 7.3 Hz, 1H), 2.04 (dd, J = 14.6, 7.4 Hz, 1H), 
1.75 (s, 3H), 1.61 (m, 3H), 1.27-1.20 (m, 6H), 1.07 (dd, J = 16.2, 7.3 Hz, 18H), 0.77-0.72 (m, 
3H); 13C-NMR (126 MHz, CDCl3): δ 204.14, 203.97, 169.61, 165.76, 156.39, 154.62, 154.57, 
138.76, 136.47, 136.41, 133.46, 133.41, 129.52, 129.46, 127.81, 127.45, 118.77, 118.75, 
118.68, 118.62, 117.77, 117.52, 117.50, 117.44, 82.86, 82.84, 76.12, 76.04, 62.57, 58.71, 
58.66, 54.86, 27.78, 27.55, 13.99, 13.84, 13.72, 12.58, 8.08, 8.06; FTIR (thin film): 2946, 2869, 
1776, 1752, 1709, 1598, 1490, 1444, 1377, 1355, 1262, 1113; HRMS (ESI–APCI) m/z calc’d for 






































To a solution of methyl carbonate 462 (130 mg, 0.211 mmol) in THF (4.5 mL) cooled to –
15 °C was added TBAF (0.23 mL, 1.0 M in THF, 0.23 mmol). The reaction was monitored by 
TLC and after 5 min quenched with water (10 mL) and extracted with EtOAc (3 x 5 mL). The 
combined organics were dried over MgSO4, filtered and concentrated in vacuo. The crude 
material was purified via column chromatography (20% EtOAc/hexanes) to yield phenol 275 
(0.097 mg, quant. yield) as an inseparable mixture of diastereomers as a colorless oil.   
1H-NMR (500 MHz; CDCl3): δ 7.23 (tt, J = 7.3, 3.6 Hz, 1H), 6.99-6.95 (m, 2H), 6.76 (d, J 
= 7.6 Hz, 1H), 6.49 (d, J = 8.3 Hz, 1H), 5.81-5.74 (m, 1H), 5.64 (d, J = 4.0 Hz, 1H), 5.38-5.36 
(m, 1H), 5.33 (m, 1H), 5.30 (m, 1H), 4.28-4.20 (m, 2H), 3.81-3.80 (s, 3H), 2.24-2.02 (m, 2H), 
1.76-1.72 (m, 3H), 1.66-1.63 (m, 3H), 1.29-1.23 (m, 3H), 0.81-0.75 (m, 3H); 13C-NMR (126 MHz, 
CDCl3): δ 203.97, 203.86, 169.85, 169.80, 165.57, 165.53, 156.75, 156.69, 156.66, 155.25, 
155.21, 139.63, 139.42, 135.93, 135.90, 133.20, 133.04, 129.92, 129.88, 128.35, 127.24, 
119.11, 118.45, 118.22, 118.01, 114.79, 114.75, 113.29, 113.24, 83.37, 83.18, 75.67, 75.24, 
62.88, 62.83, 58.99, 58.87, 55.13, 29.15, 28.78, 17.75, 17.53, 14.59, 13.88, 13.33, 8.09, 7.96; 
FTIR (thin film): 3368, 2985, 2942, 1775, 1750, 1704, 1683, 1595, 1491, 1445, 1383, 1335, 
1262, 1160, 1113; HRMS (ESI–APCI) m/z calc’d for C24H30NO8 (M+H)+: 460.1971, found: 
460.1977. 
 
Preparation of  tricycle 276 
 
A flame dried vial was charged with methyl carbonate 275 (0.020 g, 0.0435 mmol), 

























under N2. DMF (1 mL) and toluene (1 mL) was added and the reaction mixture heated to 120 °C 
overnight. The crude mixture was loaded directly on to silica gel and purified via flash 
chromatography (20% EtOAc/hexanes) to yield tricycle 276 (11.5 mg, 69% yield) as an 
inseparable mixture of diastereomers or olefin isomers as a colorless oil.  
1H-NMR (500 MHz; CDCl3): δ 7.56 (s, 1H), 7.11-7.08 (m, 1H), 6.99-6.95 (m, 1H), 6.83-
6.76 (m, 2H), 6.70 (dd, J = 8.3, 2.2 Hz, 1H), 5.95 (d, J = 10.9 Hz, 1H), 5.28 (d, J = 16.0 Hz, 1H), 
5.21 (d, J = 10.2 Hz, 1H), 4.35 (s, 1H), 4.30-4.24 (m, 3H), 2.08-1.98 (m, 2H), 1.61-1.53 (m, 6H), 
1.32-1.27 (m, 3H), 1.11-1.07 (m, 3H), 1.04-0.98 (m, 3H); 13C-NMR (126 MHz, CDCl3): δ 200.57, 
167.98, 165.69, 157.29, 139.43, 133.12, 131.40, 130.28, 126.29, 126.25, 124.96, 118.19, 
118.14, 114.00, 113.77, 105.41, 105.35, 81.45, 63.16, 48.85, 32.05, 20.06, 17.04, 13.88, 7.80; 
FTIR (thin film): 3333, 2972, 2939, 1775, 1685, 1618, 1600, 1499, 1465, 1381, 1294, 1224, 
1167, 1108, 1015; HRMS (ESI–APCI) m/z calc’d for C22H25NO5 (M+H)+: 384.1811, found: 
384.1815. 
 
Preparation of  tetramic acid 280 
 
A solution of aniline 2819 (4.00 g, 23.9 mmol), bromide 238 (3.87 g, 12.0 mmol), and KI 
(0.199 g, 1.2 mmol) in EtOH (60 mL) was heated to 60 °C for 48 h. The solution was then 
cooled to room temperature and the volatiles were removed in vacuo. The crude material was 
purified by flash chromatography (10%→15%→20% EtOAc/hexanes) to give aniline 286 (1.703 
g, 17% yield) as a mixture of diastereomers. 
To aniline 286 (1.703 g, 4.16 mmol) was added toluene (42 mL) then AcOH (4.2 mL) 
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2) TIPSCl, imid.
       CH2Cl2
(84% yield, two steps)
281 286 280
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and the volatiles were removed in vacuo. The crude mixture was purified by flash 
chromatography (20%→30% EtOAc/hexanes) to yield phenol 463 (1.324 g, 88% yield) as a 
mixture of diastereomers.  
1H-NMR (400 MHz; CDCl3): δ 7.75 (s, 1H), 7.45 (t, J = 1.6 Hz, 1H), 7.40-7.39 (m, 1H), 
7.33 (t, J = 2.2 Hz, 1H), 4.84 (dd, J = 5.6, 2.9 Hz, 1H), 4.25-4.14 (m, 2H), 3.89-3.87 (s, 3H), 
2.01-1.93 (m, 1H), 1.81-1.74 (m, 1H), 1.58 (s, 3H), 1.25-1.21 (m, 3H), 0.72 (t, J = 7.4 Hz, 3H); 
1H-NMR (400 MHz; CDCl3): δ 7.82 (s, 1H), 7.42 (t, J = 1.6 Hz, 1H), 7.40-7.39 (m, 1H), 7.37 (t, J 
= 2.2 Hz, 1H), 4.59 (dd, J = 7.1, 3.6 Hz, 1H), 4.25-4.14 (m, 2H), 3.88 (s, J = 3.6, 1.6 Hz, 1H), 
2.01-1.93 (m, 1H), 1.87-1.79 (m, 1H), 1.62 (s, 3H), 1.23-1.19 (m, 3H), 0.85 (t, J = 7.5 Hz, 3H); 
13C-NMR (101 MHz, CDCl3): δ 204.22, 203.88, 194.67, 191.40, 170.13, 166.33, 165.13, 157.49, 
157.47, 136.16, 132.06, 116.92, 116.82, 115.83, 115.81, 115.67, 115.47, 68.02, 67.56, 63.12, 
62.95, 59.77, 59.72, 52.51, 22.38, 21.15, 17.16, 14.96, 13.88, 13.82, 8.56, 7.92; FTIR (thin film): 
3339, 2979, 2941, 1777, 1746, 1704, 1681, 1598, 1455, 1437, 1330, 1295, 1209, 1107, 1006 
cm-1; HRMS (ESI–APCI) m/z calc’d for C18H22NO7 (M+H)+: 364.1396, found: 364.1394. 
To a solution of phenol 463 (1.324 g, 3.64 mmol) and imidazole (0.372 g, 5.46 mmol) in 
CH2Cl2 (36 mL) was added TIPSCl (1.0 mL, 4.74 mmol). The reaction was stirred for 17.5 h 
then water (30 mL) was added and the mixture was extracted with CH2Cl2 (3 × 20 mL). The 
combined organics were washed with brine (50 mL), dried over MgSO4, filtered and 
concentrated in vacuo. The crude material was purified by flash chromatography to yield 
tetramic acid 280 (1.818 g, 96% yield) as a mixture of diastereomers.  
1H-NMR (400 MHz; CDCl3): δ 7.58 (t, J = 0.8 Hz, 1H), 7.44-7.43 (m, 1H), 7.28 (t, J = 2.1 
Hz, 1H), 4.82 (dd, J = 5.5, 2.7 Hz, 1H), 4.20-4.15 (m, 2H), 3.89 (s, 3H), 2.00-1.94 (m, 1H), 1.81-
1.76 (m, 1H), 1.56 (s, 3H), 1.31-1.19 (m, 6H), 1.08 (s, 18H), 0.70 (t, J = 7.4 Hz, 3H); 1H-NMR 
(400 MHz; CDCl3): δ 7.55 (t, J = 0.8 Hz, 1H), 7.43 (t, J = 1.2 Hz, 1H), 7.30 (t, J = 2.1 Hz, 1H), 
4.56 (dd, J = 7.0, 3.5 Hz, 1H), 4.26-4.21 (m, 2H), 3.89 (s, 3H), 1.96 (m, 1H), 1.86 (m, 1H), 1.59 
(s, 3H), 1.31-1.19 (m, 6H), 1.09 (d, J = 7.4 Hz, 18H), 0.85 (t, J = 7.4 Hz, 3H); 13C-NMR (101 
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MHz, CDCl3): δ 204.83, 204.59, 168.83, 166.11, 165.35, 164.95, 156.78, 156.74, 136.84, 
136.66, 132.03, 132.01, 120.56, 119.14, 119.11, 116.90, 116.60, 67.50, 66.98, 62.84, 62.67, 
59.55, 59.43, 52.40, 22.31, 21.09, 17.82, 17.19, 14.89, 13.86, 13.83, 12.56, 12.53, 8.50, 7.81; 
FTIR (thin film): 2945, 2893, 2868, 1777, 1707, 1593, 1453, 1386, 1372, 1331, 1243, 1212, 
1104, 1013 cm-1; HRMS (ESI–APCI) m/z calc’d for C27H42NO7Si (M+H)+: 520.2731, found: 
520.2723. 
 
Preparation of  diene 287 
 
To a  –78 °C solution of ketone 280 (1.318 g 2.54 mmol) in THF (25 mL) was added 
NaHMDS (2.79 mL, 1.0 M in THF, 2.79 mmol) and the reaction mixture was allowed to warm 
slowly to –50 °C then cooled to –78 °C. Meanwhile, the vinyl bromide (0.568 g, 3.81 mmol) was 
added slowly to a solution of the Lewis acid (generated from slow addition of AlMe3 (2.29 mL, 
2.0 M in hexanes, 4.57 mmol) to a solution of 2,6-diphenylphenol (3.128 g, 12.7 mmol) in 
toluene (25 mL) at room temperature) at -78 °C and maintained for 20 min. The solution 
containing aldehyde complex 245 was then transferred via cannula to the sodium enolate of 
ketone 280. The reaction mixture was maintained at –78 °C for 1 h then allowed to warm slowly 
to room temperature over 3 h. The reaction mixture was quenched with sat. aq. Rochelle’s salt 
(50 mL), stirred vigorously overnight, and extracted with EtOAc (3 x 25 mL). The combined 
organics were dried over MgSO4, filtered and concentrated in vacuo. The crude material was 
purified via flash chromatography (5%→10%→20% EtOAc/hexanes) to yield an intermediate 



























(14% yield, two steps)
1) NaHMDS
    THF, Toluene
2) KHDMS,
    PPh3MeBr, THF
 173 
KHMDS (0.5 M in THF, 2.8 mL, 1.4 mmol) was added to PPh3MeBr (0.536g, 1.5 mmol). 
After 1 h the enal from the last step (0.287 g, 0.489 mmol) in THF (5 mL) was added. After 10 
min sat. aq. NH4Cl (10 mL) was added. The mixture was extracted with EtOAc (3 × 5 mL) and 
the combined organics were washed with brine (10 mL), dried over MgSO4, filtered and 
concentrated in vacuo. The crude material was purified by flash chromatography (10% 
EtOAc/hexanes) to give triene 287 (0.071 g, 25% yield).  
1H-NMR (400 MHz; CDCl3): δ 7.72 (t, J = 1.7 Hz, 1H), 7.46-7.44 (m, 1H), 7.12 (t, J = 2.2 
Hz, 1H), 6.35-6.28 (dd, J = 17.3, 10.7 Hz, 1H), 5.52 (s, 1H), 5.29 (d, J = 17.3 Hz, 1H), 5.14 (d, J 
= 10.7 Hz, 1H), 4.28-4.22 (m, 2H), 3.89-3.87 (s, 3H), 2.24 (dt, J = 14.6, 7.3 Hz, 1H), 2.10-2.03 
(m, 1H), 1.82 (s, 3H), 1.65-1.63 (s, 3H), 1.29-1.26 (m, 3H), 1.25-1.16 (m, 3H), 1.05 (d, J = 4.2 
Hz, 18H), 0.75 (t, J = 7.4 Hz, 3H); 13C-NMR (101 MHz, CDCl3): δ 222.27, 203.87, 194.65, 
191.46, 169.72, 166.14, 165.59, 156.44, 140.74, 139.58, 136.63, 131.93, 130.28, 120.99, 
119.76, 119.30, 119.27, 114.85, 76.08, 62.78, 58.76, 52.33, 28.66, 18.00, 17.85, 17.79, 17.67, 
13.84, 12.95, 12.51, 8.07; FTIR (thin film): 2945, 2893, 2868, 1776, 1708, 1592, 1453, 1376, 
1361, 1312, 1239, 1186, 1146, 1107, 1020 cm-1; HRMS (ESI–APCI) m/z calc’d for C32H48NO7Si 
(M+H)+: 586.3200, found: 586.3201. 
 
Preparation of  tetramic acid 295 
 
A solution of phenol 294 (10.9 g, 35.8 mmol), K2CO3 (14.9 g, 107 mmol), and MeI (13.4 
mL, 215 mmol) in acetone (358 mmol) was heated to 60 °C for 5.5 h. The reaction was cooled 




















plug of silica gel (100% EtOAc) to yield tetramic acid 295 (10.6 g, 93% yield) as a mixture of 
diastereomers.  
1H-NMR (400 MHz; CDCl3): δ 7.31 (td, J = 8.1, 4.1 Hz, 1H), 7.03 (s, 1H), 6.94 (d, J = 7.7 
Hz, 1H), 6.81 (ddd, J = 8.1, 5.3, 2.6 Hz, 1H), 4.77 (dd, J = 5.5, 2.9 Hz, 1H), 4.15 (dt, J = 13.6, 
6.5 Hz, 2H), 3.79 (s, 3H), 1.95 (dddt, J = 14.5, 10.8, 7.2, 3.5 Hz, 1H), 1.83-1.71 (m, 1H), 1.55 (s, 
3H), 1.22-1.18 (m, 3H), 0.72 (t, J = 7.4 Hz, 3H); 1H-NMR (400 MHz; CDCl3): δ 7.31 (td, J = 8.1, 
4.1 Hz, 1H), 7.03 (s, 1H), 6.94 (d, J = 7.7 Hz, 1H), 6.81 (ddd, J = 8.1, 5.3, 2.6 Hz, 1H), 4.50 (dd, 
J = 7.1, 3.6 Hz, 1H), 4.15 (dt, J = 13.6, 6.5 Hz, 2H), 3.79 (s, 3H), 1.95 (dddt, J = 14.5, 10.8, 7.2, 
3.5 Hz, 1H), 1.88-1.80 (m, 1H), 1.57 (s, 3H), 1.24 (dd, J = 7.4, 6.9 Hz, 3H), 0.88-0.81 (m, 3H); 
13C-NMR (101 MHz, CDCl3): δ 205.24, 205.03, 194.66, 194.64, 191.46, 168.86, 168.83, 165.52, 
165.13, 160.20, 160.17, 136.79, 136.65, 129.96, 129.92, 116.05, 115.97, 112.41, 112.28, 
110.47, 110.39, 67.78, 67.26, 62.76, 62.64, 59.57, 59.47, 55.41, 22.45, 21.19, 17.18, 14.88, 
13.88, 8.64, 7.94; FTIR (thin film): 2974, 2939, 2881, 1775, 1744, 1603, 1589, 1493, 1455, 
1386, 1291, 1123, 1106, 1039, 1010 cm-1; HRMS (ESI–APCI) m/z calc’d for C17H22NO5 (M+H)+: 
320.1498, found: 320.1488. 
 
Preparation of  aryl boronic ester 296 
 
Tetramic acid 295 (2.33 g, 7.3 mmol), [Ir(OMe)(cod)]2 (0.048 g, 0.073 mmol), dtbpy 
(0.063 g, 0.23 mmol), B2Pin2 (1.85 g, 7.3 mmol), and THF (15 mL) were added to a Schlenk 
flask and the solvent was degassed by the freeze/ pump/ thaw method (3x). The mixture was 
then heated to 80 °C and maintained that that temperature for 18 h. The reaction was cooled to 























flash chromatography (15%→30% EtOAc/hexanes) to yield aryl boronic ester 296 (2.194 g, 
68% yield). 
1H-NMR (400 MHz; CDCl3): δ 7.28 (d, J = 2.0 Hz, 1H), 7.17 (t, J = 2.9 Hz, 1H), 7.10 (dd, 
J = 5.0, 2.5 Hz, 1H), 4.78 (dd, J = 5.5, 2.8 Hz, 1H), 4.20-4.07 (m, 2H), 3.77-3.75 (m, 3H), 1.95-
1.85 (m, 1H), 1.76-1.70 (m, 1H), 1.48 (d, J = 6.5 Hz, 3H), 1.25 (d, J = 4.6 Hz, 12H), 1.21-1.11 
(m, 3H), 0.67-0.64 (m, 3H); 1H-NMR (400 MHz; CDCl3): δ 7.25 (t, J = 2.3 Hz, 1H), 7.17 (t, J = 
2.9 Hz, 1H), 7.10 (dd, J = 5.0, 2.5 Hz, 1H), 4.52 (t, J = 3.4 Hz, 1H), 4.20-4.13 (m, 2H), 3.77-3.75 
(m, 3H), 1.95-1.85 (m, 1H), 1.78 (t, J = 7.3 Hz, 1H), 1.48 (d, J = 6.5 Hz, 3H), 1.25 (d, J = 4.6 Hz, 
12H), 1.21-1.11 (m, 3H), 0.79 (t, J = 7.3 Hz, 3H); 13C-NMR (101 MHz, CDCl3): δ 205.20, 205.07, 
194.71, 168.76, 165.55, 165.11, 159.65, 159.61, 136.34, 136.22, 121.87, 121.72, 117.56, 
117.50, 114.56, 114.51, 114.20, 84.05, 67.76, 67.22, 62.66, 62.65, 62.49, 59.42, 59.31, 55.44, 
55.41, 24.76, 22.40, 21.18, 17.09, 14.89, 13.82, 8.52, 7.91; FTIR (thin film): 2978, 2938, 1777, 
1745, 1702, 1588, 1450, 1430, 1372, 1359, 1294, 1252, 1166, 1143, 1105, 1048, 1010, 968, 
954 cm-1; HRMS (ESI–APCI) m/z calc’d for C17H21NO5 (M+H)+: 446.2350, found: 446.2351. 
 
Preparation of  styrene 297 
 
Aryl boronic ester 296 (0.460 g, 1.04 mmol), PdCl2(PPh3)2 (0.073 g, 0.104 mmol), KOtBu 
(0.350 g, 3.12 mmol), 2-bromobutene (0.13 mL, 1.25 mmol), and toluene (3.2 mL) were added 
together and heated to 80 °C. After 14 h the reaction was cooled to room temperature and water 
(10 mL) was added. The solution was extracted with EtOAc (3 × 5 mL) and the combined 

























The crude material was purified by flash chromatography (15%→20% EtOAc/hexanes) to yield 
styrene 297 (0.116 g, 30% yield) as a mixture of diastereomers. 
1H-NMR (300 MHz; CDCl3): δ 7.00 (m, 1H), 6.96 (m, 1H), 6.89-6.85 (m, 1H), 5.30-5.26 
(m, 1H), 5.10-5.08 (m, 1H), 4.82-4.52 (m, 1H), 4.28-4.16 (m, 2H), 3.84-3.78 (m, 3H), 2.52-2.43 
(m, 2H), 2.06-1.72 (m, 2H), 1.60-1.55 (m, 3H), 1.33-1.04 (m, 6H), 0.95-0.71 (m, 3H). 
 
Preparation of  ketone 298  
 
Styrene 297 (0.155 g, 0.415 mmol) was dissolved in THF (3 mL) and water (1.5mL) and 
OsO4 (0.08 M, 0.052 mL, 0.0415 mmol) and NaIO4 (0.462 g, 2.2 mmol) were added. The 
reaction was stirred for 3 h the water (5 mL) was added and the solution was extracted with 
EtOAc (3 × 5 mL). The combined organics were washed with brine (10 mL), dried over MgSO4, 
filtered and concentrated in vacuo. The crude material was purified by flash chromatography 
(25% EtOAc/hexanes) to yield ketone 298 (0.073 g, 47% yield) as a mixture of diastereomers. 
1H-NMR (300 MHz; CDCl3): δ 7.59 (m, 1H), 7.40 (m, 1H), 7.29 (m, 1H), 4.88-4.58 (m, 
1H), 4.29-4.16 (m, 2H), 3.90-3.84 (m, 3H), 3.04-2.96 (m, 2H), 2.05-1.76 (m, 2H), 1.61-1.52 (m, 





























Preparation of  aryl bromide 301 from aryl boronic ester 296 
 
CuBr2 (0.599 g, 2.68 mmol) was dissolved in water (11.2 mL). In a separate flask aryl 
boronic ester 296 (0.397 g, 0.89 mmol) was dissolved in MeOH (11.2 mL). The solution of 296 
in MeOH was then poured into the aqueous solution and heated to 80 °C. The reaction was 
stirred for 4.5 h then cooled to room temperature and brine (20 mL) was added. The mixture 
was extracted with EtOAc (3 × 20 mL). The combined organics were washed with brine (50 mL), 
dried over MgSO4, filtered and concentrated in vacuo. The crude material was purified by flash 
chromatography (15% EtOAc/hexanes) to yield aryl bromide 301 (0.262 g, 77% yield) as a 
mixture of diastereomers.  
1H-NMR (400 MHz; CDCl3): δ 7.12 (m, 1H), 6.95 (m, 1H), 6.95-6.90 (m, 1H), 4.72 (dd, J 
= 5.4, 2.7 Hz, 1H), 4.20-4.10 (m, 2H), 3.74 (s, 3H), 1.97-1.73 (m, 2H), 1.53-1.49 (m, 3H), 1.23-
1.14 (m, 3H), 0.73-0.65 (m, 3H); 1H-NMR (400 MHz; CDCl3): δ 7.12 (m, 1H), 6.95 (m, 1H), 6.95-
6.90 (m, 1H), 4.47 (dd, J = 7.2, 3.6 Hz, 1H), 4.20-4.10 (m, 2H), 3.74 (s, 3H), 1.97-1.73 (m, 2H), 
1.53-1.49 (m, 3H), 1.23-1.14 (m, 3H), 0.84-0.78 (m, 3H); 13C-NMR (101 MHz, CDCl3): δ 204.54, 
204.37, 194.65, 194.63, 194.62, 168.86, 168.80, 165.31, 164.86, 160.69, 160.64, 137.66, 
137.58, 122.96, 122.90, 121.38, 118.89, 118.87, 118.75, 116.34, 116.28, 115.42, 115.25, 
115.16, 112.00, 111.81, 109.50, 109.43, 67.50, 67.00, 62.85, 62.69, 59.51, 59.41, 55.69, 55.66, 
55.62, 22.34, 21.11, 17.13, 14.88, 13.87, 8.56, 7.90; FTIR (thin film): 2975, 2939, 2880, 1777, 
1744, 1702, 1598, 1571, 1449, 1381, 1287, 1251, 1179, 1106, 1042, 1010 cm-1; HRMS (ESI–

























Preparation of  aryl bromide 301 from arene 295 
 
Alternative to the two–step procedure, aryl bromide 301 can be synthesized from arene 
295 by subjecting the crude material of the borylation reaction directly into the bromination step. 
This was performed as followed:  
 Arene 295 (3.91 g, 12.6 mmol), [Ir(OMe)(cod)]2 (0.084 g, 0.126 mmol), dtbpy (0.108 g, 
0.40 mmol), B2Pin2 (3.20 g, 12.6 mmol), and THF (25 mL) were added to a Schlenk flask and 
the solvent was degassed by the freeze/ pump/ thaw method (3x). The mixture was then heated 
to 80 °C and maintained that that temperature for 13.5 h. The reaction was cooled to room 
temperature and the solvent was removed in vacuo. The crude material was dissolved in MeOH 
(158 mL) and added to a solution of CuBr2 (8.44 g, 37.8 mmol) in water (158 mL). The reaction 
was stirred for 5 h then cooled to room temperature and brine (150 mL) was added. The mixture 
was extracted with EtOAc (3 × 150 mL). The combined organics were washed with brine (300 
mL), dried over MgSO4, filtered and concentrated in vacuo. The crude material was purified by 
flash chromatography (15% EtOAc/hexanes) to yield aryl bromide 301 (2.745 g, 57% yield, two 
steps) as a mixture of diastereomers. All spectral data was identical to the material produced in 
























      B2Pin2, THF, 80 °C
2) CuBr2, MeOH, H2O
(57% yield, two steps)
301
 179 
Preparation of  enone 300 
 
Aryl bromide 301 (0.439 g, 1.15 mmol), vinyl stannane 302 (1.52 g, 4.58 mmol), 
PdCl2(PPh3)2 (0.081 g, 0.115 mmol), and DMF (11.5 mL) were added to a steel bomb. The 
bomb was flushed with CO by filling to 30 bar and venting three times. The bomb was then filled 
with CO to 30 bar and heated to 80 °C. The reaction was stirred for 19 h then cooled to room 
temperature. The bomb was vented and water (30 mL) was added. The mixture was extracted 
with EtOAc (3 × 20 mL) and the combined organics were washed with brine (30 mL), dried over 
MgSO4, filtered and concentrated in vacuo. The crude material was purified by flash 
chromatography (15% EtOAc/hexanes) to give enone 300 (0.164 g, 38% yield) as a mixture of 
diastereomers and starting material 301 (0.174 g, 40% recovery). 
1H-NMR (400 MHz; CDCl3): δ 7.33-7.29 (m, 1H), 7.24-7.22 (m, 1H), 7.16-7.13 (m, 1H), 
5.93 (s, 1H), 5.69 (d, J = 4.9 Hz, 1H), 4.81 (dd, J = 5.5, 2.7 Hz, 1H), 4.17 (td, J = 6.6, 3.0 Hz, 
2H), 3.83 (s, 3H), 2.03 (s, 3H), 2.03-1.79 (m, 2H), 1.56 (m, 3H), 1.20 (t, J = 6.8 Hz, 3H), 0.70 (t, 
J = 7.2 Hz, 3H); 1H-NMR (400 MHz; CDCl3): δ 7.33-7.29 (m, 1H), 7.24-7.22 (m, 1H), 7.16-7.13 
(m, 1H), 5.93 (s, 1H), 5.69 (m, 1H), 4.55 (dd, J = 7.1, 3.5 Hz, 1H), 4.21 (dt, J = 12.2, 5.7 Hz, 
2H), 3.83 (s, 3H), 2.03 (s, 3H), 2.03-1.79 (m, 2H), 1.57 (s, 3H), 1.24 (td, J = 7.1, 3.6 Hz, 3H), 
0.85 (t, J = 7.4 Hz, 3H); 13C-NMR (101 MHz, CDCl3): δ 204.65, 204.46, 203.26, 196.96, 196.94, 
169.02, 168.97, 165.35, 164.92, 160.02, 159.98, 159.93, 143.34, 139.49, 136.59, 136.50, 
127.95, 116.95, 116.76, 113.85, 113.82, 112.57, 112.42, 67.48, 66.98, 62.86, 62.72, 59.56, 
59.46, 55.71, 55.67, 55.65, 22.37, 21.08, 18.52, 18.49, 18.08, 17.19, 14.91, 13.87, 8.58, 7.90; 


























1214, 1182, 1108, 1061, 1034, 1011 cm-1; HRMS (ESI–APCI) m/z calc’d for C21H26NO6 (M+H)+: 
388.1760, found: 388.1765. 
 
Preparation of   triene 303 
 
To a  –78 °C solution of ketone 300 (0.164 g 0.49 mmol) in THF (4.4 mL) was added 
NaHMDS (0.48 mL, 1.0 M in THF, 0.48 mmol) and the reaction mixture was allowed to warm 
slowly to –50 °C then cooled to –78 °C. Meanwhile, the vinyl bromide (0.098 g, 0.66 mmol) was 
added slowly to a solution of the Lewis acid (generated from slow addition of AlMe3 (0.40 mL, 
2.0 M in hexanes, 0.79 mmol) to a solution of 2,6-diphenylphenol (0.542 g, 2.2 mmol) in toluene 
(4.4 mL) at room temperature) at –78 °C and maintained for 20 min. The solution containing 
aldehyde complex 245 was then transferred via cannula to the sodium enolate of ketone 300. 
The reaction mixture was maintained at –78 °C for 1 h then allowed to warm slowly to room 
temperature over 3 h. The reaction mixture was quenched with sat. aq. Rochelle’s salt (10 mL), 
stirred vigorously overnight, and extracted with EtOAc (3 x 10 mL). The combined organics were 
dried over MgSO4, filtered and concentrated in vacuo. The crude material was purified via flash 
chromatography (15%→30% EtOAc/hexanes) to provide enal 464 (0.088 g, 44% yield) as an 
inseparable mixture of diastereomers.  
1H-NMR (400 MHz; CDCl3): δ 9.41 (s, 1H), 7.29 (s, 1H), 7.18 (s, 1H), 7.10 (s, 1H), 6.45 
(s, 1H), 5.92 (t, J = 5.6 Hz, 1H), 5.66 (s, 1H), 4.29-4.21 (m, 2H), 3.85-3.82 (s, 3H), 2.45-2.39 (m, 









(11% yield, two steps)
1) NaHMDS
    THF, Toluene
2) KHDMS,





















3H), 0.89-0.77 (m, 3H); 13C-NMR (101 MHz, CDCl3): δ 202.49, 196.65, 193.96, 193.70, 193.67, 
169.68, 165.01, 160.11, 160.02, 149.47, 149.03, 148.87, 143.42, 142.11, 139.52, 135.93, 
129.97, 127.81, 127.75, 118.92, 118.39, 117.28, 115.16, 112.55, 112.37, 111.86, 63.03, 58.80, 
55.68, 27.88, 27.82, 18.51, 17.92, 16.09, 14.03, 13.90, 10.33, 8.62, 8.11; FTIR (thin film): 2981, 
2940, 2842, 1777, 1747, 1659, 1628, 1595, 1493, 1455, 1376, 1358, 1284, 1221, 1162, 1125, 
1032 cm-1; HRMS (ESI–APCI) m/z calc’d for C25H30NO7 (M+H)+: 456.2022, found: 456.2021.` 
NaHMDS (1 M in THF, 0.22 mL, 0.22 mmol) was added to PPh3MeBr (0.086 g, 0.24 
mmol). After 1 h enal 464 (0.088 g, 0.20 mmol) in THF (2 mL) was added. After 10 min sat. aq. 
NH4Cl (10 mL) was added. The mixture was extracted with EtOAc (3 × 5 mL) and the combined 
organics were washed with brine (10 mL), dried over MgSO4, filtered and concentrated in vacuo. 
The crude material was purified by flash chromatography (10% EtOAc/hexanes) to give triene 
303 (0.021 g, 24% yield) as a mixture of diastereomers.  
1H-NMR (400 MHz; CDCl3): δ 7.35 (d, J = 1.2 Hz, 1H), 7.20 (dd, J = 6.9, 1.6 Hz, 1H), 
7.13 (t, J = 2.1 Hz, 1H), 6.96 (dd, J = 4.4, 2.1 Hz, 1H), 6.31 (ddd, J = 17.3, 10.7, 2.8 Hz, 1H), 
5.90 (s, 1H), 5.66 (s, 1H), 5.52 (d, J = 6.5 Hz, 1H), 5.29 (dd, J = 17.3, 3.0 Hz, 1H), 5.12 (dt, J = 
10.5, 5.2 Hz, 1H), 4.25 (dt, J = 11.0, 5.3 Hz, 2H), 3.85-3.78 (m, 3H), 2.24 (ddd, J = 14.4, 7.3, 5.5 
Hz, 1H), 2.08 (ddd, J = 14.6, 7.3, 3.8 Hz, 1H), 2.03 (s, 3H), 1.82 (s, 3H), 1.65 (s, 3H), 1.27 (tdd, 
J = 7.7, 6.9, 6.0 Hz, 3H), 0.78 (td, J = 7.4, 1.9 Hz, 3H); 13C-NMR (101 MHz, CDCl3): δ 204.22, 
203.70, 169.88, 169.71, 165.78, 165.56, 159.87, 143.35, 140.92, 140.69, 139.71, 139.42, 
139.16, 136.56, 136.23, 130.59, 130.13, 129.63, 127.56, 119.55, 118.01, 115.77, 115.02, 
114.74, 112.64, 112.35, 111.93, 76.67, 62.81, 62.69, 58.81, 58.78, 55.61, 55.30, 28.83, 28.71, 






Preparation of  allylic alcohol 304 
 
Enone 303 (0.017 g, 0.037 mmol) was dissolved in MeOH (0.4 mL) and cooled to 0 °C. 
CeCl3 • 7H2O (0.015 g, 0.041 mmol) was added and after 7 min NaBH4 (0.002 g, 0.041 mmol) 
was added. After 1 h CeCl3 • 7H2O (0.015 g, 0.041 mmol) then NaBH4 (0.002 g, 0.041 mmol) 
was added again. After 10 min the reaction was allowed to warm to room temperature. After 2 h 
the reaction mixture was concentrated in vacuo. The crude material was purified by flash 
chromatography (15%→20%→30% EtOAc/hexanes) to give allylic alcohol 304 (0.010 g, 59% 
yield). 
1H-NMR (400 MHz; CDCl3): δ 6.97 (d, J = 7.2 Hz, 1H), 6.89-6.87 (m, 2H), 6.33-6.26 (m, 
1H), 5.49 (d, J = 2.4 Hz, 1H), 5.27 (d, J = 17.1 Hz, 1H), 5.14-5.07 (m, 3H), 4.92-4.91 (m, 1H), 
4.25 (qd, J = 7.1, 0.9 Hz, 2H), 3.81-3.77 (m, 3H), 2.25-2.19 (m, 1H), 2.06 (ddd, J = 13.8, 6.6, 3.5 
Hz, 1H), 1.80 (dd, J = 2.5, 1.1 Hz, 3H), 1.65-1.62 (m, 3H), 1.59-1.56 (m, 3H), 1.29-1.22 (m, 3H), 
0.77 (tt, J = 7.4, 3.7 Hz, 3H); 13C-NMR (101 MHz, CDCl3): δ 204.16, 204.15, 169.71, 165.74, 
159.98, 159.94, 146.33, 146.28, 144.12, 141.37, 140.85, 139.48, 139.46, 136.41, 136.38, 
130.41, 130.39, 130.03, 116.32, 116.27, 114.69, 111.99, 111.73, 111.07, 111.05, 110.70, 
110.52, 62.73, 62.71, 58.83, 58.82, 55.43, 55.39, 29.67, 28.94, 28.87, 17.97, 17.86, 17.76, 
13.88, 13.09, 13.07, 12.89, 8.13, 8.12; FTIR (thin film): 3456, 2979, 2940, 2849, 1774, 1745, 
1599, 1461, 1378, 1288, 1226, 1152, 1126, 1052 cm-1; HRMS (ESI–APCI) m/z calc’d for 

























Preparation of  styrene 313 
 
Aryl bromide 301 (0.507 g, 1.32 mmol), PdCl2(PPh3)2 (0.093 g, 0.132 mmol), vinyl 
stannane (0.77 mL, 2.64 mmol), and DMF (13.2 mL) were heated to 80 °C. After 16 h the 
reaction was cooled to room temperature and water (20 mL) was added. The mixture was 
extracted with EtOAc (3 × 15 mL) and the combined organics were washed with water (2 × 20 
mL) then brine (30 mL), dried over MgSO4, filtered and concentrated in vacuo. The crude 
material was purified by flash chromatography (15%→20% EtOAc/hexanes) to give styrene 313 
(0.367 g, 80% yield). 
1H-NMR (300 MHz; CDCl3): δ 7.03 (q, J = 1.8 Hz, 1H), 6.93 (t, J = 2.1 Hz, 1H), 6.88 (t, J 
= 1.9 Hz, 1H), 6.68 (dd, J = 17.5, 10.9 Hz, 1H), 5.76 (d, J = 17.5 Hz, 1H), 5.32 (d, J = 10.9 Hz, 
1H), 4.66 (m, J = 3.3 Hz, 1H), 4.28-4.17 (m, 2H), 3.84 (s, 3H), 1.92 (m, 2H), 1.59 (m, 3H), 1.31-
1.22 (m, 3H), 0.94-0.73 (m, 3H). 
 
Preparation of  benzaldehyde 312 
 
Styrene 313 (0.367 g, 1.06 mmol) was dissolved in THF (7 mL) and water (3.5 mL) and 
OsO4 (0.08 M, 1.33 mL, 0.106 mmol) and NaIO4 (1.18 g, 5.51 mmol) were added. The reaction 
was stirred for 3 h the water (10 mL) was added and the solution was extracted with EtOAc (3 × 









































and concentrated in vacuo. The crude material was purified by flash chromatography (20% 
EtOAc/hexanes) to yield ketone 312 (0.231 g, 63% yield) as a mixture of diastereomers. 
1H-NMR (400 MHz; CDCl3): δ 9.98-9.94 (m, 1H), 7.52 (dd, J = 1.9, 1.2 Hz, 1H), 7.35 (dt, 
J = 5.7, 2.2 Hz, 1H), 7.30 (ddd, J = 4.0, 2.5, 1.3 Hz, 1H), 4.85 (dd, J = 5.6, 2.8 Hz, 1H), 4.29-
4.21 (m, 2H), 3.89-3.88 (m, 3H), 2.03-1.98 (m, 1H), 1.82-1.80 (m, 1H), 1.60-1.56 (m, 3H), 1.24-
1.20 (m, 3H), 0.73 (q, J = 7.5 Hz, 3H); 1H-NMR (400 MHz; CDCl3): δ 9.98-9.94 (m, 1H), 7.52 
(dd, J = 1.9, 1.2 Hz, 1H), 7.35 (dt, J = 5.7, 2.2 Hz, 1H), 7.30 (ddd, J = 4.0, 2.5, 1.3 Hz, 1H), 4.58 
(dd, J = 7.2, 3.5 Hz, 1H), 4.21-4.15 (m, 2H), 3.89-3.88 (m, 3H), 2.03-1.98 (m, 1H), 1.89 (dd, J = 
14.6, 7.3 Hz, 1H), 1.60 (q, J = 5.1 Hz, 3H), 1.30-1.24 (m, 3H), 0.88 (t, J = 7.5 Hz, 3H); 13C-NMR 
(101 MHz, CDCl3): δ 204.42, 204.20, 194.70, 191.14, 169.10, 165.28, 164.82, 160.80, 160.77, 
138.18, 137.69, 137.58, 119.42, 119.23, 117.25, 117.10, 116.45, 116.43, 111.54, 111.23, 67.37, 
66.89, 62.95, 62.81, 59.59, 59.49, 55.85, 22.33, 21.05, 17.28, 14.95, 13.91, 8.55, 7.89; FTIR 
(thin film): 2976, 2939, 2880, 2849, 1777, 1744, 1595, 1458, 1384, 1291, 1214, 1153, 1107, 
1079, 1010 cm-1; HRMS (ESI–APCI) m/z calc’d for C18H22NO6 (M+H)+: 348.1447, found: 
348.1440. 
 
Preparation of  vinyl iodide 314 
 
n-BuLi (1.6 M in hexanes, 0.14 mL, 0.216 mmol) was added to EtPPh3Br (0.080 g, 0.216 
mmol) in THF (0.43 mL) at room temperature. After 30 min this solution was added via cannula 
to a mixture of I2 (0.055 g, 0.216 mmol) in THF (1.3 mL) at –78 °C. The reaction was slowly 
warmed to –10 °C over 1 hr 15 min then cooled to –45 °C at which point NaHMDS (1.0 M in 























0.216 mmol) in THF (3 mL) was added and the mixture was allowed to slowly warm to room 
temperature. After 1 hr 45 min MeOH (5 mL) was added and the volatiles were removed in 
vacuo. The crude material was purified by flash chromatography (20% EtOAc/hexanes) to 
provide vinyl iodide 314 (0.028 g, 27% yield). 
1H-NMR (300 MHz; CDCl3): δ 7.04 (m, 2H), 6.90-6.88 (m, 1H), 6.63 (s, 1H), 4.67 (m, J = 
3.3 Hz, 1H), 4.29-4.07 (m, 2H), 3.84 (s, 3H), 2.71-2.68 (m, 3H), 2.06-1.82 (m, 2H), 1.63-1.55 (m, 
3H), 1.31-1.19 (m, 3H), 0.93-0.73 (m, 3H). 
 
Preparation of  alkyne 315 
 
To a  –78 °C solution of ketone 314 (0.052 g 0.107 mmol) in THF (1.1 mL) was added 
NaHMDS (0.12 mL, 1.0 M in THF, 0.12 mmol) and the reaction mixture was allowed to warm 
slowly to –50 °C then cooled to –78 °C. Meanwhile, the vinyl bromide (0.024 g, 0.161 mmol) 
was added slowly to a solution of the Lewis acid (generated from slow addition of AlMe3 (0.096 
mL, 2.0 M in hexanes, 0.193 mmol) to a solution of 2,6-diphenylphenol (0.132 g, 0.535 mmol) in 
toluene (1.1 mL) at room temperature) at –78 °C and maintained for 20 min. The solution 
containing aldehyde complex 245 was then transferred via cannula to the sodium enolate of 
ketone 314. The reaction mixture was maintained at –78 °C for 1 h then allowed to warm slowly 
to room temperature over 3 h. The reaction mixture was quenched with sat. aq. Rochelle’s salt 
(5 mL), stirred vigorously overnight, and extracted with EtOAc (3 × 5 mL). The combined 































purified via flash chromatography (5%→10%→20% EtOAc/hexanes) to yield alkyne 315 (0.024 
g, 52% yield).  
1H-NMR (400 MHz; CDCl3): δ 9.41 (s, 1H), 6.90 (d, J = 1.3 Hz, 1H), 6.87 (t, J = 2.2 Hz, 
1H), 6.84 (d, J = 2.2 Hz, 1H), 6.44 (t, J = 1.3 Hz, 1H), 4.25 (qd, J = 7.1, 1.2 Hz, 2H), 3.77-3.75 
(m, 3H), 2.39 (dd, J = 14.6, 7.3 Hz, 1H), 2.17 (dd, J = 14.6, 7.4 Hz, 1H), 2.01 (d, J = 2.4 Hz, 3H), 
1.88-1.85 (m, 3H), 1.63-1.57 (m, 3H), 1.28-1.24 (m, 3H), 0.87-0.80 (m, 3H); 13C-NMR (101 MHz, 
CDCl3): δ 202.82, 194.68, 194.00, 165.14, 159.78, 149.35, 142.07, 136.05, 125.90, 120.16, 
115.09, 111.87, 87.25, 78.84, 62.95, 58.77, 55.44, 27.77, 17.95, 13.91, 10.31, 8.12, 4.32; FTIR 
(thin film): 2981, 2940, 2847, 1776, 1747, 1589, 1450, 1428, 1378, 1361, 1319, 1299, 1285, 
1222, 1201, 1171, 1124, 1062, 1014 cm-1; HRMS (ESI–APCI) m/z calc’d for C24H28NO6 (M+H)+: 
426.1917, found: 426.1901. 
 
Preparation of  alkyne 315 
 
In a Schlenk flask was added PdCl2(PPh3)2 (0.043 g, 0.061 mmol) and CuI (0.006 g, 
0.0304 mmol) then aryl bromide 301 (0.233 g, 0.608 mmol) in Et3N (6.1 mL). Propyne gas was 
then bubble through the solution for 30 s and the Schlenk flask was closed under the propyne 
atmosphere. The reaction was heated at 50 °C for 19 h then was cooled to room temperature 
and sat. aq. NH4Cl (15 mL) was added. The mixture was extracted with EtOAc (3 × 10 mL) and 
the combined organics were washed with brine (15 mL), dried over MgSO4, filtered and 
concentrated in vacuo. The crude material was purified by flash chromatography (20% 




















(48% yield, two steps)
1)
2) NaHMDS, 243
    THF, Toluene
301 315
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1H-NMR (400 MHz; CDCl3): δ 7.15 (t, J = 1.6 Hz, 1H), 7.01-6.95 (m, 2H), 4.74 (dd, J = 
5.5, 2.8 Hz, 1H), 4.25-4.16 (m, 2H), 3.80 (s, 3H), 2.02 (s, 3H), 1.99-1.87 (m, 2H), 1.59-1.56 (s, 
3H), 1.27-1.24 (m, 3H), 0.90-0.86 (m, 3H); 1H-NMR (400 MHz; CDCl3): δ 7.15 (t, J = 1.6 Hz, 
1H), 7.01-6.95 (m, 2H), 4.47 (dd, J = 7.2, 3.6 Hz, 1H), 4.25-4.16 (m, 2H), 3.79 (s, 3H), 2.02 (s, 
4H), 1.99-1.87 (m, 2H), 1.55 (s, 3H), 1.22 (td, J = 4.6, 2.5 Hz, 3H), 0.72 (td, J = 7.4, 2.9 Hz, 3H); 
13C-NMR (101 MHz, CDCl3): δ 205.07, 204.38, 168.88, 168.86, 168.76, 165.31, 165.03, 160.69, 
159.92, 159.90, 137.57, 136.67, 134.07, 128.40, 128.33, 125.77, 123.01, 118.99, 118.89, 
115.50, 115.36, 114.93, 114.78, 110.61, 109.53, 109.45, 86.95, 78.92, 67.63, 67.04, 62.80, 
62.76, 59.46, 55.73, 55.51, 22.41, 21.15, 17.24, 14.91, 13.91, 13.90, 8.60, 7.92, 4.28; FTIR (thin 
film): 2974, 2939, 1777, 1744, 1703, 1593, 1572, 1449, 1435, 1289, 1251, 1202, 1174, 1107 
cm-1; HRMS (ESI–APCI) m/z calc’d for C20H24NO5 (M+H)+: 358.1654, found: 358.1645. 
To a  –78 °C solution of alkyne 358 (0.160 g 0.448 mmol) in THF (4.5 mL) was added 
NaHMDS (0.49 mL, 1.0 M in THF, 0.49 mmol) and the reaction mixture was allowed to warm 
slowly to –50 °C then cooled to –78 °C. Meanwhile, the vinyl bromide (0.100 g, 0.672 mmol) 
was added slowly to a solution of the Lewis acid (generated from slow addition of AlMe3 (0.40 
mL, 2.0 M in hexanes, 0.806 mmol) to a solution of 2,6-diphenylphenol (0.552 g, 2.24 mmol) in 
toluene (4.5 mL) at room temperature) at –78 °C and maintained for 20 min. The solution 
containing aldehyde complex 243 was then transferred via cannula to the sodium enolate of 
ketone 358. The reaction mixture was maintained at –78 °C for 1 h then allowed to warm slowly 
to room temperature over 3 h. The reaction mixture was quenched with sat. aq. Rochelle’s salt 
(15 mL), stirred vigorously overnight, and extracted with EtOAc (3 × 10 mL). The combined 
organics were dried over MgSO4, filtered and concentrated in vacuo. The crude material was 
purified via flash chromatography (5%→10%→20% EtOAc/hexanes) to yield alkyne 315 (0.024 
g, 65% yield). The spectral data was identical to that obtained when alkyne 315 was 
synthesized from vinyl iodide 314. 
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Preparation of  synthesis of aldehyde 325 
 
To a solution of 295 (0.500 g, 1.57 mmol) in THF (20 mL) was added NaHMDS (1 M in 
THF, 1.9 mL, 1.88 mmol) dropwise at –78 °C and the mixture was allowed to stir for 20 min at 
this temperature. Meanwhile, AlMe3 (2 M in toluene, 1.4 mL, 2.82 mmol) was added to a 
solution of 2,6-diphenylphenol (1.97 g, 7.99 mmol) in toluene (20 mL). After 10 min stirring at 
room temperature the toluene solution was cooled to –78 °C and methacrolein (0.20 mL, 2.35 
mmol) was added, which resulted in the formation of a bright yellow solution. The THF solution 
of the sodium enolate of 295 was then transferred via cannula to the methacrolein–Lewis Acid 
complex at –78 °C, the solution stirred for another 10 min at –78 °C and then slowly warmed to 
room temperature. After stirring for 1 h at room temperature the reaction was quenched by 
addition of saturated aqueous Rochelle’s salt (30 mL) and the mixture stirred vigorously for 30 
min. Then diethyl ether (10 mL) was added and the phases separated. The aqueous phase was 
extracted with diethyl ether (2 × 10 mL) and the combined organic phase was washed with brine 
(30 mL), dried over MgSO4, filtered and concentrated in vacuo. The crude material was purified 
by flash chromatography (5:1→2:1 hexanes:EtOAc) to yield aldehyde 325 (0.460 g, 75% yield) 
as a mixture of diastereomers.  
1H-NMR (400 MHz; CDCl3): δ 9.47-9.36 (m, 1H), 7.35 (t, J = 8.0 Hz, 1H), 6.92 (dd, J = 
8.0, 6.1 Hz, 1H), 6.80 (d, J = 7.9 Hz, 1H), 6.74 (s, 1H), 4.31-4.16 (m, 2H), 2.80-2.40 (m, 3H), 
1.99 (m, J = 7.5 Hz, 1H), 1.89-1.77 (m, 1H), 1.60-1.50 (m, 3H), 1.33-1.20 (m, 3H), 1.07-1.00 (m, 
3H), 0.96-0.88 (m, 3H); 13C-NMR (101 MHz, CDCl3): δ 208.08, 207.93, 207.79, 207.08, 202.61, 





























160.33, 160.31, 149.57, 135.54, 135.48, 135.39, 130.26, 130.21, 130.14, 120.72, 120.65, 
120.54, 115.87, 114.86, 114.84, 114.74, 114.68, 114.07, 114.02, 113.94, 113.29, 75.73, 75.55, 
75.24, 74.81, 63.08, 62.90, 62.68, 62.58, 58.62, 58.58, 58.38, 55.39, 41.63, 41.11, 40.99, 40.88, 
36.94, 36.91, 36.51, 36.32, 29.62, 29.00, 28.43, 28.22, 18.00, 17.34, 16.40, 16.17, 15.94, 15.77, 
15.75, 14.02, 13.92, 13.86, 8.90, 8.81, 8.56, 8.54; FTIR (thin film): 2977, 2940, 2883, 2838, 
1772, 1702, 1603, 1588, 1512, 1492, 1455, 1383, 1288, 1270, 1218, 1038 cm-1; HRMS (ESI–
APCI) m/z calc’d for C21H28NO6 (M+H)+: 390.1917, found: 390.1907. 
 
Preparation of  vinyl carbonate 321 
 
To a solution of aldehyde 325 (0.150 g, 0.385 mmol) in THF (5 mL) was added 
vinylmagnesium bromide (1.1 M in THF, 0.42 mL, 0.462 mmol) at –78 °C and the mixture stirred 
for 1 h at this temperature. Methyl chloroformate (75 mL, 0.963 mmol) was added and the 
mixture was allowed to warm to room temperature. Aqueous saturated sodium bicarbonate (10 
mL) and diethylether (10 mL) were added and the phases separated. The aqueous phase was 
extracted with diethyl ether (2 × 5 mL) and the combined organic phase was washed with brine 
(20 mL), dried over MgSO4, filtered and concentrated in vacuo. The crude material was purified 
by flash chromatography (3:1→2:1 hexanes:EtOAc) to provide vinyl carbonate 321 (0.087 g, 
48% yield) as a mixture of diastereomers.  
1H-NMR (400 MHz; CDCl3): δ 7.34 (m, 1H), 6.94-6.90 (m, 1H), 6.86-6.82 (m, 1H), 6.79 



























(m, 7H), 2.18-1.80 (m, 5H), 1.70-1.62 (m, 3H), 1.28-1.18 (m, 3H), 1.01-0.84 (m, 6H); 13C-NMR 
(101 MHz, CDCl3): δ 207.63, 207.31, 170.41, 170.19, 165.67, 165.58, 160.24, 160.20, 154.99, 
135.61, 132.72, 132.69, 130.07, 129.99, 120.76, 120.66, 120.57, 120.51, 119.58, 118.90, 
114.86, 114.81, 114.53, 113.85, 113.72, 96.97, 82.18, 75.81, 75.61, 62.64, 62.56, 62.52, 58.84, 
58.63, 58.58, 55.44, 55.38, 55.33, 55.30, 54.99, 54.70, 40.27, 40.21, 34.52, 32.04, 31.33, 28.80, 
28.76, 18.58, 18.52, 18.42, 17.94, 17.42, 17.27, 17.20, 13.87, 9.03, 8.69, 8.59; FTIR (thin film): 
2979, 2941, 1770, 1745, 1701, 1602, 1587, 1492, 1442, 1381, 1134, 1036, 1018 cm-1; HRMS 
(ESI–APCI) m/z calc’d for C25H34NO8 (M+H)+: 476.2284, found: 476.2277. 
 
Preparation of  epoxide 334 
 
To a suspension of known allylic alcohol 33310 (1.50 g, 13.37 mmol) and VO(acac)2 (196 
mg, 0.76 mmol) in benzene (50 mL) was added TBHP (7.3 M in H2O, 2.3 mL, 16.79 mmol) at 
room temperature. The dark reddish–brown solution was stirred for 14 h at ambient temperature 
before MgSO4 was added. The mixture was stirred for 30 min, filtered and concentrated in 
vacuo. The crude material was purified by flash chromatography (5:1→4:1 hexanes:EtOAc) to 
provide allylic epoxide 334 (1.18 g, 69% yield). All spectral data matched that known in the 



















Preparation of  bromide 335 
 
Triphenylphosphine (675 mg, 2.575 mmol) was suspended in acetonitrile (5 mL) and 
cooled to 0 °C before bromine (130 mL, 2.575 mmol) was added dropwise. The tan suspension 
was stirred for 20 min at 0 °C then a solution of allylic epoxide 334 (300 mg, 2.341 mmol) and 
triethylamine (390 mL, 2.809 mmol) in acetonitrile (1 mL) was added. The mixture was allowed 
to warm to room temperature and stirred for 30 min before diethyl ether (10 mL) was added. 
The precipitate was filtered off, the filtrate concentrated in vacuo and the crude material was 
purified by flash chromatography (50:1→20:1 hexanes:EtOAc) to furnish allylic bromide 335 
(202 mg, 45% yield). 
1H-NMR (400 MHz; CDCl3): δ 4.97 (s, 1H), 4.88 (s, 1H), 3.42 (d, J = 10.2 Hz, 1H), 3.29 
(d, J = 10.3 Hz, 1H), 3.26 (s, 1H), 1.74 (s, 3H), 1.28 (s, 3H); 13C-NMR (101 MHz, CDCl3): δ 
138.26, 112.47, 66.03, 61.31, 38.99, 19.58, 13.71; FTIR (thin film): 3093, 2970, 2935, 2857, 
1656, 1446, 1423, 1384, 1216, 1070, 1040, 1015 cm-1. 
 
Preparation of  tosylate 336 
 
To an ice cold solution of epoxy alcohol 334 (300 mg, 2.341 mmol) in CH2Cl2 (10 mL) 
was added DMAP (30 mg, 0.234 mmol), triethylamine (0.35 mL, 2.575 mmol) and p–TsCl (470 
mg, 2.458 mmol). The white suspension formed was stirred for 30 min at 0 °C and then warmed 
to room temperature where it was stirred for 1 h. The mixture was quenched by addition of 


















(3 × 5 mL) and the combined organic phases were washed with brine (20 mL), dried over 
MgSO4, filtered and concentrated in vacuo. The crude material was purified by flash 
chromatography (10:1 hexanes:EtOAc) to give allylic tosylate 336 (473 mg, 72% yield). 
1H-NMR (400 MHz; CDCl3): δ 7.78-7.76 (d, J = 8.1 Hz, 2H), 7.33 (d, J = 8.1 Hz, 2H), 
4.97 (s, 1H), 4.87 (s, 1H), 4.00 (d, J = 10.7 Hz, 1H), 3.99-3.95 (d, J = 10.7 Hz, 1H), 3.20 (s, 1H), 
2.42 (s, 3H), 1.70 (s, 3H), 1.16 (s, 3H); 13C-NMR (101 MHz, CDCl3): δ 145.04, 137.69, 132.62, 
129.89, 127.91, 112.83, 73.72, 62.67, 59.55, 21.62, 19.60, 12.76; FTIR (thin film): 2975, 2939, 
1656, 1598, 1495, 1448, 1359, 1175, 1096 cm-1; HRMS (ESI–APCI) m/z calc’d for C14H18NaO4S 
(M+Na)+: 305.0823, found: 305.0810. 
 
Preparation of  carboxylic acid 337 
 
To a solution of aldehyde 325 (570 mg, 1.46 mmol) in acetonitrile (3 mL) was added a 
solution of NaH2PO2 (53 mg, 0.438 mmol) in water (1.5 mL) followed by H2O2 (30% (w/w) in 
H2O, 0.15 mL, 1.42 mmol). The biphasic mixture was cooled to 0 °C and stirred vigorously, 
while a solution of NaClO2 (80% (w/w), 232 mg, 2.05 mmol) in water (1.5 mL) was added over 
45 min. After stirring for 1 h at 0 °C the reaction was quenched by addition of saturated aqueous 
sodium bisulfite solution (1 mL) and saturated aqueous ammonium chloride (5 mL). Then EtOAc 
(10 mL) was added and the phases separated. The aqueous phase was extracted with EtOAc 
(2 × 10 mL) and the combined organic phase was washed with brine (50 mL), dried over 
MgSO4, filtered and concentrated in vacuo to provide carboxylic acid 337 (460 mg, 91% yield) 






















MeCN, H2O, 0 °C
(95% yield)
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1H-NMR (400 MHz; CDCl3): δ 7.34 (m, 1H), 6.92 (m, 1H), 6.85-6.78 (m, 1H), 6.75 (m, 
1H), 4.25-4.16 (m, 2H), 3.79-3.77 (m, 3H), 2.59 (m, 1H), 2.35-2.31 (m, 1H), 1.97-1.67 (m, 3H), 
1.65-1.52 (m, 3H), 1.33-1.21 (m, 3H), 1.17-1.10 (m, 3H), 0.91 (m, 3H); 13C-NMR (101 MHz, 
CDCl3): δ 207.70, 207.40, 207.13, 206.42, 181.57, 181.10, 180.91, 180.62, 170.60, 170.58, 
170.34, 170.21, 165.49, 165.39, 165.33, 164.86, 160.34, 160.29, 136.50, 135.58, 135.55, 
135.37, 135.32, 130.25, 130.18, 130.12, 120.80, 120.68, 120.58, 120.56, 114.86, 114.67, 
114.60, 114.17, 114.14, 113.92, 75.83, 75.62, 75.57, 74.89, 65.79, 62.98, 62.88, 62.65, 62.57, 
58.70, 58.67, 58.57, 58.50, 55.39, 55.35, 55.27, 40.63, 39.85, 39.76, 39.20, 34.77, 34.67, 34.44, 
34.06, 29.63, 29.19, 28.42, 27.74, 27.18, 20.16, 20.01, 19.95, 19.89, 17.88, 17.78, 15.68, 15.63, 
15.12, 14.01, 13.86, 13.78, 8.92, 8.74, 8.54, 8.52; FTIR (thin film): 3084, 2979, 2941, 2885, 
1772, 2740, 1603, 1588, 1492, 1455, 1385, 1288, 1269, 1217, 1177, 1149 cm-1; HRMS (ESI–
APCI) m/z calc’d for C21H28NO7 (M+H)+: 406.1866, found: 406.1845. 
 
Preparation of  ketone 339 
 
To a solution of carboxylic acid 337 (530 mg, 1.31 mmol) in CH2Cl2 (5 mL) was added 
oxalyl chloride (0.22 mL, 2.61 mmol) followed by a drop of DMF. The solution was stirred for 30 
min and then concentrated in vacuo. The residue was dissolved in 1,2-dichloroethane (20 mL) 
and AlCl3 (261 mg, 1.96 mmol) was added and the suspension heated at 65 °C for 4 h. The 
yellowish mixture was then cooled to room temperature and a saturated aqueous Rochelle’s salt 
(20 mL) was added and the mixture stirred vigorously for 30 min. The mixture was then diluted 




















         CH2Cl2
2) AlCl3, DCE, 65 °C
(70% yield, two steps)
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extracted with CH2Cl2 (2 × 5 mL) and the combined organic phase was washed with brine (15 
mL), dried over MgSO4, filtered and concentrated in vcauo. The crude material was purified by 
flash chromatography (4:1→3:1 hexanes:EtOAc) to yield ketone 339 (356 mg, 70% yield) as a 
mixture of diastereomers. 
1H-NMR (400 MHz; CDCl3): δ 8.11 (m, 1H), 7.01-6.94 (m, 2H), 4.29-4.18 (m, 2H), 3.86 
(m, 3H), 2.47-2.38 (m, 2H), 1.84-1.70 (m, 3H), 1.67-1.59 (m, 3H), 1.31-1.17 (m, 6H), 0.79 (m, 
3H); 13C-NMR (101 MHz, CDCl3): δ 208.16, 206.63, 197.99, 197.57, 169.11, 165.32, 165.19, 
163.71, 163.62, 136.72, 136.60, 132.52, 125.57, 114.48, 114.43, 114.37, 113.76, 75.56, 75.10, 
62.99, 62.88, 58.42, 58.39, 55.81, 55.76, 42.39, 41.98, 41.45, 40.56, 31.10, 30.76, 17.03, 16.91, 
15.80, 15.63, 13.90, 8.83, 7.99; FTIR (thin film): 2977, 2938, 2873, 1775, 1745, 1704, 1673, 
1600, 1496, 1445, 1378, 1298, 1151, 1112, 1032 cm-1; HRMS (ESI–APCI) m/z calc’d for 
C21H26NO6 (M+H)+: 388.1760, found: 388.1762. 
 
Preparation of  aldehyde 342 
 
To a solution of ketone 295 (1.00 g, 3.13 mmol) in THF (30 mL) was added NaHMDS (1 
M in THF, 3.7 mL, 3.76 mmol) dropwise at –78 °C and the mixture was allowed to stir for 20 
min. Meanwhile, AlMe3 (2 M in toluene, 2.8 mL, 2.82 mmol) was added to a solution of 2,6–
diphenylphenol (3.94 g, 15.98 mmol) in toluene (30 mL). After 10 min stirring at room 
temperature the toluene solution was cooled to –78 °C and methacrolein (0.40 mL, 4.70 mmol) 
was added, which resulted in the formation of a bright yellow solution. The THF solution of the 































complex at –78 °C. The solution was stirred for another 10 min at –78 °C and then was allowed 
to slowly warm to room temperature. After stirring for 1 h at room temperature the reaction was 
cooled to –78 °C and bromine (0.24 mL, 4.70 mmol) was added dropwise. The reaction mixture 
was allowed to warm to room temperature and quenched by addition of saturated aqueous 
Rochelle’s salt solution (50 mL), which was stirred vigorously for 30 min. The aqueous phase 
was extracted with diethyl ether (3 × 20 mL) and the combined organic phases were washed 
with brine (50 mL), dried over MgSO4, filtered and concentrated in vacuo. The crude material 
was purified by flash chromatography (5:1→3:1 hexanes:EtOAc) to give aldehyde 342 (1.16 g, 
79% yield) as a mixture of diastereomers in form of a brownish oil.  
1H-NMR (400 MHz; CDCl3): δ 9.23-9.10 (m, 1H), 7.42-7.35 (m, 1H), 6.98-6.74 (m, 3H), 
4.34-4.16 (m, 2H), 3.81-3.75 (m, 3H), 3.10 (m, 1H), 2.63-2.44 (m, 1H), 2.25-1.97 (m, 2H), 1.94-
1.84 (m, 3H), 1.76-1.51 (m, 3H), 1.38-1.21 (m, 3H), 0.94-0.86 (m, 3H); 13C-NMR (101 MHz, 
CDCl3): δ 207.02, 206.75, 205.95, 205.54, 192.36, 190.64, 189.86, 189.64, 169.92, 169.78, 
169.76, 165.33, 165.17, 164.85, 160.44, 160.33, 135.38, 135.37, 135.14, 134.85, 130.48, 
130.45, 130.27, 130.26, 121.05, 120.70, 120.64, 120.62, 115.09, 115.03, 114.89, 114.75, 
114.69, 114.27, 114.22, 114.18, 114.10, 75.95, 75.84, 74.83, 74.65, 66.64, 66.42, 65.64, 65.20, 
63.29, 63.21, 62.94, 62.79, 59.10, 58.82, 58.79, 58.57, 55.42, 46.31, 45.08, 44.76, 42.25, 31.76, 
31.54, 28.99, 28.37, 27.62, 25.18, 24.72, 24.53, 18.20, 17.31, 15.69, 15.33, 14.05, 13.96, 13.89, 
8.95, 8.77, 8.66, 8.62; FTIR (thin film): 2980, 2941, 2838, 1773, 1602, 1587, 1492, 1451, 1380, 
1312, 1269, 1235, 1209, 1158, 1138, 1038 cm-1; HRMS (ESI–APCI) m/z calc’d for 







Preparation of  carboxylic acid 343 
 
To a solution of aldehyde 342 (1.00 g, 2.135 mmol) in acetonitrile (5 mL) was added a 
solution of NaH2PO2 (77 mg, 0.641 mmol) in water (3 mL) followed by H2O2 (30% (w/w) in H2O, 
0.22 mL, 2.24 mmol). The biphasic mixture was cooled to 0 °C and stirred vigorously while a 
solution of NaClO2 (80% (w/w), 483 mg, 4.27 mmol) in water (2 mL) was added over 45 min. 
After stirring for 1 h at 0 °C the reaction was quenched by addition of saturated aqueous sodium 
bisulfite solution (2 mL) and saturated aqueous ammonium chloride (10 mL). The aqueous 
phase was extracted with EtOAc (3 × 20 mL) and the combined organic phase was washed with 
brine (50 mL), dried over MgSO4, filtered and concentrated in vacuo to yield carboxylic acid 343 
(400 mg, 97% yield) as a mixture of diastereomers, which was used without further purification. 
1H-NMR (400 MHz; CDCl3): δ 7.41-7.27 (m, 1H), 6.98-6.73 (m, 3H), 4.31-4.16 (m, 2H), 
3.84-3.73 (m, 3H), 3.36-3.18 (m, 1H), 2.96 (m, 1H), 2.67-2.26 (m, 2H), 2.09-1.94 (m, 3H), 1.73-
1.48 (m, 3H), 1.39-1.18 (m, 3H), 0.97-0.83 (m, 3H); 13C-NMR (101 MHz, CDCl3): δ 206.31, 
205.82, 205.64, 205.35, 204.81, 177.58, 177.44, 174.14, 173.85, 173.53, 173.10, 171.65, 
171.54, 170.98, 170.68, 170.33, 170.27, 170.11, 165.44, 165.30, 164.90, 164.48, 160.40, 
160.28, 160.25, 160.20, 137.13, 135.26, 135.24, 135.10, 134.77, 130.43, 130.33, 130.28, 
130.24, 130.20, 130.06, 121.02, 120.97, 120.82, 120.48, 120.35, 115.01, 114.97, 114.79, 
114.70, 114.51, 114.39, 114.33, 114.31, 114.28, 113.51, 109.98, 83.18, 77.93, 76.03, 75.53, 
74.95, 71.75, 64.48, 63.35, 63.21, 62.81, 62.72, 62.70, 62.38, 60.53, 59.09, 58.95, 58.58, 58.01, 
57.62, 56.58, 55.43, 55.39, 55.37, 49.09, 48.86, 47.69, 46.73, 46.15, 44.39, 30.86, 30.71, 30.55, 
29.64, 29.34, 29.19, 28.94, 28.87, 28.72, 28.38, 27.50, 25.92, 25.33, 21.01, 20.97, 19.06, 18.45, 
NaOCl2, H2O2
NaH2PO4























18.26, 17.37, 15.90, 15.67, 15.48, 14.13, 14.04, 14.00, 13.96, 13.87, 13.69, 13.66, 9.30, 8.95, 
8.73, 8.68, 8.47, 8.10; HRMS (ESI–APCI) m/z calc’d for C21H27BrNO7 (M+H)+: 470.1001, found: 
470.1004. 
 
Preparation of  ketone 344 
 
To a solution of carboxylic acid 343 (1.27 g, 2.62 mmol) in CH2Cl2 (10 mL) was added 
oxalyl chloride (0.44 mL, 5.24 mmol) followed by a drop of DMF. The solution was stirred for 30 
min and then concentrated in vacuo. The residue was dissolved in 1,2–dichloroethane (20 mL) 
and AlCl3 (699 mg, 5.24 mmol) was added and the suspension was heated at 65 °C for 4 h. The 
yellowish mixture was cooled to room temperature and saturated aqueous Rochelle’s salt (20 
mL) was added and the mixture was stirred vigorously for 30 min. The aqueous phase was 
extracted with CH2Cl2 (3 × 5 mL) and the combined organic phases were washed with brine (15 
mL), dried over MgSO4, filtered and concentrated in vacuo. The crude material was purified by 
flash chromatography (5:1→2:1 hexanes:EtOAc) to yield ketone 344 (0.254 g, 21% yield, higher 
Rf diastereomer contaminated with inseparable acid chloride intermediate; 0.345 g, 28% yield, 
lower Rf diastereomer, pure). Only the lower Rf diastereomer is characterized. 
1H-NMR (300 MHz; CDCl3): δ 8.06 (d, J = 8.9 Hz, 1H), 7.08 (d, J = 2.5 Hz, 1H), 6.98 (dd, 
J = 8.9, 2.5 Hz, 1H), 4.29 (q, J = 7.1 Hz, 3H), 3.90 (s, 3H), 3.19-3.14 (m, 1H), 2.21-2.15 (m, 1H), 
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Preparation of  enone 345 
 
To a solution of α–bromo ketone 344 (345 mg, 0.740 mmol) in CH2Cl2 (5 mL) was added 
DBU (220 mL, 1.48 mmol) and the dark solution was stirred for 2 h at ambient temperature. The 
reaction mixture was diluted with saturated aqueous ammonium chloride (10 mL) and the 
aqueous phase was extracted with CH2Cl2 (3 × 5 mL). The combined organic phases were 
washed with brine (15 mL), dried over MgSO4, filtered and concentrated in vacuo. The crude 
material was purified by flash chromatography (5:1→4:1 hexanes:EtOAc) to furnish 345 (226 
mg, 79% yield) of a separable mixture of diastereomers. 
Diastereomer A: 1H-NMR (400 MHz; CDCl3): δ 7.92 (d, J = 8.9 Hz, 1H), 7.01 (d, J = 2.5 
Hz, 1H), 6.95 (dd, J = 8.9, 2.5 Hz, 1H), 6.48 (s, 1H), 4.14-4.02 (m, 2H), 3.87 (s, 3H), 2.04-1.98 
(m, 4H), 1.66-1.58 (m, 4H), 1.09 (t, J = 7.1 Hz, 3H), 0.76 (t, J = 7.3 Hz, 3H); 13C-NMR (101 MHz, 
CDCl3): δ 205.13, 194.71, 188.23, 168.32, 164.30, 163.11, 139.76, 136.92, 133.78, 133.41, 
128.45, 114.47, 112.41, 62.90, 57.68, 55.81, 27.57, 20.91, 15.23, 13.69, 8.47. 
Diastereomer B: 1H-NMR (400 MHz; CDCl3): δ 7.95 (d, J = 8.9 Hz, 1H), 7.03 (d, J = 2.5 
Hz, 1H), 6.96 (dd, J = 8.9, 2.5 Hz, 1H), 6.46 (s, 1H), 4.27 (q, J = 7.1 Hz, 2H), 3.88 (s, 3H), 2.06-
2.00 (m, 4H), 1.69 (dd, J = 14.7, 7.4 Hz, 1H), 1.57 (s, 3H), 1.29 (t, J = 7.1 Hz, 3H), 0.84 (t, J = 
7.4 Hz, 3H); 13C-NMR (101 MHz, CDCl3): δ 204.98, 194.96, 187.48, 168.60, 165.17, 163.28, 
139.27, 138.48, 134.14, 133.51, 127.96, 114.36, 112.75, 62.82, 57.94, 55.73, 28.08, 21.03, 

























Preparation of  alcohol 346 
 
To a solution of enone 345 (94 mg, 0.244 mmol) in THF (4 mL) was added 
isopropenylmagnesium bromide (0.5 M in THF, 540 mL, 0.268 mmol) at –78 °C. The dark green 
mixture was stirred for 15 min at –78 °C and then warmed to 0 °C. After 1 h at 0 °C the reaction 
was quenched by addition of saturated aqueous ammonium chloride solution (10 mL) and the 
aqueous phase extracted with diethyl ether (3 × 5 mL). The combined organic phases were 
washed with brine (15 mL), dried over MgSO4, filtered and concentrated in vacuo. The crude 
material was purified by flash chromatography (4:1→3:1 hexanes:EtOAc) to provide allylic 
alcohol 346 (43 mg, 41% yield) and starting material (345, 30 mg, 32% yield). 
1H-NMR (400 MHz; CDCl3): δ 7.76 (d, J = 8.8 Hz, 1H), 6.92 (dd, J = 8.9, 2.7 Hz, 1H), 
6.86 (d, J = 2.7 Hz, 1H), 5.65 (s, 1H), 4.87 (s, 1H), 4.83 (s, 1H), 4.24 (q, J = 7.2 Hz, 2H), 3.82-
3.81 (m, 3H), 2.00-1.99 (m, 3H), 1.73 (m, 2H), 1.48-1.46 (m, 6H), 1.28 (m, 3H), 0.76 (t, J = 7.4 
Hz, 3H); 13C-NMR (101 MHz, CDCl3): δ 206.44, 205.33, 167.55, 167.24, 165.68, 165.39, 
159.20, 159.09, 148.09, 147.24, 140.55, 138.95, 133.47, 132.62, 129.14, 127.73, 125.81, 
123.30, 114.63, 113.89, 113.49, 113.42, 113.36, 112.90, 112.85, 111.58, 78.93, 73.47, 62.75, 
62.66, 62.59, 62.43, 62.40, 57.75, 57.31, 55.51, 55.45, 31.21, 29.65, 23.67, 23.61, 22.77, 18.34, 
18.10, 17.71, 16.31, 13.91, 8.71, 8.30; FTIR (thin film): 3475, 2979, 2940, 1776, 1745, 1701, 
1609, 1502, 1448, 1380, 1276, 1261, 1233, 1110, 1036 cm-1; HRMS (ESI–APCI) m/z calc’d for 


























Preparation of  tetracycle 347 
 
To a solution of allylic alcohol 346 (83 mg, 0.194 mmol) in CH2Cl2 (3 mL) was added 
BF3•OEt2 (50 mL, 0.388 mmol) at –78 °C. The yellowish solution was stirred for 10 min at –78 
°C and then warmed to 0 °C. After 20 min at 0 °C, the reaction was quenched by addition of 
saturated aqueous sodium bicarbonate solution (5 mL) and the aqueous phase was extracted 
with CH2Cl2 (3 × 5 mL). The combined organic phases were washed with brine (15 mL), dried 
over MgSO4, filtered and concentrated in vacuo. The crude material was purified by flash 
chromatography (5:1→4:1 hexanes:EtOAc) to provide tetracycle 347 (56 mg, 71% yield). 
1H-NMR (400 MHz; CDCl3): δ 7.24 (s, 2H), 6.85 (s, 1H), 5.54 (s, 1H), 4.24 (q, J = 7.1 Hz, 
2H), 3.88-3.79 (s, 3H), 3.40 (s, 2H), 2.28 (s, 3H), 2.16 (s, 3H), 2.05-2.00 (m, 1H), 1.87-1.82 (m, 
1H), 1.63-1.58 (m, 3H), 1.29-1.21 (m, 3H), 0.77-0.71 (m, 3H); 13C-NMR (101 MHz, CDCl3): δ 
207.58, 167.93, 165.83, 157.35, 144.08, 142.71, 142.08, 135.95, 133.65, 130.10, 128.92, 
128.50, 127.94, 108.93, 108.76, 108.19, 75.61, 62.47, 58.69, 55.75, 55.71, 45.65, 31.55, 28.35, 
28.25, 25.38, 25.23, 18.66, 17.82, 17.78, 15.59, 14.10, 13.89, 13.81, 8.92, 8.63; FTIR (thin film): 
2979, 2938, 1776, 1746, 1702, 1653, 1609, 1480, 1456, 1445, 1384, 1289, 1232, 1132, 1043 




























Preparation of  aldehyde 355 
 
To a solution of aryl bromide 301 (300 mg, 0.753 mmol) in THF (10 mL) was added 
NaHMDS (1 M in THF, 0.83 mL, 0.829 mmol) dropwise at –78 °C and the mixture allowed to stir 
for 20 min. Meanwhile, AlMe3 (2 M in toluene, 0.68 mL, 1.36 mmol) was added to a solution of 
2,6–diphenylphenol (946 mg, 3.84 mmol) in toluene (10 mL). After 10 min stirring at room 
temperature the toluene solution was cooled to –78 °C and methacrolein (95 mL, 1.13 mmol) 
was added, which resulted in the formation of a bright yellow solution. The THF solution of the 
sodium enolate of 301 was then transferred via cannula to the methacrolein–Lewis Acid 
complex at –78 °C. The reaction was stirred for another 10 min at –78 °C and then was allowed 
to slowly warm to room temperature. After stirring for 1 h at room temperature the reaction was 
quenched by addition of saturated aqueous Rochelle’s salt solution (15 mL) and the mixture 
stirred vigorously for 30 min. The aqueous phase was extracted with diethyl ether (3 × 10 mL) 
and the combined organic phases were washed with brine (20 mL), dried over MgSO4, filtered 
and concentrated in vacuo. The crude material was purified by flash chromatography (5:1→3:1 
hexanes:EtOAc) to furnish aldehyde 355 (160 mg, 45% yield) as a mixture of diastereomers in 
form of a yellowish oil. 
1H-NMR (400 MHz; CDCl3): δ 9.57-9.37 (m, 1H), 7.07 (m, 1H), 6.96-6.91 (m, 1H), 6.69 
(s, 1H), 4.22-4.07 (m, 2H), 3.79-3.76 (m, 3H), 2.59-2.44 (m, 3H), 1.81 (m, 2H), 1.58-1.51 (m, 
3H), 1.26-1.20 (m, 3H), 1.10-1.02 (m, 3H), 0.95-0.88 (m, 3H); 13C-NMR (101 MHz, CDCl3): δ 
207.57, 207.36, 207.27, 206.53, 202.83, 202.46, 202.02, 201.84, 201.64, 171.09, 170.28, 































155.71, 143.27, 136.51, 136.43, 136.32, 123.79, 123.75, 123.68, 123.66, 123.24, 123.19, 
123.12, 122.73, 122.61, 117.34, 117.28, 117.18, 115.81, 114.36, 114.27, 114.16, 114.12, 
112.99, 75.83, 75.61, 75.34, 74.89, 64.30, 63.23, 63.03, 62.81, 62.71, 60.34, 58.71, 58.57, 
58.54, 58.32, 55.76, 55.73, 55.72, 55.70, 55.64, 53.21, 51.03, 45.87, 41.62, 41.08, 40.95, 40.86, 
36.85, 36.75, 36.29, 36.20, 30.58, 29.58, 29.00, 28.41, 28.16, 21.01, 20.97, 19.07, 17.96, 17.32, 
16.38, 16.20, 16.16, 15.98, 15.74, 15.71, 14.16, 14.04, 13.92, 13.88, 13.67, 11.68, 8.89, 8.79, 
8.57, 8.54; FTIR (thin film): 2976, 2940, 2877, 1772, 1702, 1596, 1571, 1448, 1426, 1306, 1276, 
1233, 1213, 1078, 1054, 1037 cm-1; HRMS (ESI–APCI) m/z calc’d for C21H27BrNO6 (M+H)+: 
470.1001, found: 470.1004. 
 
Preparation of  carboxylic acid 356 
 
To a solution of aldehyde 355 (255 mg, 0.544 mmol) in acetonitrile (1 mL) was added a 
solution of NaH2PO2 (20 mg, 0.163 mmol) in water (0.5 mL) followed by H2O2 (30% (w/w) in 
H2O, 0.60 mL, 0.566 mmol). The biphasic mixture was cooled to 0 °C and stirred vigorously, 
while a solution of NaClO2 (80% (w/w), 86 mg, 1.09 mmol) in water (0.5 mL) was added over 45 
min. After stirring for 1 h at 0 °C the reaction was quenched by addition of saturated aqueous 
sodium bisulfite solution (1 mL) and saturated aqueous ammonium chloride (5 mL). The 
aqueous phase was extracted with EtOAc (3 × 5 mL) and the combined organic phases were 
washed with brine (20 mL), dried over MgSO4, filtered and concentrated in vacuo to provide 




























1H-NMR (400 MHz; CDCl3): δ 7.07 (m, 1H), 6.94 (m, 1H), 6.76-6.68 (m, 1H), 4.27-4.14 
(m, 2H), 3.79-3.72 (m, 3H), 2.73-2.51 (m, 2H), 2.30 (m, 1H), 2.06-1.69 (m, 2H), 1.67-1.59 (m, 
3H), 1.28-1.21 (m, 3H), 1.21-1.10 (m, 3H), 0.94-0.86 (m, 3H); 13C-NMR (101 MHz, CDCl3): δ 
207.12, 206.83, 206.49, 205.85, 181.51, 180.95, 180.82, 180.56, 180.03, 170.81, 170.78, 
170.48, 170.39, 165.30, 165.21, 165.17, 164.71, 160.82, 160.77, 160.49, 156.06, 143.21, 
136.40, 136.17, 123.78, 123.74, 123.68, 123.62, 123.26, 123.19, 123.11, 122.81, 122.49, 
117.49, 117.45, 117.28, 115.94, 114.35, 114.18, 114.07, 114.03, 112.84, 76.03, 75.79, 75.17, 
63.27, 63.15, 62.91, 62.86, 58.74, 58.51, 55.78, 55.74, 55.70, 55.65, 53.31, 52.82, 40.46, 39.70, 
39.61, 39.02, 38.36, 34.77, 34.70, 34.41, 34.03, 29.21, 28.58, 27.84, 27.18, 20.18, 20.03, 19.98, 
19.85, 17.78, 17.76, 15.68, 15.64, 14.54, 14.03, 13.89, 13.80, 8.94, 8.73, 8.53; FTIR (thin film): 
3086, 2978, 2940, 1773, 1704, 1596, 1571, 1449, 1426, 1383, 1276, 1210, 1176, 1038 cm-1; 
HRMS (ESI–APCI) m/z calc’d for C21H27BrNO7 (M+H)+: 484.0971, found: 484.0958. 
 
Preparation of  aldehyde 359 
 
To a solution of alkyne 358 (810 mg, 2.27 mmol) in THF (25 mL) was added NaHMDS (1 
M in THF, 2.70 mL, 2.72 mmol) dropwise at –78 °C and the mixture was allowed to stir for 20 
min. Meanwhile, AlMe3 (2 M in toluene, 2.00 mL, 4.08 mmol) was added to a solution of 2,6–
diphenylphenol (2.85 g, 11.56 mmol) in toluene (25 mL). After 10 min stirring at room 
temperature the toluene solution was cooled to –78 °C and methacrolein (290 mL, 3.40 mmol) 
was added, which resulted in the formation of a bright yellow solution. The THF solution of the 































complex at –78 °C. The solution was stirred for another 10 min at –78 °C and then slowly 
warmed to room temperature. After stirring for 1 h the reaction was quenched by addition of 
saturated aqueous Rochelle’s salt solution (50 mL) and the mixture stirred vigorously for 30 min. 
The aqueous phase was extracted with diethyl ether (3 × 20 mL) and the combined organic 
phases were washed with brine (50 mL), dried over MgSO4, filtered and concentrated in vacuo. 
The crude material was purified by flash chromatography (5:1→2:1 hexanes:EtOAc) to give 
aldehyde 359 (652 mg, 67% yield) as a mixture of diastereomers. 
1H-NMR (400 MHz; CDCl3): δ 9.46-9.36 (m, 1H), 6.93 (m, 1H), 6.81 (m, 1H), 6.66 (s, 
1H), 4.31-4.18 (m, 2H), 3.77 (m, 3H), 2.69-2.42 (m, 3H), 2.04-2.00 (m, 3H), 1.88-1.75 (m, 2H), 
1.68-1.51 (m, 3H), 1.37-1.20 (m, 3H), 1.07-1.01 (m, 3H), 0.96-0.87 (m, 3H); 13C-NMR (101 MHz, 
CDCl3): δ 207.94, 207.79, 207.66, 206.91, 202.57, 202.15, 201.95, 201.66, 170.17, 169.95, 
169.88, 165.39, 165.29, 165.25, 165.03, 160.00, 135.47, 135.39, 135.28, 126.25, 126.22, 
126.14, 123.93, 123.86, 123.70, 116.53, 116.44, 116.41, 115.03, 115.00, 114.95, 114.86, 87.40, 
87.37, 87.34, 78.75, 78.73, 75.72, 75.50, 75.23, 74.74, 63.13, 62.94, 62.71, 62.60, 58.69, 58.58, 
58.54, 58.33, 55.50, 55.48, 55.46, 55.44, 41.63, 41.09, 40.97, 40.88, 37.02, 36.83, 36.43, 36.24, 
29.66, 28.89, 28.33, 28.23, 18.09, 17.35, 16.40, 16.17, 15.94, 15.77, 15.70, 14.15, 14.04, 13.93, 
13.87, 8.93, 8.84, 8.61, 8.57, 4.29; FTIR (thin film): 2977, 2940, 2882, 2242, 1772, 1702, 1590, 
1451, 1426, 1385, 1297, 1217, 1201, 1171, 1062 cm-1; HRMS (ESI–APCI) m/z calc’d for  









Preparation of  carboxylic acid 360 
 
To a solution of aldehyde 359 (200 mg, 0.468 mmol) in acetonitrile (1 mL) was added a 
solution of NaH2PO2 (17 mg, 0.140 mmol) in water (0.5 mL) followed by H2O2 (30% (w/w) in 
H2O, 0.50 mL, 0.487 mmol). The biphasic mixture was cooled to 0 °C and stirred vigorously 
while a solution of NaClO2 (80% (w/w), 106 mg, 0.936 mmol) in water (0.5 mL) was added over 
45 min. After stirring for 1 h at 0 °C the reaction was quenched by addition of saturated aqueous 
sodium bisulfite solution (1 mL) and saturated aqueous ammonium chloride (5 mL). The 
aqueous phase was extracted with EtOAc (3 × 5 mL) and the combined organic phases were 
washed with brine (20 mL), dried over MgSO4, filtered and concentrated in vacuo to furnish 
carboxylic acid 360 (197 mg, 95% yield) as a mixture of diastereoisomers, which was used 
without further purification. 
1H-NMR (400 MHz; CDCl3): δ 6.96-6.93 (m, 1H), 6.87-6.81 (m, 1H), 6.72-6.66 (m, 1H), 
4.28-4.15 (m, 2H), 3.82-3.75 (m, 3H), 2.68-2.54 (m, 2H), 2.32 (ddd, J = 14.5, 8.0, 3.3 Hz, 1H), 
2.06-2.00 (m, 3H), 2.00-1.70 (m, 2H), 1.64-1.50 (m, 3H), 1.35-1.21 (m, 3H), 1.20-1.12 (m, 3H), 
0.95-0.88 (m, 3H); 13C-NMR (101 MHz, CDCl3): δ 207.60, 207.32, 207.00, 206.29, 181.69, 
181.13, 181.02, 180.75, 170.44, 170.17, 170.06, 165.45, 165.33, 165.30, 164.79, 160.02, 
159.99, 135.53, 135.46, 135.27, 135.24, 126.24, 126.21, 126.19, 126.11, 124.03, 123.91, 
123.80, 123.68, 116.65, 116.63, 116.45, 116.40, 115.11, 115.03, 114.90, 114.81, 87.35, 87.29, 
78.77, 75.79, 75.54, 74.79, 63.04, 62.93, 62.68, 62.59, 58.65, 58.53, 58.45, 55.49, 55.44, 40.74, 
39.80, 39.70, 39.12, 34.75, 34.62, 34.43, 34.04, 31.55, 29.23, 28.29, 27.70, 27.19, 25.23, 22.61, 
20.17, 20.03, 19.96, 19.91, 18.00, 17.80, 15.68, 15.59, 14.08, 14.04, 13.87, 13.80, 8.97, 8.77, 
NaOCl2, H2O2
NaH2PO4
























8.57, 4.30; FTIR (thin film): 3058, 2978, 2940, 2242, 1773, 1740, 1590, 1452, 1426, 1386, 1325, 
1265, 1200, 1171, 1148, 1126, 1061, 1017 cm-1; HRMS (ESI–APCI) m/z calc’d for C24H30NO7 
(M+H)+: 444.2022, found: 444.2025. 
 
Preparation of  phenol 365 
 
To a solution of enone 345 (172 mg, 0.446 mmol), [bis(trifluoroacetoxy)iodo]benzene 
(384 mg, 893 mmol) and palladium(II) acetate (5 mg, 0.022 mmol) in 1,2-dichloroethane (4.5 
mL) was added trifluoroacetic acid (0.5 mL) and the mixture was heated at 80 °C for 2.5 h. After 
cooling to room temperature, the mixture was diluted with saturated aqueous sodium 
bicarbonate solution (10 mL) and extracted with CH2Cl2 (3 × 5 mL). The combined organic 
phases were washed with brine (15 mL), dried over MgSO4, filtered and concentrated in vacuo. 
The crude material was purified by flash chromatography (5:1→4:1 hexanes:EtOAc) to give 
phenol 365 (127 mg, 71% yield). 
1H-NMR (400 MHz; CDCl3): δ 13.47 (m, 1H), 6.59 (m, 1H), 6.50-6.45 (m, 2H), 4.29-4.06 
(m, 2H), 3.85 (m, 3H), 2.08-1.99 (m, 4H), 1.71 (td, J = 16.2, 7.4 Hz, 1H), 1.58 (m, 3H), 1.30-1.11 
(m, 3H), 0.81 (m, 3H); 13C-NMR (101 MHz, CDCl3): δ 204.97, 204.77, 191.52, 191.13, 168.61, 
168.29, 167.42, 167.20, 164.98, 164.83, 164.65, 164.36, 141.22, 140.48, 139.47, 137.80, 
135.09, 134.80, 111.94, 111.78, 108.88, 108.68, 101.08, 101.03, 76.45, 75.67, 62.88, 57.80, 
57.50, 55.79, 55.75, 27.37, 26.93, 21.16, 21.13, 18.72, 15.52, 13.94, 13.78, 8.07; FTIR (thin 
film): 2981, 2939, 1781, 1713, 1617, 1578, 1447, 1429, 1375, 1347, 1289, 1239, 1210, 1167, 























Preparation of  triflate 366 
 
To a solution of phenol 365 (112 mg, 0.279 mmol) in CH2Cl2 (5 mL) was added pyridine 
(45 mL, 0.558 mmol) followed by triflic anhydride (0.71 mL, 0.419 mmol) at –78 °C. The mixture 
was warmed to 0 °C and stirred for 2 h before it was quenched by addition of saturated aqueous 
ammonium chloride solution (2 mL). The aqueous phase was extracted with CH2Cl2 (3 × 5 mL) 
and the combined organic phases were washed with brine (15 mL), dried over MgSO4, filtered 
and concentrated in vacuo. The crude material was purified by flash chromatography (4:1 
hexanes:EtOAc) to deliver aryl triflate 366 (112 mg, 76% yield). 
1H-NMR (400 MHz; CDCl3): δ 7.02 (d, J = 2.4 Hz, 1H), 6.86 (d, J = 2.4 Hz, 1H), 6.36 (m, 
1H), 4.29-4.05 (m, 2H), 3.89 (s, 3H), 2.04-2.00 (m, 4H), 1.71 (t, J = 7.4 Hz, 1H), 1.60-1.55 (m, 
3H), 1.29 (t, J = 7.1 Hz, 2H), 0.87-0.77 (m, 3H); 13C-NMR (101 MHz, CDCl3): δ 203.70, 203.60, 
188.23, 187.57, 168.76, 168.61, 164.92, 163.81, 162.05, 161.90, 148.15, 147.88, 138.36, 
137.95, 137.73, 137.33, 134.56, 134.16, 124.90, 124.49, 120.08, 120.07, 116.88, 113.14, 
112.93, 109.63, 77.81, 77.08, 63.18, 62.98, 57.81, 57.63, 56.33, 56.27, 28.39, 27.71, 20.53, 
20.35, 18.96, 15.00, 13.93, 13.60, 8.40, 8.35; 19F-NMR (376 MHz, CDCl3): δ  -73.07; FTIR (thin 
film): 2983, 2941, 2851, 1782, 1750, 1716, 1660, 1614, 1426, 1381, 1358, 1290, 1211, 1171, 



























Preparation of  alkyne 351 
 
Triflate 366 (40 mg, 0.075 mmol), PdCl2(PPh3)2 (5.3 mg, 7.5 mmol) and copper(I) iodide 
(0.7 mg, 3.7 mmol) were suspendend in triethylamine (3 mL). Propyne gas was bubbled into the 
solution for 10 s and the mixture was heated to 60 °C. After 30 min at elevated temperature 
propyne was again bubbled in for 10 seconds and the mixture stirred at 60 °C for an additional 4 
hours. The dark reaction mixture was cooled to room temperature, diluted with diethyl ether (10 
mL) and saturated aqueous ammonium chloride solution (10 mL) was added. The aqueous 
phase was extracted with diethyl ether (3 × 5 mL) and the combined organic phases were 
washed with brine (20 mL), dried over MgSO4, filtered and concentrated in vacuo. The crude 
material was purified by flash chromatography (4:1→3:1 hexanes:EtOAc) to furnish alkyne 351 
(24 mg, 75% yield) as a brown crystalline solid. 
1H-NMR (400 MHz; CDCl3): δ 7.02 (m, 1H), 6.85 (m, 1H), 6.23 (m, 1H), 4.26-4.03 (m, 
2H), 3.83 (m, 3H), 2.02-2.01 (m, 6H), 1.95 (m, 1H), 1.66 (m, 1H), 1.56-1.52 (m, 3H), 1.28-1.06 
(m, 3H), 0.82 (m, 3H); 13C-NMR (101 MHz, CDCl3): δ 204.38, 204.35, 191.35, 190.29, 168.71, 
168.66, 165.17, 164.14, 160.94, 160.80, 138.32, 137.42, 136.63, 136.10, 133.23, 133.20, 
132.80, 132.62, 126.30, 125.94, 119.28, 119.19, 113.46, 113.30, 90.76, 90.70, 63.00, 62.77, 
57.89, 57.70, 55.76, 55.72, 28.05, 27.53, 20.76, 20.58, 19.02, 14.98, 13.90, 13.53, 8.30, 8.26, 
4.64, 4.56; FTIR (thin film): 2980, 2939, 2237, 1778, 1747, 1710, 1659, 1594, 1567, 1431, 1385, 
1357, 1317, 1292, 1241, 1147, 1126, 1103 cm-1; HRMS (ESI–APCI) m/z calc’d for C24H26NO6 

























Preparation of  allylic alcohol 367 
 
To a solution of enone 345 (37 mg, 0.096 mmol) and cerium(III) chloride heptahydrate 
(39 mg, 0.106 mmol) in MeOH (2.5 mL) and THF (0.5 mL) was added sodium borohydride (4.4 
mg, 0.115 mmol) at 0 °C. After 40 minutes the reaction was quenched by addition of saturated 
aqueous ammonium chloride (5 mL). The aqueous phase was extracted with diethyl ether (3 × 5 
mL) and the combined organic phases were washed with brine (15 mL), dried over MgSO4, 
filtered and concentrated in vacuo. The crude material was purified by flash chromatography 
(4:1→3:1 hexanes:EtOAc) to provide allylic alcohol 367 (27 mg, 73% yield) as a separable 
mixture of diastereomers. Single crystals suitable for X–ray analysis were obtained by slow 
diffusion of hexane into a concentrated solution of 367 in diethyl ether/CH2Cl2. 
Diastereomer A: 1H-NMR (400 MHz; CDCl3): δ 7.49 (d, J = 8.7 Hz, 1H), 6.94 (dd, J = 
8.6, 2.5 Hz, 1H), 6.82 (d, J = 2.5 Hz, 1H), 5.82 (d, J = 0.3 Hz, 1H), 5.16 (s, 1H), 4.17-4.00 (m, 
2H), 3.80 (s, 3H), 2.37 (d, J = 4.9 Hz, 1H), 1.88 (s, 3H), 1.80 (dd, J = 14.6, 7.4 Hz, 1H), 1.63-
1.59 (m, 3H), 1.32 (dd, J = 14.6, 7.4 Hz, 1H), 1.17 (t, J = 7.2 Hz, 3H), 0.80 (t, J = 7.4 Hz, 3H); 
FTIR (thin film): 3455, 2976, 2940, 1774, 1743, 1691, 1661, 1612, 1585, 1500, 1447, 1383, 
1290, 1218, 1169, 1111, 1044, 1031, 1010 cm-1; HRMS (ESI–APCI) m/z calc’d for C21H26NO6 
(M+H)+: 388.1760, found: 388.1755. 
Diastereomer B: 1H-NMR (400 MHz; CDCl3): δ 7.49-7.46 (m, 1H), 6.93 (dd, J = 8.6, 2.6 
Hz, 1H), 6.88 (d, J = 2.6 Hz, 1H), 5.43 (s, 1H), 5.17 (s, 1H), 4.30-4.19 (m, 2H), 3.82 (s, 3H), 2.50 
(d, J = 5.0 Hz, 1H), 1.89 (s, 3H), 1.88-1.81 (m, 1H), 1.60 (s, 3H), 1.46 (dd, J = 14.6, 7.4 Hz, 1H), 
1.27 (t, J = 7.1 Hz, 3H), 0.85 (t, J = 7.4 Hz, 3H); 13C-NMR (101 MHz, CDCl3): δ 205.20, 194.80, 






















62.65, 58.27, 55.57, 29.58, 20.89, 18.96, 13.89, 7.95; FTIR (thin film): 3444, 2981, 2935, 2852, 
1774, 1740, 1613, 1586, 1503, 1448, 1391, 1292, 1238, 1228, 1139, 1109, 1072, 1032 cm-1; 
HRMS (ESI–APCI) m/z calc’d for C21H26NO6 (M+H)+: 388.1760, found: 388.1767. 
 
Preparation of  aldehyde 370 
 
To a solution of ketone 234 (11.02 g, 23.88 mmol) in THF (250 mL) was added 
NaHMDS (1 M in THF, 26.3 mL, 26.27 mmol) dropwise at –78 °C and the mixture was stirred for 
30. Meanwhile, AlMe3 (neat, 4.3 mL, 42.98 mmol) was added to a solution of 2,6–
diphenylphenol (30.0 g, 121.8 mmol) in toluene (250 mL). After 10 min the toluene solution was 
cooled to –78 °C and methacrolein (3.0 mL, 35.82 mmol) was added, which resulted in the 
formation of a bright yellow solution. The THF solution of the sodium enolate of 234 was then 
transferred via cannula to the methacrolein–Lewis Acid complex at –78 °C. The solution was 
stirred for another 10 min at –78 °C and then slowly warmed to room temperature. After stirring 
for 2 h at room temperature the reaction was cooled to –78 °C and bromine (2.2 mL, 42.98 
mmol) was added dropwise. The reaction mixture was allowed to warm to room temperature 
and quenched by addition of saturated aqueous Rochelle’s salt (200 mL) and the mixture stirred 
vigorously for 30 min. The aqueous phase was extracted with diethyl ether (3 × 50 mL) and the 
combined organic phases were washed with brine (200 mL), dried over MgSO4, filtered and 
concentrated in vacuo. The crude material was purified by flash chromatography (20:1→3:1 
hexanes:EtOAc) to furnish aldehyde 370 (7.84 g, 54% yield) as a mixture of diastereoisomers in 






























1H-NMR (400 MHz; CDCl3): δ 9.09 (m, 1H), 7.31 (m, 1H), 6.98-6.84 (m, 2H), 6.79-6.75 
(m, 1H), 4.32-4.20 (m, 2H), 3.03 (d, J = 15.2 Hz, 1H), 2.66-2.59 (m, 1H), 1.92-1.84 (m, 4H), 
1.65-1.47 (m, 4H), 1.36 (t, J = 7.2 Hz, 3H), 1.25 (m, 3H), 1.08 (m, 18H), 0.90 (m, 3H); 13C-NMR 
(101 MHz, CDCl3): δ 206.05, 205.70, 190.54, 189.53, 169.72, 169.63, 165.15, 164.83, 157.01, 
156.91, 135.33, 134.67, 130.39, 130.17, 121.00, 120.89, 120.86, 120.67, 120.54, 120.36, 75.95, 
74.81, 66.70, 65.41, 63.17, 62.91, 58.68, 58.49, 45.00, 42.77, 31.56, 28.25, 24.45, 24.40, 17.90, 
17.28, 15.71, 14.01, 13.86, 12.58, 12.55, 8.74, 8.61; FTIR (thin film): 2945, 2892, 2868, 1777, 
1746, 1706, 1596, 1486, 1464, 1446, 1381, 1282, 1205, 1060, 1015, 1005 cm-1; HRMS (ESI–
APCI) m/z calc’d for C29H45BrNO6Si (M+H)+: 610.2200, found: 610.2188. 
 
Preparation of  carboxylic acid 371 
 
To a solution of aldehyde 370 (7.80 g, 12.80 mmol) in acetonitrile (30 mL) was added a 
solution of NaH2PO2 (768 mg, 6.40 mmol) in water (5 mL) followed by H2O2 (30% (w/w) in H2O, 
1.3 mL, 13.44 mmol). The biphasic mixture was cooled to 0 °C and stirred vigorously, while a 
solution of NaClO2 (80% (w/w), 2.89 g, 25.61 mmol, 2.0 equiv) in water (20 mL) was added over 
45 min. After stirring for 1 h at 0 °C, the reaction was quenched by addition of saturated 
aqueous ammonium chloride (50 mL). The aqueous phase was extracted with diethyl ether (3 × 
30 mL) and the combined organic phases were washed with brine (100 mL), dried over MgSO4, 
filtered and concentrated in vacuo to provide carboxylic acid 371 (7.22 g, 91% yield) as a 


























1H-NMR (400 MHz; CDCl3): δ 7.31 (td, J = 8.0, 0.9 Hz, 1H), 6.97-6.75 (m, 3H), 4.30-4.09 
(m, 2H), 3.05-2.95 (m, 1H), 2.62 (m, 1H), 2.03-1.97 (m, 3H), 1.88 (td, J = 7.4, 4.2 Hz, 1H), 1.73-
1.52 (m, 3H), 1.39-1.19 (m, 6H), 1.08-1.05 (m, 18H), 0.91 (m, J = 6.1 Hz, 3H); 13C-NMR (101 
MHz, CDCl3): δ 206.04, 205.49, 174.96, 174.75, 169.95, 169.78, 169.77, 165.38, 164.90, 
156.87, 135.01, 134.58, 130.27, 130.15, 121.14, 121.03, 121.01, 120.96, 120.75, 120.66, 75.39, 
63.15, 62.79, 58.77, 58.47, 57.13, 56.14, 56.13, 46.60, 46.46, 29.12, 28.65, 28.45, 25.87, 18.30, 
17.83, 15.72, 14.16, 14.02, 13.85, 12.56, 12.53, 8.68, 8.50; FTIR (thin film): 2945, 2892, 2868, 
1777, 1743, 1706, 1671, 1596, 1488, 1462, 1384, 1284, 1265, 1215,1157, 1136, 1015, 1005, 
996 cm-1; HRMS (ESI–APCI) m/z calc’d for C29H45BrNO7Si (M+H)+: 626.2149, found: 626.2153. 
 
Preparation of  ketone 372 
 
To a solution of carboxylic acid 371 (7.22 g, 11.52 mmol) in CH2Cl2 (50 mL) was added 
oxalyl chloride (1.95 mL, 23.05 mmol) followed by three drops of DMF. The solution was stirred 
for 30 min and then concentrated in vacuo. The residue was then dissolved in 1,2–
dichloroethane (80 mL) and SnCl4 (2.7 mL, 23.05 mmol) was added and the suspension was 
heated at 90 °C for 8 h. 1H-NMR analysis of the reaction mixture revealed the presence of 
starting material, therefore more SnCl4 (0.5 mL, 4.25 mmol) was added and the suspension 
heated at 90 °C for 11 h. The dark mixture was then cooled to room temperature and filtered 
over a short plug of celite, which was washed with CH2Cl2 (50 mL) and the CH2Cl2 was removed 
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to provide α–bromo ketone 372 (4.25 g, 61% yield) as a mixture of diastereomers in form of a 
brownish oil. 
1H-NMR (400 MHz; CDCl3): δ 7.96 (d, J = 8.8 Hz, 1H), 7.07 (d, J = 2.4 Hz, 1H), 6.92 (dd, 
J = 8.8, 2.4 Hz, 1H), 4.28-4.23 (m, 2H), 3.12 (d, J = 16.1 Hz, 1H), 2.18 (m, 1H), 1.96 (s, 3H), 
1.85 (dd, J = 14.4, 7.0 Hz, 1H), 1.76 (m, 3H), 1.70 (m, 1H), 1.31-1.22 (m, 6H), 1.08 (m, J = 13.6 
Hz, 18H), 0.76 (t, J = 7.5 Hz, 3H); 1H-NMR (400 MHz; CDCl3): δ 7.91 (d, J = 8.8 Hz, 1H), 7.29 
(d, J = 2.3 Hz, 1H), 6.84 (dd, J = 8.8, 2.3 Hz, 1H), 4.28-4.23 (m, 2H), 3.32 (d, J = 16.2 Hz, 1H), 
2.22 (d, J = 16.2 Hz, 1H), 1.96 (s, 3H), 1.85 (dd, J = 14.4, 7.0 Hz, 1H), 1.76 (m, 3H), 1.70 (dd, J 
= 14.1, 7.2 Hz, 1H), 1.31-1.22 (m, 6H), 1.08 (d, J = 13.6 Hz, 18H), 0.51 (t, J = 7.2 Hz, 3H); 13C-
NMR (101 MHz, CDCl3): δ 206.19, 204.03, 193.32, 191.65, 168.80, 168.46, 165.64, 165.06, 
161.45, 160.82, 136.88, 136.12, 133.99, 132.85, 123.95, 122.38, 121.02, 120.22, 119.86, 
118.74, 117.02, 74.09, 73.02, 63.05, 62.97, 62.59, 60.02, 58.97, 57.76, 50.48, 46.06, 31.71, 
31.56, 30.99, 28.92, 18.57, 17.87, 17.84, 17.79, 17.77, 17.67, 14.04, 13.86, 12.58, 12.56, 8.56, 
7.73; FTIR (thin film): 2945, 2893, 2868, 1777, 1712, 1671, 1595, 1493, 1463, 1426, 1376, 
1284, 1262, 1228, 1139, 1118, 1055, 983 cm-1; HRMS (ESI–APCI) m/z calc’d for C29H43BrNO6Si 
(M+H)+: 610.2023, found: 610.2019. 
 
Preparation of  enone 373 
 
To a solution of α–bromo ketone 372 (4.25 g, 7.00 mmol) in CH2Cl2 (50 mL) was added 
DBU (2.1 mL, 14.01 mmol) and the dark solution stirred for 2 h at ambient temperature. The 






















aqueous phase was extracted with CH2Cl2 (3 × 20 mL). The combined organic phases were 
washed with brine (50 mL), dried over MgSO4, filtered and concentrated in vacuo. The crude 
material was purified by flash chromatography (5:1→4:1 hexanes:EtOAc) to give enone 373 
(3.31 g, 89% yield) of a clear oil that solidified upon standing. 
1H-NMR (400 MHz; CDCl3): δ 7.88 (m, 1H), 7.02 (m, 1H), 6.93 (m, 1H), 6.47 (m, 1H), 
4.26 (dd, J = 14.7, 7.2 Hz, 2H), 2.03-2.00 (m, 4H), 1.61-1.57 (m, 4H), 1.27 (m, J = 3.7 Hz, 6H), 
1.10-1.09 (m, 18H), 0.78 (t, J = 7.4 Hz, 3H); 13C-NMR (101 MHz, CDCl3): δ 205.29, 205.06, 
188.37, 187.42, 168.52, 168.13, 165.10, 164.33, 160.43, 160.22, 139.79, 139.19, 138.58, 
136.92, 133.99, 133.64, 133.37, 133.20, 128.77, 128.04, 120.46, 120.16, 118.50, 118.44, 77.03, 
76.22, 62.87, 62.72, 57.91, 57.66, 28.02, 27.54, 21.00, 20.87, 18.88, 17.88, 17.85, 17.76, 17.74, 
17.65, 17.61, 15.22, 13.81, 13.67, 12.60, 12.57, 12.51, 12.25, 8.37; FTIR (thin film): 2944, 2892, 
2867, 1781, 1751, 1714, 1633, 1497, 1492, 1430, 1378, 1359, 1291, 1258, 1235, 1149, 1103, 
1015, 997, 985 cm-1; HRMS (ESI–APCI) m/z calc’d for C29H42NO6Si (M+H)+: 528.2781, found: 
528.2779. 
 
Preparation of  phenol 374 
 
A solution of enone 373 (1.00 g, 1.895 mmol), [bis(trifluoroacetoxy)iodo] benzene (1.63 
g, 3.79 mmol) and palladium(II) trifluoroacetate (31 mg, 0.095 mmol) in 1,2–dichloroethane (15 
mL) was heated at 80 °C for 4 h. After cooling to room temperature the mixture was diluted with 
aqueous ammonium hydroxide (1M, 30 mL) and CH2Cl2 (15 mL). The aqueous phase was 
extracted with CH2Cl2 (3 × 10 mL) and the combined organic phases were washed with brine 























by flash chromatography (15:1→10:1 hexanes:EtOAc) to furnish phenol 374 (870 mg, 84% 
yield). 
1H-NMR (400 MHz; CDCl3): δ 13.23 (s, 1H), 6.60-6.45 (m, 3H), 4.28-4.05 (m, 2H), 2.05-
1.99 (m, 4H), 1.68 (m, 1H), 1.61-1.54 (m, 3H), 1.32-1.23 (m, 6H), 1.15-1.09 (m, 18H), 0.79 (t, J 
= 7.3 Hz, 3H); 13C-NMR (101 MHz, CDCl3): δ 205.10, 191.60, 168.62, 168.22, 166.80, 166.55, 
164.38, 162.21, 161.99, 141.22, 140.38, 139.60, 137.86, 135.15, 134.88, 112.88, 112.83, 
112.56, 112.34, 108.41, 108.14, 76.41, 75.65, 62.89, 62.82, 57.80, 57.49, 29.66, 27.25, 26.85, 
21.10, 18.74, 17.76, 17.74, 17.73, 17.70, 15.53, 13.82, 13.78, 12.60, 12.58, 8.05, 8.03; HRMS 
(ESI–APCI) m/z calc’d for C29H42NO7Si (M+H)+: 544.2731, found: 544.2726. 
 
Preparation of  triflate 375 
 
To a solution of phenol 374 (850 mg, 1.563 mmol) in CH2Cl2 (10 mL) was added pyridine 
(0.50 mL, 6.253 mmol) followed by triflic anhydride (530 mL, 3.127 mmol) at –78 °C. The 
mixture was warmed to 0 °C and stirred for 2 h before it was quenched by addition of saturated 
aqueous ammonium chloride (10 mL). The aqueous phase extracted with CH2Cl2 (3 × 10 mL) 
and the combined organic phases were washed with brine (30 mL), dried over MgSO4, filtered 
and concentrated in vacuo. The crude material was purified by flash chromatography (4:1 
hexanes:EtOAc) to provide aryl triflate 375 (896 mg, 85% yield). 
1H-NMR (400 MHz; CDCl3): δ 7.01 (d, J = 2.3 Hz, 1H), 6.83 (t, J = 2.6 Hz, 1H), 6.36 (m, 
1H), 4.26 (dd, J = 9.7, 7.2 Hz, 2H), 2.02 (m, 4H), 1.56 (s, 3H), 1.29-1.23 (m, 6H), 1.10-1.06 (m, 
18H), 0.79 (t, J = 7.4 Hz, 3H); 13C-NMR (101 MHz, CDCl3): δ 203.82, 203.63, 188.29, 187.50, 























137.28, 134.35, 133.98, 125.21, 124.70, 120.08, 119.18, 119.02, 116.89, 115.05, 114.74, 77.69, 
63.14, 62.86, 57.74, 57.62, 28.39, 27.69, 20.49, 20.30, 18.87, 17.63, 17.61, 14.97, 13.80, 13.58, 
12.49, 12.46, 12.24, 8.31, 8.29; 19F-NMR (376 MHz, CDCl3): δ  -73.41, -73.50; FTIR (thin film): 
2946, 2894, 2869, 1782, 1752, 1718, 1660, 1608, 1427, 1360, 1291, 1243, 1140, 1113, 1015 
cm-1; HRMS (ESI–APCI) m/z calc’d for C30H41F3NO9SSi (M+H)+: 676.2223, found: 676.2220. 
 
Preparation of  alkyne 376 
 
Triflate 375 (300 mg, 0.444 mmol), PdCl2(PPh3)2 (31 mg, 0.044 mmol) and CuI (4.2 mg, 
0.022 mmol) were suspendend in triethylamine (10 mL). Propyne gas was bubbled into the 
solution for 10 s and the mixture was heated to 50 °C. After 30 min at elevated temperature 
propyne was bubbled through the solution for 10 s and the mixture stirred at 50 °C for 4 hours. 
The dark reaction mixture was cooled to room temperature and diluted with diethyl ether (50 
mL) and saturated aqueous ammonium chloride solution (50 mL). The aqueous phase was 
extracted with diethyl ether (3 × 10 mL) and the combined organic phases were washed with 
brine (50 mL), dried over MgSO4, filtered and concentrated in vacuo. The crude material was 
purified by flash chromatography (20:1→10:1 hexanes:EtOAc) to give alkyne 376 (200 mg, 80% 
yield) as a brown crystalline solid. 
1H-NMR (400 MHz; CDCl3): δ 6.99 (d, J = 2.3 Hz, 1H), 6.82 (d, J = 2.3 Hz, 1H), 6.22 (m, 
1H), 5.25 (s, 1H), 4.24-4.01 (m, 2H), 2.00 (s, 3H), 1.97-1.94 (m, 1H), 1.67 (m, 1H), 1.55-1.51 
(m, 3H), 1.27-1.18 (m, 6H), 1.04 (m, 18H), 0.79 (t, J = 7.4 Hz, 3H); 13C-NMR (101 MHz, CDCl3): 
δ 204.44, 204.31, 191.56, 190.24, 168.66, 168.52, 165.09, 164.13, 157.92, 157.74, 138.26, 
























118.86, 118.64, 90.60, 90.56, 77.16, 76.55, 62.97, 62.68, 57.83, 57.69, 28.00, 27.46, 20.73, 
20.53, 18.93, 17.76, 17.73, 17.62, 17.60, 14.92, 13.76, 13.51, 12.55, 12.51, 12.44, 12.23, 8.28, 
8.24, 4.63, 4.55; FTIR (thin film): 3421, 2945, 2894, 2868, 2235, 2159, 1780, 1750, 1654, 1593, 
1561, 1541, 1463, 1427, 1387, 1317, 1293, 1243, 1206, 1124, 1014 cm-1; HRMS (ESI–APCI) 
m/z calc’d for C32H44NO6Si (M+H)+: 566.2938, found: 566.2933. 
 
Preparation of  allylic alcohol 377 
 
To a solution of enone 373 (528 mg, 1.00 mmol) and cerium(III) chloride heptahydrate 
(410 mg, 1.1 mmol) in MeOH (10 mL) and THF (5 mL) was added sodium borohydride (42 mg, 
1.1 mmol) at 0 °C. After 1 h the reaction was quenched by addition of saturated aqueous 
ammonium chloride (5 mL). The aqueous phase was extracted with diethyl ether (3 × 5 mL) and 
the combined organic phases were washed with brine (15 mL), dried over MgSO4, filtered and 
concentrated in vacuo. The crude material was purified by flash chromatography (10:1→5:1 
hexanes:EtOAc) to give allylic alcohol 377 (398 mg, 75% yield).  
1H-NMR (400 MHz; CDCl3): δ 7.40 (m, 1H), 6.88 (m, 1H), 6.80 (m, 1H), 5.21 (s, 1H), 
5.11 (m, 1H), 4.21 (m, 2H), 3.25 (d, J = 5.0 Hz, 1H), 1.85-1.82 (m, 3H), 1.82-1.76 (m, 1H), 1.54 
(s, 3H), 1.39 (m, 1H), 1.28-1.17 (m, 6H), 1.12-1.01 (m, 18H), 0.82-0.73 (m, 3H); 13C-NMR (101 
MHz, CDCl3): δ 205.55, 205.19, 169.63, 169.38, 165.52, 165.04, 155.37, 155.27, 141.78, 
141.19, 136.02, 135.17, 131.50, 131.31, 125.03, 124.50, 120.97, 120.95, 120.29, 119.75, 
119.69, 75.44, 74.50, 67.59, 67.58, 62.74, 62.58, 58.26, 58.09, 29.43, 29.29, 21.04, 20.62, 
18.82, 17.80, 15.43, 13.77, 13.57, 12.57, 12.55, 8.01, 7.91; FTIR (thin film): 3492, 2944, 2893, 






















1: 2344, 2894, 2868, 1782, 1752, 1614, 1574, 1462, 1402, 1369, 1344, 1236, 1196, 1178, 1144, 
1122, 1101, 1072, 1056, 1015, 997, 993 cm-1; HRMS (ESI–APCI) m/z calc’d for C29H44NO6Si 
(M+H)+: 530.2938, found: 530.2941. 
 
Preparation of  phenol 368 
 
To a solution of allylic alcohol 377 (40 mg, 0.076 mmol) in THF (1 mL) was added TBAF 
(1M in THF, 150 mL, 0.151 mmol) at room temperature. After stirring for 1 h at ambient 
temperature the reaction was quenched by addition of saturated aqueous ammonium chloride 
(1 mL). The aqueous phase was extracted with diethyl ether (3 × 1 mL) and the combined 
organic phases were dried over MgSO4, filtered and concentrated in vacuo. The crude material 
was purified by flash chromatography (1:1 hexanes:EtOAc) to supply diol 368 (20 mg, 71% 
yield).  
1H-NMR (400 MHz; acetone-d6): δ 7.49 (d, J = 8.5 Hz, 1H), 6.91 (m, 1H), 6.84 (m, 1H), 
5.51 (s, 1H), 5.20 (m, 1H), 4.78 (d, J = 5.7 Hz, 1H), 4.24-4.10 (m, 2H), 1.91 (m, 3H), 1.84 (m, 
2H), 1.49 (s, 3H), 1.27-1.17 (m, 3H), 0.85 (t, J = 7.4 Hz, 3H); 13C-NMR (101 MHz, acetone-d6): δ 
168.77, 168.44, 165.75, 165.34, 156.60, 156.42, 143.11, 142.33, 135.19, 134.45, 132.47, 
132.18, 125.04, 124.82, 120.80, 120.74, 115.50, 115.38, 115.35, 115.24, 74.97, 74.11, 67.11, 
66.98, 62.28, 62.11, 57.93, 57.65, 29.58, 29.49, 20.40, 20.24, 18.08, 15.01, 13.30, 13.17, 7.55, 
























Preparation of  carbonate 378 
 
To a solution of allylic alcohol 377 (340 mg, 0.642 mmol) in THF (7 mL) was added 
Boc2O (420 mg, 1.925 mmol) and sodium hydride (60% in mineral oil, 77 mg, 1.925 mmol). The 
suspension was stirred for 20 h at ambient temperature and then quenched by addition of 
saturated aqueous ammonium chloride (10 mL). The aqueous phase was extracted with diethyl 
ether (3 × 5 mL) and the combined organic phases were washed with brine (20 mL), dried over 
MgSO4, filtered and concentrated in vacuo. The crude material was purified by flash 
chromatography (10:1→5:1 hexanes:EtOAc) to provide allylic carbonate 378 (215 mg, 53% 
yield) starting material (377, 99 mg, 29% yield). 
1H-NMR (400 MHz; CDCl3): δ 7.36 (m, 1H), 6.90 (m, 2H), 6.37 (s, 1H), 5.24 (m, 1H), 
4.25 (m, 2H), 1.79 (m, 2H), 1.70 (s, 3H), 1.49-1.47 (m, 6H), 1.29-1.20 (m, 6H), 1.09 (m, 18H), 
0.86 (t, J = 7.4 Hz, 3H); 13C-NMR (101 MHz, CDCl3): δ 205.20, 169.29, 165.61, 155.84, 152.66, 
138.43, 131.88, 130.99, 124.63, 122.50, 120.35, 120.30, 82.89, 74.14, 72.26, 62.54, 58.37, 
29.83, 27.67, 27.63, 20.34, 19.10, 17.82, 17.76, 17.74, 13.81, 12.56, 7.92; HRMS (ESI–APCI) 
m/z calc’d for C34H52NO8Si (M+H)+: 630.3462, found: 630.3451. 
 
Preparation of  aldehyde 425 
 
Known β–hydroxy ester 42711 (5.0 g, 29 mmol) and imidazole (4.34 g, 63.8 mmol) were 
















































(50 mL) was added and the mixture was extracted with EtOAc (3 × 40 mL) and the combined 
organics were washed with brine (75 mL), dried over MgSO4, filtered and concentrated in vacuo. 
The crude material was purified by flash chromatography (5% EtOAc/hexanes) to give silyl ether 
465 (7.875 g, 95% yield). This compound was contaminated with a small amount of a 
compound lacking the α–methyl group due to incomplete conversion in the previous step. This 
compound could however could be removed after the next step.  
1H-NMR (400 MHz; CDCl3): δ 4.87-4.85 (m, 2H), 4.16 (d, J = 9.7 Hz, 1H), 4.09 (qd, J = 
7.2, 0.8 Hz, 2H), 2.56-2.52 (m, 1H), 1.62 (s, 3H), 1.26-1.22 (m, 3H), 0.91 (d, J = 7.1 Hz, 3H), 
0.83-0.81 (m, 9H), -0.01 (s, 3H), -0.04 (s, 3H); 13C-NMR (101 MHz, CDCl3): δ 175.63, 144.62, 
114.31, 79.74, 60.22, 44.72, 17.95, 15.81, 14.11, 13.99, -4.85, -5.59; FTIR (thin film): 2955, 
2930, 2887, 2857, 1736, 1473, 1463, 1389, 1376, 1362, 1251, 1175, 1071 cm-1; HRMS (ESI–
APCI) m/z calc’d for C15H31O3Si (M+H)+: 287.2042, found: 287.2034. 
Ester 465 (1.5 g, 5.24 mmol) was dissolved in CH2Cl2 (52 mL) and cooled to –78 °C. 
DIBAL–H (1 M in hexanes, 15.7 mL, 15.7 mmol) was added and the reaction was allowed to 
warm to room temperature. After 1 h 45 min sat. aq. Rochelles salt (50 mL) was added. The 
mixture was extracted with CH2Cl2 (3 × 30 mL) and the combined organics were washed with 
brine (75 mL), dried over MgSO4, filtered and concentrated in vacuo. The crude material was 
purified by flash chromatography (10% EtOAc/hexanes) to give alcohol 466 (0.679 g, 53% 
yield). 
1H-NMR (400 MHz; CDCl3): δ 4.86 (t, J = 0.9 Hz, 1H), 4.83 (t, J = 1.5 Hz, 1H), 3.87 (d, J 
= 7.4 Hz, 1H), 3.57 (d, J = 5.6 Hz, 2H), 2.85 (s, 1H), 1.78-1.75 (m, 1H), 1.64 (s, 3H), 0.84 (d, J = 
7.7 Hz, 9H), 0.81 (d, J = 8.4 Hz, 3H), 0.04 (s, 3H), -0.03 (s, 3H); 13C-NMR (101 MHz, CDCl3): δ 
145.78, 112.80, 82.44, 66.24, 37.98, 25.76, 18.02, 17.17, 14.26, -4.61, -5.33; FTIR (thin film): 
3388, 2957, 2930, 2886, 2858, 1472, 1463, 1388, 1373, 1256, 1065, 1040 cm-1; HRMS (ESI–
APCI) m/z calc’d for C13H29O2Si (M+H)+: 245.1937, found: 245.1925. 
 221 
Oxalyl chloride (0.57 mL, 6.53 mmol) was added to a solution of DMSO (0.78 mL, 11.04 
mmol) in CH2Cl2 (26 mL) at –78 °C. After 10 min alcohol 466 (1.228 g, 5.02 mmol) in CH2Cl2 (26 
mL) was added. The reaction was stirred for 45 min then Et3N (3.5 mL, 25.1 mmol) was added. 
After 45 min the reaction was warmed to room temperature and the reaction was quenched with 
sat. aq. NH4Cl (50 mL). The mixture was extracted with CH2Cl2 (3 × 40 mL) and the combined 
organics were washed with brine (100 mL), dried over MgSO4, filtered and concentrated in 
vacuo. The crude material was purified by flash chromatography (10% EtOAc/hexanes) to give 
aldehyde 425 (1.028 g, 84% yield).  
1H-NMR (400 MHz; CDCl3): δ 9.73 (s, 1H), 4.92-4.90 (m, 2H), 4.14 (d, J = 8.1 Hz, 1H), 
2.52 (ddd, J = 7.9, 7.1, 2.8 Hz, 1H), 0.90 (d, J = 7.0 Hz, 3H), 0.85 (s, 9H), 0.03 (s, 3H), -0.01 (s, 
3H); 13C-NMR (101 MHz, CDCl3): δ 204.94, 144.52, 113.78, 78.64, 49.82, 25.64, 18.05, 16.63, 
11.01, -4.64, -5.37; FTIR (thin film): 2956, 2930, 2886, 2857, 1727, 1472, 1462, 1389, 1373, 
1362, 1251, 1117, 1065 cm-1; HRMS (ESI–APCI) m/z calc’d for C13H27O3Si (hydrate of the 
aldehyde) (M-H)-: 259.1729, found: 259.1725. 
 
Preparation of  phenol 429 
 
n-BuLi (1.6 M in hexanes, 3.18 mL, 5.09 mmol) was added to aryl bromide 42812 (2.077 
g, 5.09 mmol) in THF (11.3 mL) at –78 °C. After 10 min aldehyde 425 (1.028 g, 4.24 mmol) in 
THF (2.1 mL) was added. The reaction was stirred for 20 min then warmed to room 
temperature. After 20 min the reaction was quenched with sat. aq. NH4Cl (10 mL) and extracted 



















MgSO4, filtered and concentrated in vacuo. The crude material was purified by flash 
chromatography (10% EtOAc/hex) to give alcohol 467 (2.4 g, quant. yield). 
1H-NMR (400 MHz; CDCl3): δ 6.98 (s, 1H), 6.87 (t, J = 2.0 Hz, 1H), 6.74 (d, J = 1.1 Hz, 
1H), 5.11 (s, 1H), 5.04 (s, 1H), 5.01 (s, 1H), 4.12 (s, 1H), 3.41 (s, 1H), 1.78 (m, 1H), 1.74 (s, 
3H), 1.27-1.19 (m, 3H), 1.11-1.03 (m, 18H), 0.94-0.91 (s, 9H), 0.77 (d, J = 7.1 Hz, 3H), 0.10-
0.08 (s, 3H), 0.04 (s, 3H); 13C-NMR (101 MHz, CDCl3): δ 156.56, 147.27, 146.17, 145.41, 
144.81, 122.90, 122.22, 122.02, 121.35, 121.10, 117.91, 116.06, 114.62, 112.66, 84.84, 80.51, 
78.80, 71.21, 42.80, 41.92, 25.96, 25.87, 25.82, 25.78, 18.98, 18.09, 17.90, 17.85, 17.76, 16.38, 
14.29, 12.63, 12.57, 10.16, -4.23, -4.67, -5.27, -5.30; FTIR (thin film): 3487, 2946, 2930, 2893, 
2867, 1596, 1567, 1471, 1463, 1442, 1278, 1257, 1151, 1106, 1090, 1061, 1013, 1001 cm-1; 
HRMS (ESI–APCI) m/z calc’d for C28H51BrNaO3Si2 (M+Na)+: 595.2437, found: 595.2434. 
TBAF (1 M in THF, 4.12 mL, 4.12 mmol) was added to alcohol 467 (1.07 g, 1.87 mmol) 
in THF (18.7 mL). After 1 h the solvent was removed in vacuo and the crude material was 
purified by flash chromatography (30%→50% EtOAc/hexanes) to give phenol 429 (0.254 g, 
45% yield). 
1H-NMR (400 MHz; CDCl3): δ 6.89 (s, 1H), 6.86 (s, 1H), 6.78 (s, 1H), 5.01 (s, 1H), 4.96 
(m, 2H), 4.06 (d, J = 6.9 Hz, 1H), 3.81-3.76 (m, 1H), 3.00-2.95 (m, 1H), 2.00-1.96 (m, 1H), 1.74 
(s, 3H), 0.77-0.76 (m, 3H); 13C-NMR (101 MHz, CDCl3): δ 156.61, 146.01, 145.24, 122.46, 
121.19, 117.52, 113.01, 112.04, 79.32, 73.55, 40.70, 17.96, 10.93; FTIR (thin film): 3310, 2972, 
2921, 1597, 1576, 1377, 1266, 1149, 1090 cm-1; HRMS (ESI–APCI) m/z calc’d for C13H17BrClO3 







Preparation of   β–hydroxy ketone 437 
 
LDA was prepared by addition of n–BuLi (1.6 M in hexanes, 3.0 mg, 4.802 mmol) to a 
solution of diisopropylamine (730 mL, 5.239 mmol) in THF (10 mL). After stirring for 30 min at –
78 °C, acetophenone 436 (1.00 g, 4.356 mmol) in THF (2 mL) was added and the orange 
solution was stirred for 45 min at –78 °C. Methacrolein (80%, 450 mL, 4.365 mmol) was added 
and the greenish solution formed was stirred for another 45 min at –78 °C before it was 
quenched by addition of acetic acid (0.5 mL) in THF (1 mL). The mixture was then warmed to 
room temperature and the white suspension was diluted with water (30 mL). The aqueous 
phase was extracted with diethyl ether (3 × 10 mL) and the combined organic phases were 
washed with brine (40 mL), dried over MgSO4, filtered and concentrated in vacuo. The crude 
material was purified by flash chromatography (3:1 hexanes:EtOAc) to furnish allylic alcohol 437 
(921 mg, 71% yield) along with a minor amount of inseparable debrominated product. 
1H-NMR (400 MHz; CDCl3): δ 7.53 (d, J = 8.7 Hz, 1H), 7.12 (d, J = 2.5 Hz, 1H), 6.85 (dd, 
J = 8.7, 2.5 Hz, 1H), 5.03 (s, 1H), 4.85 (s, 1H), 4.60 (m, 1H), 3.80 (s, 3H), 3.21-3.07 (m, 3H), 
1.75 (s, 3H); 13C-NMR (101 MHz, CDCl3): δ 201.65, 162.01, 145.73, 132.22, 131.46, 130.43, 
119.62, 113.79, 113.12, 111.32, 71.62, 55.71, 47.19, 43.18, 18.50, 18.41; FTIR (thin film): 3445, 
2970, 2941, 2915, 2840, 1676, 1593, 1488, 1457, 1439, 1261, 1229, 1170, 1027 cm-1; HRMS 





















Preparation of  diol 438 
 
Tetramethylammonium triacetoxyborohydride (2.11 g, 8.02 mmol) was dissolved in a 
mixture of acetonitrile (3 mL) and acetic acid (3 mL) and the mixture was stirred for 30 min. 
Then a solution of allylic alcohol 437 (300 mg, 1.00 mmol) in acetonitrile (1 mL) was added and 
the mixture was stirred for 2 h at ambient temperature. The mixture was then diluted with 
saturated aqueous Rochelle’s salt solution (10 mL) and diethyl ether (10 mL) followed by slow 
addition of saturated aqueous sodium bicarbonate solution (10 mL). The aqueous phase was 
extracted with diethyl ether (3 × 10 mL) and the combined organic phases were washed with 
saturated aqueous sodium bicarbonate (30 mL) and brine (30 mL), dried over MgSO4, filtered 
and concentrated in vacuo. The crude material was purified by flash chromatography (9:1→3:1 
hexanes:EtOAc) to provide diol 438 (221 mg, 73% yield). 
1H-NMR (400 MHz; CDCl3): δ 7.50 (d, J = 8.7 Hz, 1H), 7.02 (d, J = 2.6 Hz, 1H), 6.87 (dd, 
J = 8.7, 2.6 Hz, 1H), 5.23 (dt, J = 7.7, 3.7 Hz, 1H), 5.06 (s, 1H), 4.91 (s, 1H), 4.27-4.26 (m, 1H), 
3.77 (s, 3H), 3.38 (d, J = 3.6 Hz, 1H), 2.79 (d, J = 4.4 Hz, 1H), 1.96-1.92 (m, 2H), 1.74 (s, 3H); 
13C-NMR (101 MHz, CDCl3): δ 159.10, 146.83, 135.06, 128.10, 121.39, 117.67, 113.70, 110.39, 
73.28, 70.36, 55.50, 40.19, 18.99; FTIR (thin film): 3340, 2942, 2917, 2836, 1604, 1589, 1490, 
1455, 1439, 1285, 1234, 1070, 1027 cm-1; HRMS (ESI–APCI) m/z calc’d for C13H21BrNO3 




















Preparation of  acetal 440 
 
Diol 438 (450 mg, 1.49 mmol) and p–TsOH (28 mg, 0.15 mmol) were dissolved in 2,2–
dimethoxypropane (2 mL) and heated to 56 °C for 3 h. The mixture was cooled to room 
temperature and diluted with diethyl ether (10 mL) and saturated aqueous sodium bicarbonate 
solution (10 mL). The aqueous phase was extracted with diethyl ether (3 × 5 mL) and the 
combined organic phases were washed with brine (20 mL), dried over MgSO4, filtered and 
concentrated in vacuo. The crude material was purified by flash chromatography (20:1 
hexanes:EtOAc) to provide acetal 440 (379 mg, 74% yield). 
1H-NMR (400 MHz; CDCl3): δ 7.49 (d, J = 8.7 Hz, 1H), 7.05 (t, J = 2.5 Hz, 1H), 6.89 (dd, 
J = 8.7, 2.6 Hz, 1H), 5.17 (dd, J = 9.7, 5.8 Hz, 1H), 5.04 (s, 1H), 4.86 (s, 1H), 4.37 (t, J = 7.5 Hz, 
1H), 3.77 (s, 3H), 2.24 (ddd, J = 13.2, 8.6, 5.8 Hz, 1H), 1.85-1.77 (m, 4H), 1.49 (s, 3H), 1.48 (s, 
3H); 13C-NMR (101 MHz, CDCl3): δ 159.14, 145.09, 134.03, 128.28, 121.91, 117.50, 114.02, 
110.71, 100.91, 69.93, 67.62, 55.52, 37.13, 25.44, 25.06, 18.62; FTIR (thin film): 2987, 2940, 

























Preparation of  phenol 441 
 
To a suspension of sodium hydride (60% in mineral oil, 101 mg, 2.514 mmol) in DMF (3 
mL) was added ethanethiol (181 mL, 2.514 mmol) and the foaming mixture was stirred for 15 
min until a clear solution was obtained. A solution of acetal 440 (286 mg, 0.838 mmol) in DMF 
(1 mL) was then added and the mixture was heated to 90 °C for 20 h. The reaction mixture was 
then cooled to room temperature and diluted with diethyl ether (10 mL) and saturated aqueous 
ammonium chloride solution (10 mL). The aqueous phase was extracted with diethyl ether (3 × 
5 mL) and the combined organic phases were washed with brine (2 x 20 mL), dried over 
MgSO4, filtered and concentrated in vacuo. The crude material was purified by flash 
chromatography (20:1→10:1 hexanes:EtOAc) to provide phenol 468 (220 mg, 80% yield). 
1H-NMR (400 MHz; CDCl3): δ 7.40 (dd, J = 8.6, 4.1 Hz, 1H), 6.96 (dd, J = 4.8, 2.6 Hz, 
1H), 6.76-6.73 (m, 1H), 5.99-5.92 (m, 1H), 5.20 (dd, J = 9.8, 5.7 Hz, 1H), 5.05 (s, 1H), 4.88 (s, 
1H), 4.39 (t, J = 7.4 Hz, 1H), 2.22 (ddd, J = 13.5, 8.2, 5.5 Hz, 1H), 1.92-1.83 (m, 1H), 1.79 (s, 
2H), 1.51 (s, 3H), 1.48 (s, 3H); 13C-NMR (101 MHz, CDCl3): δ 155.54, 155.52, 144.86, 133.32, 
128.63, 128.59, 122.16, 119.42, 119.40, 115.24, 111.08, 101.21, 72.56, 70.20, 67.79, 36.77, 
25.50, 25.08, 18.65; FTIR (thin film): 3347, 2989, 2936, 2159, 2030, 1976, 1608, 1583, 1495, 
1434, 1319, 1220, 1161, 1132, 1089, 1031, 1008 cm-1; HRMS (ESI–APCI) m/z calc’d for 
C15H18BrO3 (M-H)-: 325.0439, found: 325.0442. 
Acetal 468 (200 mg, 0.611 mmol) was dissolved in methanol (2 mL), cooled to 0 °C and 
TFA (14 mL, 0.183 mmol) was added. The solution was stirred 3 h at 0 °C and for an additional 


















sodium bicarbonate (10 mL). The aqueous phase was extracted with diethyl ether (3 × 5 mL) 
and the combined organic phases were washed with brine (20 mL), dried over MgSO4, filtered 
and concentrated in vacuo. The crude material was purified by flash chromatography (4:1→2:1 
hexanes:EtOAc) to furnish phenol 441 (117 mg, 66% yield).  
1H-NMR (400 MHz; acetone-d6): δ 8.65 (s, 1H), 7.47 (d, J = 8.5 Hz, 1H), 7.00 (m, 1H), 
6.85 (d, J = 8.5 Hz, 1H), 5.21 (dt, J = 9.3, 3.4 Hz, 1H), 5.00 (s, 1H), 4.79-4.77 (m, 1H), 4.60 (d, J 
= 4.1 Hz, 1H), 4.32 (m, 1H), 4.24 (d, J = 4.7 Hz, 1H), 1.85 (m, J = 2.8 Hz, 1H), 1.77-1.70 (m, 
4H); 13C-NMR (101 MHz, aceton-d6): δ 205.52, 156.91, 148.24, 135.46, 128.47, 118.68, 114.92, 
109.04, 71.94, 69.10, 42.55, 17.98; HRMS (ESI–APCI) m/z calc’d for C12H14BrO3 (M-H)-: 
285.0126, found: 285.0123. 
 
Preparation of  spirotetrahydrofuran 443 
 
To a solution of triol 441 (50 mg, 0.174 mmol) in acetonitrile (3 mL) was added 
PhI(OAc)2 (112 mg, 0.348 mmol) and the solution was stirred for 6 h. The orange solution was 
then diluted with diethyl ether (10 mL) and saturated aqueous sodium bicarbonate (10 mL). The 
aqueous phase was extracted with diethyl ether (3 × 5 mL) and the combined organic phases 
were washed with brine (20 mL), dried over MgSO4, filtered and concentrated in vacuo. The 
crude material was purified by flash chromatography (3:1→2:1 hexanes:EtOAc) to give 
spirotetrahydrofuran 443 (7 mg, 14% yield).  
1H-NMR (400 MHz; CDCl3): δ 6.93 (s, 1H), 6.74 (m, 1H), 6.55-6.51 (m, 1H), 5.03 (s, 1H), 
















13C-NMR (101 MHz, CDCl3): " 183.10, 146.45, 145.82, 143.77, 136.45, 136.40, 133.26, 111.86, 
72.90, 64.57, 58.06, 34.10, 17.77. 
Preparation of  ester 448 
DMF (0.006 mL, 0.08 mmol) was added to a solution of acid 44713 (0.244 g, 1.94 mmol) 
and oxalyl chloride (0.29 mL, 3.22 mmol) in CH2Cl2 (8 mL) at 0 °C. After 30 min the reaction was 
warmed to room temperature and after 30 min a solution of phenol 446 (0.400 g, 1.61 mmol) 
and Et3N (0.45 mL, 3.22 mmol) in CH2Cl2 (8 mL) was added. After stirring for 2 h sat. aq. NH4Cl 
(20 mL) was added and the mixture was extracted with CH2Cl2 (3 ! 15 mL). The combined 
organics were washed with sat. aq. NaHCO3 (40 mL), dried over MgSO4, filtered and 
concentrated in vacuo. The crude mixture was purified by flash chromatography (5% 
EtOAc/hexanes) to give ester 448 (0.229 g, 40% yield). 
1H-NMR (400 MHz; CDCl3): " 7.53-7.50 (m, 1H), 7.42 (dt, J = 7.3, 3.6 Hz, 1H), 7.39 (d, J
= 9.2 Hz, 1H), 7.00 (t, J = 0.5 Hz, 1H), 5.32 (s, 1H), 5.21 (s, 1H), 3.87-3.81 (m, 3H), 2.18-2.13 
(m, 3H), 2.00-1.98 (m, 3H); 13C-NMR (101 MHz, CDCl3): " 165.68, 156.98, 144.11, 142.91, 
140.49, 125.48, 124.10, 124.05, 121.84, 120.02, 109.83, 56.33, 22.64, 13.98; FTIR (thin film): 
3092, 2929, 2850, 1741, 1614, 1537, 1476, 1436, 1347, 1302, 1197, 1072, 1041 cm-1; HRMS 





















Preparation of  enone 445 
n-BuLi (1.67 M in hexanes, 0.16 mL, 0.26 mmol) was added to aryl bromide 448 (0.085 
g, 0.24 mmol) in THF (2.4 mL) at –78 °C. After 2.5 h the reaction was warmed to room 
temperature and sat. aq. NH4Cl (5 mL) was added. The mixture was extracted with EtOAc (3 !
5 mL) and the combined organics washed with brine (15 mL), dried over MgSO4, filtered and 
concentrated in vacuo. The crude material was purified by flash chromatography (5%#10% 
EtOAc/hexanes) to give enone 445 (0.006 g, 9% yield). 
1H-NMR (300 MHz; CDCl3): " 10.59 (s, 1H), 7.61 (d, J = 3.0 Hz, 1H), 7.17 (d, J = 3.2 Hz, 
1H), 6.59 (d, J = 0.6 Hz, 1H), 5.29 (d, J = 0.6 Hz, 1H), 5.11 (s, 1H), 3.82 (s, 3H), 2.12 (s, 3H), 
1.94 (s, 3H). 
Preparation of  ester 451 
DMF (3 drops) was added to a solution of acid 447 (1.24 g, 9.85 mmol) and oxalyl 
chloride (1.11 mL, 12.33 mmol) in CH2Cl2 (25 mL) at 0 °C. After 30 min the reaction was 
warmed to room temperature and after 30 min a solution of phenol 450 (1.00 g, 4.93 mmol) and 
Et3N (1.72 mL, 12.33 mmol) in CH2Cl2 (25 mL) was added. After stirring for 2 h sat. aq. NH4Cl 





































organics were washed with sat. aq. NaHCO3 (75 mL), dried over MgSO4, filtered and 
concentrated in vacuo. The crude mixture was purified by flash chromatography (2%→3%→5% 
EtOAc/hexanes) to give ester 451 (0.444 g, 29% yield). 
1H-NMR (400 MHz; CDCl3): δ 7.38 (s, 1H), 7.12 (d, J = 2.8 Hz, 1H), 7.06 (d, J = 8.9 Hz, 
1H), 6.85 (dd, J = 8.9, 2.9 Hz, 1H), 5.30 (s, 1H), 5.18 (s, 1H), 3.77 (s, 3H), 2.15 (s, 3H), 1.99 (s, 
3H); 13C-NMR (101 MHz, CDCl3): δ 166.80, 157.61, 142.83, 142.15, 140.64, 126.35, 123.93, 
121.03, 118.06, 116.31, 114.10, 55.78, 22.73, 14.03; FTIR (thin film): 2962, 2940, 2837, 1771, 
1727, 1600, 1580, 1488, 1439, 1263, 1229, 1181, 1082, 1030 cm-1; HRMS (ESI–APCI) m/z 
calc’d for  C14H16BrO3 (M+H)+: 311.0283, found: 311.2080. 
 
Preparation of  anhydride 452 
 
DCC (0.577 g, 2.79 mmol) was added to acid 447 (0.863 g, 5.6 mmol) in CH2Cl2 (28 mL) 
at 0 °C. After 35 min the solution was warmed to room temperature. After 1 h 20 min the 
reaction was placed in the freezer overnight. The solution was then filtered through a pad of 
silica while still cold. The solvent was removed in vacuo to provide anhydride 452 (0.574 g, 44% 
yield), which was used in the next step as is. 
1H-NMR (300 MHz; CDCl3): δ 7.20 (s, 2H), 5.33 (s, 2H), 5.17 (s, 2H), 2.08 (s, 6H), 1.99 
(s, 6H); 13C-NMR (75 MHz, CDCl3): δ 165.27, 144.51, 140.65, 127.12, 122.08, 22.79, 14.00; 
FTIR (thin film): 2970, 2929, 1769, 1710, 1633, 1623, 1446, 1388, 1265, 1187, 1003 cm-1; 


















Preparation of  ester 451 
 
Anhydride 452 (0.574 g, 2.45 mmol), phenol 450 (0.452 g, 2.23 mmol), Et3N (0.34 mL, 
2.45 mmol), and CH2Cl2 (22 mL) were combined and heated to 45 °C. After 15 h the reaction 
was cooled to room temperature and sat. aq. NH4Cl (25 mL) was added and extracted with 
CH2Cl2 (3 ! 15 mL). The combined organics were washed with 1 N NaOH (50 mL) and brine (50 
mL), dride over MgSO4, filtered and concentrated in vacuo. The crude material was purified by 
flash chromatography (2.5%#5% EtOAc/hexanes) to give ester 451 (0.612 g, 88% yield). All 
spectral data matched that from the acid chloride procedure. 
Preparation of  enone 449 
n-BuLi (1.67 M in hexanes, 1.28 mL, 2.14 mmol) was added to aryl bromide 451 (0.444 
g, 1.43 mmol) in THF (14.3 mL) at –78 °C. The reaction was allowed to warm to room 
temperature and stir of 17 h. MeOH (10 mL) was added and the volatiles were removed in 
vacuo. The crude material was purified by flash chromatography (5% EtOAc/hexanes) to give 
enone 449 (0.056 g, 17% yield). 
1H-NMR (400 MHz; CDCl3): " 11.33 (s, 1H), 7.12 (d, J = 3.0 Hz, 1H), 7.08 (t, J = 6.0 Hz, 
1H), 6.94 (m, 1H), 6.40 (s, 1H), 5.24 (s, 1H), 5.10 (s, 1H), 3.74 (s, 3H), 2.14 (s, 3H), 1.97 (s, 







































119.91, 119.12, 115.66, 113.79, 55.87, 15.10, 14.07; FTIR (thin film): 2955, 2933, 2871, 2860, 
2836, 1726, 1630, 1599, 1483, 1323, 1281, 1254, 1218, 1138, 1039 cm-1; HRMS (ESI–APCI) 
m/z calc’d for C14H15O3 (M-H)-: 231.1021, found: 231.1023. 
 
Preparation of  ester 453 
 
Anhydride 452 (0.519 g, 2.22 mmol), p-methoxyphenol (0.25 g, 2.01 mmol), Et3N (0.31 
mL, 2.22 mmol), and CH2Cl2 (20 mL) were combined and heated to 45 °C. After stirring for 15 h 
the reaction was cooled to room temperature and sat. aq. NH4Cl (20 mL) was added and 
extracted with CH2Cl2 (3 × 15 mL). The combined organics were washed with 1 N NaOH (30 
mL) and brine (30 mL), dried over MgSO4, filtered and concentrated in vacuo. The crude 
material was purified by flash chromatography (2%→10% EtOAc/hexanes) to give ester 453 
(0.292 g, 63% yield). 
1H-NMR (400 MHz; CDCl3): δ 7.31 (s, 1H), 7.02 (dd, J = 9.7, 3.0 Hz, 2H), 6.91-6.87 (m, 
2H), 5.28 (s, 1H), 5.15 (s, 1H), 3.78 (s, 3H), 2.12 (d, J = 1.2 Hz, 3H), 1.98 (s, 3H); 13C-NMR (101 
MHz, CDCl3): δ 167.67, 157.08, 144.59, 142.12, 140.68, 126.92, 122.37, 120.56, 114.39, 
114.37, 55.54, 22.76, 14.01; FTIR (thin film): 2958, 2934, 2836, 1721, 1633, 1610, 1596, 1504, 
1455, 1442, 1229, 1090, 1031 cm-1; HRMS (ESI–APCI) m/z calc’d for C14H17O3 (M+H)+: 























Preparation of  Aldol product 456 
 
LDA was prepared by adding n-BuLi (1.67 M in hexanes, 2.19 mL, 3.65 mmol) to i-
Pr2NH (0.58 mL, 4.2 mmol) in THF (16 mL) at –78 °C. After stirring for 30 min ketone 45514 
(0.300 g, 1.66 mmol) in THF (5 mL) was added. After 25 min methacrolein (80%, 0.21 mL, 2.49 
mmol) was added. After 40 min the reaction was quenched with AcOH (2 mL) and allowed to 
warm to room temperature. Sat. aq. NaHCO3 (40 mL) was added and the solution was estracted 
with EtOAc (3 × 20 mL). The combined organics were washed with brine (50 mL), dried over 
MgSO4, filtered and concentrated in vacuo. The crude material was purified by flash 
chromatography (10%→30% EtOAc/hexanes) to give aldol product 456 (0.371 g, 89% yield). 
1H-NMR (400 MHz; CDCl3): δ 11.82 (s, 1H), 7.14 (d, J = 2.9 Hz, 1H), 7.08-7.05 (m, 1H), 
6.87 (d, J = 9.0 Hz, 1H), 5.04 (s, 1H), 4.89 (s, 1H), 4.42 (s, 1H), 3.74 (s, 3H), 3.62-3.57 (m, 1H), 
1.71 (s, 3H), 1.21 (d, J = 7.1 Hz, 3H); 13C-NMR (101 MHz, CDCl3): δ 209.78, 157.49, 157.19, 
151.71, 144.51, 143.81, 124.35, 124.02, 119.66, 119.29, 119.02, 117.71, 114.37, 113.46, 
112.69, 112.59, 78.25, 74.72, 55.87, 42.96, 42.76, 19.26, 16.87, 15.49, 11.71; FTIR (thin film): 
3495, 2975, 2939, 2836, 1639, 1611, 1590, 1484, 1373, 1269, 1245, 1173, 1038 cm-1; HRMS 






















Preparation of  bismesylate 457 
 
MsCl (0.14 mL, 1.83 mmol) was added to alcohol 456 (0.207 g, 0.83 mmol) and Et3N 
(0.46 mL, 3.32 mmol) in CH2Cl2 (8.3 mL). The reaction was stirred for 16 h then sat. aq. NH4Cl 
(10 mL) was added and extracted with CH2Cl2 (3 × 10 mL). The combined organics were 
washed with brine (20 mL), dried over MgSO4, filtered and concentrate in vacuo. The crude 
material was purified by flash chromatography (40% EtOAc/hexanes) to give bismesylate 457 
(0.262 g, 78% yield) as a mixture of diastereomers. 
1H-NMR (400 MHz; CDCl3): δ 7.32-7.30 (m, 1H), 7.02 (d, J = 1.9 Hz, 1H), 7.01 (d, J = 
2.5 Hz, 1H), 5.27 (t, J = 5.1 Hz, 1H), 5.16-5.15 (m, 1H), 5.04 (t, J = 1.3 Hz, 1H), 3.79 (t, J = 4.1 
Hz, 3H), 3.66 (t, J = 6.8 Hz, 1H), 3.11 (s, 3H), 2.97 (s, 3H), 1.70 (s, 3H), 1.27 (d, J = 7.0 Hz, 
3H); 13C-NMR (101 MHz, CDCl3): δ 200.71, 158.18, 140.18, 139.43, 133.23, 124.43, 118.19, 
116.93, 114.91, 85.12, 55.87, 47.11, 38.98, 37.63, 18.11, 12.60; FTIR (thin film): 3389, 3022, 
2979, 2941, 1697, 1582, 1486, 1459, 1415, 1351, 1331, 1274, 1197, 1032 cm-1;HRMS (ESI–
APCI) m/z calc’d for (M+H)+: 429.0654, found: 429.0653. 
 
Preparation of  enone 458 
 
To a solution of bismesylate 457 (0.984 g, 2.42 mmol) in CH2Cl2 (24 mL) was added 
Et3N (1.35 mL, 9.68 mmol). The reaction was allowed to stir at room temperature for 3 d the 






























with CH2Cl2 (3 × 25 mL) and the combined organics were washed with brine (50 mL), dried over 
MgSO4, filtered and concentrated in vacuo. The crude material was purified by column 
chromatography (30% EtOAc/hexanes) to provide enone 458 (0.349 g, 46% yield).  
1H-NMR (400 MHz; CDCl3): δ 7.32-7.29 (m, 1H), 6.93 (dt, J = 9.0, 2.8 Hz, 1H), 6.80 (dd, 
J = 3.0, 1.6 Hz, 1H), 6.57 (d, J = 1.0 Hz, 1H), 5.23 (d, J = 1.5 Hz, 1H), 5.06 (s, 1H), 3.76-3.75 
(m, 3H), 3.01-3.01 (m, 3H), 2.05 (s, 3H), 1.89 (s, 3H); 13C-NMR (101 MHz, CDCl3): δ 196.55, 
157.67, 147.26, 147.21, 140.69, 139.31, 136.17, 134.22, 124.08, 121.90, 116.31, 114.38, 55.74, 
37.56, 22.56, 12.78; FTIR (thin film): 3058, 2966, 2940, 2840, 1652, 1611, 1583, 1485, 1464, 
1445, 1414, 1367, 1331, 1266, 1198, 1161, 1031 cm-1; HRMS (ESI–APCI) m/z calc’d for 
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Figure A2.2. 13C-NMR of DKP 72. 
 
 



























































































































































































Figure A2.5. 13C-NMR of DKP 76. 
 
 



















































































































Figure A2.8. 13C-NMR of protected amino acid 82. 
 
 




























































































































































































Figure A2.17. 13C-NMR of DKP 84. 
 
 











































































































































































Figure A2.23. 13C-NMR of amide 91. 
 
 


















































































































Figure A2.26. 13C-NMR of bisselenobenzoate 103. 
 
 


















































































































































Figure A2.29. 13C-NMR of bisselenobenzoate 104. 
 
 


































































































































Figure A2.32. 13C-NMR of diselenide 106. 
 
 
















































Figure A2.38. 13C-NMR of bisselenoether 120. 
 
 























































































Figure A2.47. 13C-NMR of bisthiomethyl ether 127. 
 
 














































































































































Figure A2.50. 13C-NMR of bromoketone 236. 
 
 













































































































































































































































































































































































































































































































































Figure A2.95. 13C-NMR of phenol 463. 
 
 












































































































































Figure A2.98. 13C-NMR of tetramic acid 280. 
 
 











































































































































Figure A2.101. 13C-NMR of diene 287. 
 
 






























































































































Figure A2.104. 13C-NMR of tetramic acid 295. 
 
 



















































































































































Figure A2.107. 13C-NMR of aryl boronic ester 296. 
 
 
















































































































































































Figure A2.112. 13C-NMR of aryl bromide 301. 
 
 


























































































































































Figure A2.115. 13C-NMR of enone 300. 
 
 






















































































































































Figure A2.118. 13C-NMR of enal 464. 
 
 










































































































































































Figure A2.123. 13C-NMR of allylic alcohol 304. 
 
 












































































































































Figure A2.127. 13C-NMR of benzaldehyde 312. 
 
 


























































































































































Figure A2.131. 13C-NMR of alkyne 315. 
 
 




















































































































































Figure A2.134. 13C-NMR of alkyne 358. 
 
 




















































































































































Figure A2.137. 13C-NMR of aldehyde 325. 
 
 























































































































































Figure A2.140. 13C-NMR of vinyl carbonate 321. 
 
 





























































































































Figure A2.143. 13C-NMR of bromide 335. 
 
 

































































































































Figure A2.146. 13C-NMR of tosylate 336. 
 
 










































































































































Figure A2.149. 13C-NMR of carboxylic acid 337. 
 
 



























































































































































Figure A2.152. 13C-NMR of ketone 339. 
 
 




























































































































































Figure A2.155. 13C-NMR of aldehyde 342. 
 
 















































































































































































































Figure A2.165. 13C-NMR of alcohol 346. 
 
 

























































































































Figure A2.168. 13C-NMR of tetracycle 347. 
 
 






















































































































Figure A2.171. 13C-NMR of aldehyde 355. 
 
 


















































































































































Figure A2.174. 13C-NMR of carboxylic acid 356. 
 
 









































































































































Figure A2.177. 13C-NMR of aldehyde 359. 
 
 







































































































































Figure A2.180. 13C-NMR of carboxylic acid 360. 
 
 






































































































































Figure A2.183. 13C-NMR of phenol 365. 
 
 




































































































































Figure A2.186. 13C-NMR of triflate 366. 
 
 


































































































































































Figure A2.190. 13C-NMR of alkyne 351. 
 
 

























































































































































































































































































































Figure A2.195. 13C-NMR of allylic alcohol 367 (diastereomer B). 
 
 









































































































































































Figure A2.198. 13C-NMR of aldehyde 370. 
 
 


























































































































































Figure A2.201. 13C-NMR of carboxylic acid 371. 
 
 




























































































































































Figure A2.204. 13C-NMR of ketone 372. 
 
 









































































































































































Figure A2.207. 13C-NMR of enone 373. 
 
 








































































































































































Figure A2.210. 13C-NMR of phenol 374. 
 
 











































































































































































Figure A2.213. 13C-NMR of triflate 375. 
 
 












































































































































































Figure A2.217. 13C-NMR of alkyne 376. 
 
 



















































































































































































Figure A2.220. 13C-NMR of allylic alcohol 377. 
 
 































































































































































































































Figure A2.227. 13C-NMR of silyl ether 465. 
 
 








































































































































Figure A2.230. 13C-NMR of alcohol 466. 
 
 



































































































































Figure A2.233. 13C-NMR of aldehyde 425. 
 
 


























































































































Figure A2.236. 13C-NMR of alcohol 467. 
 
 

















































































































































Figure A2.239. 13C-NMR of phenol 429. 
 
 























































































































Figure A2.242. 13C-NMR of β–hydroxy ketone 437. 
 
 























































































































































Figure A2.245. 13C-NMR of diol 438. 
 
 


























































































































































Figure A2.248. 13C-NMR of acetal 440. 
 
 















































































































































Figure A2.251. 13C-NMR of phenol 468. 
 
 





















































































































































































Figure A2.258. 13C-NMR of ester 448. 
 
 























































































































Figure A2.262. 13C-NMR of ester 451. 
 
 



























































































































































Figure A2.265. 13C-NMR of anhydride 452. 
 
 



































































































































Figure A2.268. 13C-NMR of enone 449. 
 
 





































































































































































Figure A2.271. 13C-NMR of ester 453. 
 
 
















































































































































Figure A2.274. 13C-NMR of aldol product 456. 
 
 




























































































































Figure A2.277. 13C-NMR of bismesylate 457. 
 
 

































































































































Figure A2.280. 13C-NMR of enone 458. 
 
 
































































































































































X–Ray Crystallography Report for Fused Tricycle 269 
 
A.  Crystal data and structure refinement. 
Identification code  wood22 
Empirical formula  C32 H47 N O5 Si 
Formula weight  553.80 
Temperature  120(2) K 
Wavelength  0.71073 Å 
Crystal system  Monoclinic 
Space group  C2/c 
Unit cell dimensions a = 55.062(4) Å α= 90°. 
 b = 8.9017(7) Å β= 100.454(4)°. 
 c = 13.1258(10) Å γ = 90°. 
Volume 6326.8(8) Å3 
Z 8 
Density (calculated) 1.163 Mg/m3 
Absorption coefficient 0.112 mm-1 
F(000) 2400 
Crystal size 0.15 x 0.15 x 0.03 mm3 
Theta range for data collection 2.96 to 26.37°. 
Index ranges -68<=h<=63, -11<=k<=11, -15<=l<=16 
Reflections collected 50816 
Independent reflections 6457 [R(int) = 0.0471] 
Completeness to theta = 26.37° 99.8 %  
Absorption correction None 
Max. and min. transmission 0.9966 and 0.9833 
Refinement method Full-matrix least-squares on F2 
Data / restraints / parameters 6457 / 0 / 352 
Goodness-of-fit on F2 1.041 
Final R indices [I>2sigma(I)] R1 = 0.0435, wR2 = 0.1080 
R indices (all data) R1 = 0.0633, wR2 = 0.1193 
Largest diff. peak and hole 0.305 and -0.304 e.Å-3 
 442 
B.  Atomic coordinates ( x 104) and equivalent isotropic displacement parameters (Å2x 
103). U(eq) is defined as one third of the trace of the orthogonalized Uij tensor. 
____________________________________________________________________________ 
 x y z U(eq) 
____________________________________________________________________________ 
Si(1) 572(1) 7802(1) 1983(1) 29(1) 
O(1) 697(1) 7541(2) 940(1) 29(1) 
C(1) 1963(1) 7766(2) 3140(1) 16(1) 
N(1) 1577(1) 8269(1) 2096(1) 17(1) 
O(5) 2067(1) 6843(1) 4012(1) 18(1) 
O(2) 1481(1) 10555(1) 2732(1) 20(1) 
O(3) 1923(1) 9357(1) 5414(1) 30(1) 
C(2) 2309(1) 6330(2) 3915(1) 20(1) 
O(4) 1589(1) 8110(1) 4594(1) 23(1) 
C(3) 2401(1) 7449(2) 3222(1) 19(1) 
C(4) 2631(1) 7877(2) 3255(1) 28(1) 
C(5) 2173(1) 8009(2) 2509(1) 18(1) 
C(6) 2097(1) 7049(2) 1551(1) 19(1) 
C(7) 2269(1) 6859(2) 804(1) 28(1) 
C(8) 1870(1) 6513(2) 1486(1) 20(1) 
C(9) 1749(1) 6979(2) 2379(1) 18(1) 
C(10) 1607(1) 5691(2) 2781(1) 22(1) 
C(11) 1752(1) 4245(2) 3080(1) 28(1) 
C(12) 1612(1) 9442(2) 2764(1) 16(1) 
C(13) 1851(1) 9204(2) 3545(1) 17(1) 
C(14) 2013(1) 10608(2) 3598(2) 26(1) 
C(15) 1796(1) 8910(2) 4627(1) 21(1) 
C(16) 1528(1) 7711(2) 5592(1) 32(1) 
C(17) 1276(1) 7083(4) 5411(2) 70(1) 
C(18) 1365(1) 8167(2) 1276(1) 17(1) 
C(19) 1395(1) 8238(2) 253(1) 21(1) 
C(20) 1188(1) 8103(2) -523(1) 25(1) 
C(21) 958(1) 7879(2) -280(1) 24(1) 
C(22) 929(1) 7807(2) 749(1) 22(1) 
C(23) 1135(1) 7970(2) 1533(1) 21(1) 
C(24) 741(1) 6631(3) 3087(2) 50(1) 
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C(25) 845(1) 5161(3) 2755(2) 69(1) 
C(26) 591(1) 6360(5) 3950(2) 90(1) 
C(27) 596(1) 9848(3) 2350(2) 54(1) 
C(28) 605(1) 10881(3) 1432(3) 85(1) 
C(29) 393(1) 10342(4) 2944(3) 89(1) 
C(30) 246(1) 7157(3) 1532(2) 40(1) 
C(31) 225(1) 5463(3) 1330(2) 56(1) 
C(32) 118(1) 8013(3) 584(2) 59(1) 
____________________________________________________________________________
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C.   Bond lengths [Å] and angles [°]. 
_____________________________________________________ 
Si(1)-O(1)  1.6567(13) 
Si(1)-C(30)  1.877(2) 
Si(1)-C(27)  1.882(2) 
Si(1)-C(24)  1.888(2) 
O(1)-C(22)  1.364(2) 
C(1)-O(5)  1.4394(18) 
C(1)-C(5)  1.553(2) 
C(1)-C(13)  1.556(2) 
C(1)-C(9)  1.568(2) 
N(1)-C(12)  1.354(2) 
N(1)-C(18)  1.438(2) 
N(1)-C(9)  1.491(2) 
O(5)-C(2)  1.4354(19) 
O(2)-C(12)  1.2211(18) 
O(3)-C(15)  1.205(2) 
C(2)-C(3)  1.497(2) 
O(4)-C(15)  1.335(2) 
O(4)-C(16)  1.456(2) 
C(3)-C(4)  1.319(2) 
C(3)-C(5)  1.506(2) 
C(5)-C(6)  1.515(2) 
C(6)-C(8)  1.326(2) 
C(6)-C(7)  1.490(2) 
C(8)-C(9)  1.510(2) 
C(9)-C(10)  1.535(2) 
C(10)-C(11)  1.528(2) 
C(12)-C(13)  1.530(2) 
C(13)-C(15)  1.528(2) 
C(13)-C(14)  1.530(2) 
C(16)-C(17)  1.475(3) 
C(18)-C(23)  1.382(2) 
C(18)-C(19)  1.383(2) 
C(19)-C(20)  1.387(2) 
C(20)-C(21)  1.379(2) 
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C(21)-C(22)  1.390(2) 
C(22)-C(23)  1.395(2) 
C(24)-C(25)  1.522(4) 
C(24)-C(26)  1.536(3) 
C(27)-C(28)  1.524(4) 
C(27)-C(29)  1.539(3) 
C(30)-C(32)  1.519(3) 











































































D.   Anisotropic displacement parameters (Å2x 103).  The anisotropic 
displacement factor exponent takes the form: -2π2[ h2a*2U11 + ... + 2 h k a* b* U12 ] 
____________________________________________________________________________ 
 U11 U22 U33 U23 U13 U12 
____________________________________________________________________________ 
Si(1) 19(1)  41(1) 29(1)  -5(1) 8(1)  -4(1) 
O(1) 14(1)  49(1) 24(1)  -2(1) 3(1)  -4(1) 
C(1) 17(1)  16(1) 15(1)  1(1) 1(1)  2(1) 
N(1) 14(1)  18(1) 18(1)  -1(1) 1(1)  2(1) 
O(5) 18(1)  20(1) 17(1)  3(1) 3(1)  4(1) 
O(2) 21(1)  20(1) 20(1)  1(1) 5(1)  6(1) 
O(3) 30(1)  36(1) 20(1)  -9(1) -4(1)  7(1) 
C(2) 18(1)  21(1) 20(1)  0(1) 2(1)  5(1) 
O(4) 28(1)  27(1) 15(1)  0(1) 6(1)  0(1) 
C(3) 19(1)  23(1) 17(1)  -1(1) 2(1)  4(1) 
C(4) 20(1)  40(1) 23(1)  5(1) 2(1)  2(1) 
C(5) 16(1)  18(1) 18(1)  1(1) 3(1)  2(1) 
C(6) 21(1)  20(1) 16(1)  3(1) 2(1)  7(1) 
C(7) 25(1)  39(1) 19(1)  0(1) 5(1)  8(1) 
C(8) 22(1)  19(1) 18(1)  -2(1) 1(1)  4(1) 
C(9) 16(1)  17(1) 20(1)  0(1) 2(1)  3(1) 
C(10) 22(1)  19(1) 23(1)  -2(1) 2(1)  -2(1) 
C(11) 32(1)  19(1) 31(1)  2(1) -1(1)  -4(1) 
C(12) 17(1)  18(1) 15(1)  2(1) 6(1)  -1(1) 
C(13) 16(1)  17(1) 19(1)  -3(1) 2(1)  2(1) 
C(14) 20(1)  19(1) 36(1)  -5(1) 2(1)  -1(1) 
C(15) 23(1)  19(1) 22(1)  -3(1) 1(1)  8(1) 
C(16) 44(1)  35(1) 17(1)  4(1) 9(1)  5(1) 
C(17) 55(2)  125(3) 32(1)  18(1) 15(1)  -27(2) 
C(18) 16(1)  16(1) 19(1)  -1(1) 0(1)  -1(1) 
C(19) 18(1)  25(1) 22(1)  2(1) 6(1)  -1(1) 
C(20) 25(1)  34(1) 16(1)  1(1) 3(1)  -3(1) 
C(21) 20(1)  30(1) 19(1)  0(1) -2(1)  -2(1) 
C(22) 15(1)  27(1) 24(1)  0(1) 4(1)  0(1) 
C(23) 19(1)  28(1) 17(1)  -1(1) 4(1)  1(1) 
C(24) 34(1)  84(2) 32(1)  14(1) 4(1)  -17(1) 
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C(25) 53(2)  56(2) 91(2)  38(2) -1(2)  -4(1) 
C(26) 62(2)  167(4) 42(2)  30(2) 12(1)  -36(2) 
C(27) 28(1)  55(1) 79(2)  -28(1) 12(1)  -2(1) 
C(28) 72(2)  38(1) 149(3)  1(2) 32(2)  7(1) 
C(29) 44(2)  100(2) 124(3)  -73(2) 22(2)  0(2) 
C(30) 21(1)  59(1) 41(1)  -7(1) 13(1)  -6(1) 
C(31) 35(1)  63(2) 65(2)  -1(1) 2(1)  -21(1) 
C(32) 23(1)  74(2) 74(2)  3(1) -7(1)  0(1) 
____________________________________________________________________________
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E.   Hydrogen coordinates ( x 104) and isotropic displacement parameters (Å2x 103). 
____________________________________________________________________________ 
 x  y  z  U(eq) 
____________________________________________________________________________ 
 
H(2A) 2301 5334 3610 23 
H(2B) 2417 6297 4586 23 
H(4A) 2757 7471 3749 33 
H(4B) 2668 8584 2785 33 
H(5A) 2189 9070 2331 21 
H(7A) 2194 6222 245 42 
H(7B) 2420 6411 1152 42 
H(7C) 2304 7823 535 42 
H(8A) 1794 5908 944 24 
H(10A) 1544 6048 3383 26 
H(10B) 1465 5450 2252 26 
H(11A) 1646 3517 3318 42 
H(11B) 1890 4453 3621 42 
H(11C) 1810 3855 2487 42 
H(14A) 1930 11436 3855 38 
H(14B) 2043 10843 2918 38 
H(14C) 2167 10427 4054 38 
H(16A) 1535 8594 6030 38 
H(16B) 1644 6975 5937 38 
H(17A) 1232 6813 6062 105 
H(17B) 1270 6207 4981 105 
H(17C) 1161 7820 5072 105 
H(19A) 1551 8373 88 25 
H(20A) 1206 8165 -1213 30 
H(21A) 821 7775 -807 28 
H(23A) 1117 7947 2225 26 
H(24A) 885 7228 3404 60 
H(25A) 929 4637 3356 103 
H(25B) 958 5369 2299 103 
H(25C) 712 4551 2402 103 
H(26A) 687 5768 4489 135 
 451 
H(26B) 441 5837 3670 135 
H(26C) 552 7308 4229 135 
H(27A) 753 9973 2827 64 
H(28A) 615 11907 1662 127 
H(28B) 458 10746 921 127 
H(28C) 747 10642 1134 127 
H(29A) 412 11389 3115 133 
H(29B) 405 9764 3569 133 
H(29C) 233 10182 2520 133 
H(30A) 155 7374 2092 47 
H(31A) 55 5197 1108 83 
H(31B) 291 4931 1955 83 
H(31C) 317 5200 800 83 
H(32A) -48 7650 383 88 
H(32B) 206 7865 25 88 
H(32C) 115 9064 744 88 
____________________________________________________________________________  
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A.  Crystal data and structure refinement. 
Identification code  wood26 
Empirical formula  C21 H25 N O6 
Formula weight  387.42 
Temperature  120(2) K 
Wavelength  0.71073 Å 
Crystal system  Monoclinic 
Space group  P 21/c 
Unit cell dimensions a = 8.9089(9) Å α= 90°. 
 b = 25.655(3) Å β= 114.678(5)°. 
 c = 9.3854(9) Å γ = 90°. 
Volume 1949.2(3) Å3 
Z 4 
Density (calculated) 1.320 Mg/m3 
Absorption coefficient 0.097 mm-1 
F(000) 824 
Crystal size 0.23 x 0.15 x 0.11 mm3 
Theta range for data collection 1.59 to 28.55°. 
Index ranges -11<=h<=11, -34<=k<=34, -11<=l<=12 
Reflections collected 40478 
Independent reflections 4899 [R(int) = 0.0375] 
Completeness to theta = 28.55° 98.7 %  
Absorption correction Semi-empirical from equivalents 
Max. and min. transmission 0.9895 and 0.9776 
Refinement method Full-matrix least-squares on F2 
Data / restraints / parameters 4899 / 0 / 259 
Goodness-of-fit on F2 1.074 
Final R indices [I>2sigma(I)] R1 = 0.0393, wR2 = 0.1014 
R indices (all data) R1 = 0.0510, wR2 = 0.1146 
Largest diff. peak and hole 0.366 and -0.262 e.Å-3 
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B.  Atomic coordinates  ( x 104) and equivalent  isotropic displacement parameters (Å2x 
103).  U(eq) is defined as one third of  the trace of the orthogonalized Uij tensor. 
____________________________________________________________________________ 
 x y z U(eq) 
____________________________________________________________________________ 
O(1) 1855(1) -566(1) 10109(1) 22(1) 
O(2) -3549(1) 306(1) 3717(1) 23(1) 
O(3) 545(1) 2371(1) 6575(1) 18(1) 
O(4) 3022(1) 767(1) 6421(1) 16(1) 
O(5) 4478(1) 1807(1) 8281(1) 19(1) 
O(6) 4288(1) 2198(1) 6068(1) 27(1) 
N(1) 819(1) 1015(1) 6938(1) 12(1) 
C(1) 922(1) -249(1) 8896(1) 15(1) 
C(2) -670(2) -427(1) 7969(1) 17(1) 
C(3) -1707(2) -146(1) 6667(1) 16(1) 
C(4) -1185(1) 321(1) 6266(1) 14(1) 
C(5) 361(1) 510(1) 7270(1) 13(1) 
C(6) 1439(1) 229(1) 8569(1) 14(1) 
C(7) 3543(2) -425(1) 11000(2) 28(1) 
C(8) -2176(2) 603(1) 4727(1) 16(1) 
C(9) -2821(1) 1134(1) 4953(1) 15(1) 
C(10) -4625(2) 1240(1) 3960(2) 24(1) 
C(11) -1884(1) 1498(1) 5939(1) 15(1) 
C(12) -74(1) 1484(1) 7059(1) 13(1) 
C(13) 113(2) 1578(1) 8749(1) 16(1) 
C(14) 1889(2) 1609(1) 9988(1) 20(1) 
C(15) 819(1) 1912(1) 6569(1) 13(1) 
C(16) 2036(1) 1664(1) 6011(1) 13(1) 
C(17) 2073(1) 1097(1) 6500(1) 12(1) 
C(18) 1315(2) 1698(1) 4212(1) 19(1) 
C(19) 3730(1) 1923(1) 6758(1) 16(1) 
C(20) 6089(2) 2051(1) 9144(2) 27(1) 
C(21) 6797(2) 1844(1) 10783(2) 33(1) 
____________________________________________________________________________
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C.   Bond lengths [Å] and angles [°]. 
_____________________________________________________  
O(1)-C(1)  1.3635(14) 
O(1)-C(7)  1.4288(16) 
O(2)-C(8)  1.4162(14) 
O(3)-C(15)  1.2035(15) 
O(4)-C(17)  1.2196(14) 
O(5)-C(19)  1.3337(15) 
O(5)-C(20)  1.4616(14) 
O(6)-C(19)  1.1987(15) 
N(1)-C(17)  1.3576(15) 
N(1)-C(5)  1.4312(15) 
N(1)-C(12)  1.4738(15) 
C(1)-C(6)  1.3888(17) 
C(1)-C(2)  1.3949(17) 
C(2)-C(3)  1.3872(17) 
C(3)-C(4)  1.3933(17) 
C(4)-C(5)  1.3909(15) 
C(4)-C(8)  1.5239(16) 
C(5)-C(6)  1.3956(16) 
C(8)-C(9)  1.5288(17) 
C(9)-C(11)  1.3336(17) 
C(9)-C(10)  1.5080(16) 
C(11)-C(12)  1.5135(16) 
C(12)-C(15)  1.5344(16) 
C(12)-C(13)  1.5430(17) 
C(13)-C(14)  1.5250(17) 
C(15)-C(16)  1.5256(17) 
C(16)-C(17)  1.5213(16) 
C(16)-C(19)  1.5259(16) 
C(16)-C(18)  1.5379(16) 






















































D.   Anisotropic displacement parameters  (Å2x 103).  The anisotropic 
displacement factor exponent takes the form:  -2π2[ h2 a*2U11 + ...  + 2 h k a* b* U12 ] 
____________________________________________________________________________ 
 U11 U22  U33 U23 U13 U12 
____________________________________________________________________________ 
O(1) 20(1)  15(1) 22(1)  7(1) 2(1)  0(1) 
O(2) 20(1)  14(1) 23(1)  -4(1) -2(1)  0(1) 
O(3) 22(1)  9(1) 26(1)  0(1) 12(1)  1(1) 
O(4) 15(1)  12(1) 22(1)  0(1) 8(1)  2(1) 
O(5) 13(1)  22(1) 20(1)  -3(1) 5(1)  -5(1) 
O(6) 27(1)  25(1) 33(1)  3(1) 16(1)  -9(1) 
N(1) 13(1)  8(1) 17(1)  1(1) 7(1)  0(1) 
C(1) 19(1)  12(1) 15(1)  1(1) 7(1)  2(1) 
C(2) 22(1)  12(1) 18(1)  0(1) 9(1)  -4(1) 
C(3) 17(1)  13(1) 17(1)  -2(1) 5(1)  -4(1) 
C(4) 15(1)  11(1) 15(1)  -1(1) 5(1)  0(1) 
C(5) 15(1)  9(1) 17(1)  0(1) 8(1)  0(1) 
C(6) 13(1)  12(1) 16(1)  -1(1) 5(1)  0(1) 
C(7) 18(1)  25(1) 31(1)  8(1) 1(1)  2(1) 
C(8) 16(1)  13(1) 16(1)  -1(1) 3(1)  0(1) 
C(9) 15(1)  14(1) 18(1)  2(1) 7(1)  0(1) 
C(10) 14(1)  19(1) 32(1)  -2(1) 3(1)  1(1) 
C(11) 12(1)  13(1) 20(1)  1(1) 7(1)  2(1) 
C(12) 14(1)  8(1) 17(1)  -1(1) 6(1)  0(1) 
C(13) 18(1)  14(1) 20(1)  -1(1) 10(1)  -1(1) 
C(14) 22(1)  19(1) 17(1)  -2(1) 7(1)  0(1) 
C(15) 13(1)  12(1) 13(1)  0(1) 4(1)  -1(1) 
C(16) 14(1)  10(1) 14(1)  0(1) 6(1)  -1(1) 
C(17) 11(1)  11(1) 10(1)  -1(1) 2(1)  -2(1) 
C(18) 22(1)  19(1) 15(1)  3(1) 8(1)  1(1) 
C(19) 15(1)  11(1) 22(1)  -2(1) 9(1)  0(1) 
C(20) 14(1)  32(1) 31(1)  -9(1) 6(1)  -8(1) 
C(21) 22(1)  30(1) 33(1)  -7(1) -2(1)  2(1) 
____________________________________________________________________________
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E.   Hydrogen coordinates ( x 104) and isotropic  displacement parameters (Å2x 10 3). 
____________________________________________________________________________  
 x  y  z  U(eq) 
____________________________________________________________________________ 
  
H(2) -3231 8 3600 34 
H(2A) -1046 -744 8232 20 
H(3) -2785 -273 6042 19 
H(6) 2503 362 9214 17 
H(7A) 4111 -405 10304 41 
H(7B) 4080 -688 11810 41 
H(7C) 3597 -85 11497 41 
H(8) -1433 660 4185 20 
H(10A) -4885 1600 4121 36 
H(10B) -5300 1001 4261 36 
H(10C) -4862 1188 2852 36 
H(11) -2438 1815 5937 18 
H(13A) -457 1907 8770 19 
H(13B) -456 1292 9036 19 
H(14A) 2458 1280 10007 29 
H(14B) 1889 1670 11018 29 
H(14C) 2461 1896 9734 29 
H(18A) 2050 1517 3836 28 
H(18B) 1213 2064 3893 28 
H(18C) 223 1533 3762 28 
H(20A) 5965 2435 9155 32 
H(20B) 6834 1970 8633 32 
H(21A) 6045 1923 11274 50 
H(21B) 7870 2008 11387 50 
H(21C) 6941 1466 10762 50 
____________________________________________________________________________ 
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[O]   oxidation 
°C   degrees Celsius 
Å   angstrom 
Ac   acetyl 
acac   acetylacetone 
ACS   American Chemical Society 
AHBA   3–amino–5–hydroxybenzoic acid 
AIBN   azoisobutyronitrile 
aq.   aqueous 
atm   atmosphere 
B2Pin2   bis(pinacolato)diboron 
Bn   benzyl 
Boc   tert–butoxycarbonyl 
BOM   benzyl methyl ether 
BPin   pinacolborane 
Bz   benzoyl 
CHDA   cyclohexyldiamine 
cm-1   inverse centimeters 
cod   1,5–cyclooctadiene 
COSY   correlation spectroscopy 
Cy   cyclohexyl 
d   doublet 
d.r.    diastereomeric ratio 
dba   dibenzylidene acetone 
DBU   1,8–diazabicyclo[5.4.0]–undec–7–ene 
DCC   dicyclohexylcarbodiimide 
DCE   dichloroethane 
DCM   dichloromethane 
dd   doublet of doublets 
ddd   doublet of doublet of doublets 
DDQ   2,3–dichloro–5,6–dicyano benzoquinone 
ddt   doublet of doublet of triplets 
DEPT   distortionless enhancement by polarization transfer 
DIBAL–H  diisobutylaluminum hydride 
DIPHOS (dppe) 1,2-bis(diphenylphosphino)ethane 
DKP   diketopiperazine 
DMAP   N,N–dimethylamino pyridine 
DMEDA  N,N–dimethylethylenediamine 
DMF   N,N–dimethylformamide 
DMS   dimethyl sulfide 
DMSO   dimethyl sulfoxide 
dt   doublet of triplets 
dtbpy   4,4–di–tert–butyl bipyridine 
DTT   dithiothreitol 
E0   reduction potential at 25 °C 
EDCI   N-Ethyl-N′-(3-dimethylaminopropyl)carbodiimide hydrochloride 
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ESeP   epidiselenodiketopiperazine 
ESI–APCI  electrospray ionization–atmospheric pressure chemical ionization 
Et   ethyl 
EtOH   ethanol 
ETP   epidithiodiketopiperazine 
FTIR   Fourier transform infrared spectroscopy 
g   gram 
HMBC   heteronuclear multiple bond correlation 
HMPA   hexamethylphosphoramide 
HMQC   heteronuclear multiple quantum correlation 
HPLC   high performance liquid chromatography 
HRMS   high–resolution mass spectroscopy 
Hz   hertz 
hν   light 
i–Pr   isopropyl 
IBX   2–iodoxybenzoic acid 
IC50   half maximum inhibitory concentration 
IMes•HCl  1,3–dimesitylimidazolium chloride 
imid.   imidazole 
INADEQUATE incredible natural abundance double quantum transfer experiment 
J   coupling constant 
kg   kilogram 
KHMDS  potassium hexamethyldisilazide 
L   liter 
LA   Lewis acid 
LDA   lithium diisopropylaminde 
LHMDS  lithium hexamethyldisilazide 
LTMP   lithium 2,2,6,6–tetramethylpiperidide 
M   molar 
m   multiplet 
m–CPBA  meta–chloroperoxybenzoic acid 
m/z   mass to charge ratio 
Me   methyl 
MeOH   methanol 
mg   milligram 
MHz   megahertz 
MIC   minimum inhibitory concentration 
mL   milliliter 
mmol   millimole 
mol   mole 
MOM   methoxy methyl  
Ms   mesyl 
MTB   Mycobacterium tuberculosis 
mV   millivolts 
N   normal 
n–Bu (Bu)  normal butyl 
NaHMDS  sodium hexamethyldisilazide 
NBS   N–bromosuccinimide 
NCS   N–chlorosuccinimide 
NHK   Nozaki–Hiyama–Kishi 
nm   nanometer 
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nM   nanomolar 
NMR   nuclear magnetic resonance 
NOE   nuclear Overhauser effect 
NOESY  nuclear Overhauser effect spectroscopy 
NuH   nucleophile 
OTFA   trifluoroacetate 
Pg   protecting group 
Ph   phenyl 
PhH   benzene 
PIDA   bisacetoxyiodo benzene 
PIFA   [bis(trifluoroacetoxy)iodo]benzene 
Piv   pivaloyl 
PMB   para–methoxybenzyl 
PMP   para–methoxyphenyl 
PPA   polyphosphoric acid 
pTSA   para–toluenesulfonic acid 
pyr.   pyridine 
q   quartet 
R   generic carbon group or hydrogen 
RCM   ring–closing metathesis 
Rf   retention factor 
ROS   reactive oxygen species 
s   singlet 
sat.   saturated 
SBL   soybean lipoxygenase 
SEM   methyl 2-trimethylsilylethyl ether 
t   triplet 
t–Bu   tert–butyl 
TASF   tris(dimethylamino)sulfonium difluorotrimethylsilicate 
TB   tuberculosis 
TBAF   tetrabutylammonium fluoride 
TBAI   tetrabutylammonium iodide 
TBAT   tetrabutylammonium difluorotriphenylsilicate 
TBDPS  tert–butyldiphenyl silyl 
TBHP   tert–butyl hydrogenperoxide 
TBS   tert–butyldimethyl silyl 
Tf   triflate 
TFA   trifluoroacetic acid 
THF   tetrahydrofuran 
TIPS   triisopropyl silyl 
TMS   trimethyl silyl 
Ts   tosyl 
tt   triplet of triplets 
UV   ultraviolet  
X   generic halogen 
µg   microgram 
µM   micromolar 
 
 
 
 
